<SEC-DOCUMENT>0001193125-22-111079.txt : 20220420
<SEC-HEADER>0001193125-22-111079.hdr.sgml : 20220420
<ACCEPTANCE-DATETIME>20220420160114
ACCESSION NUMBER:		0001193125-22-111079
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20220601
FILED AS OF DATE:		20220420
DATE AS OF CHANGE:		20220420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vaxcyte, Inc.
		CENTRAL INDEX KEY:			0001649094
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				464233385
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39323
		FILM NUMBER:		22837999

	BUSINESS ADDRESS:	
		STREET 1:		825 INDUSTRIAL ROAD, STE. 300
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070
		BUSINESS PHONE:		650-837-0111

	MAIL ADDRESS:	
		STREET 1:		825 INDUSTRIAL ROAD, STE. 300
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SutroVax, Inc.
		DATE OF NAME CHANGE:	20150724
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d305886ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. ) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Under &#167; <FONT STYLE="white-space:nowrap">240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>VAXCYTE, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of
Registrant as Specified in its Charter) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement if Other Than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit requirement by Item 25(b) per Exchange Act Rules <FONT
STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g305886g02m02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vaxcyte, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>825 Industrial Road </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 300 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Carlos,
California 94070 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD AT 8:30 A.M. PACIFIC TIME ON WEDNESDAY, JUNE&nbsp;1, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the
virtual Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) of Vaxcyte, Inc., a Delaware corporation (the &#147;Company&#148;). The Annual Meeting will be held on Wednesday, June&nbsp;1, 2022 at 8:30 a.m. Pacific Time via live webcast
for the following purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect the two nominees for Class&nbsp;II director named in the accompanying Proxy Statement to hold office
until the Company&#146;s 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed
in this proxy statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of
the Company&#146;s named executive officers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as the Company&#146;s independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To conduct any other business properly brought before the Annual Meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These items of business are more fully described in the Proxy Statement accompanying this notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This year&#146;s Annual Meeting will be accessible through the internet via a live webcast. You will be able to attend the virtual Annual Meeting as well as
vote during the meeting by visiting www.virtualshareholdermeeting.com/PCVX2022 and entering the <FONT STYLE="white-space:nowrap">16-digit</FONT> number included in your proxy card. Please refer to the additional logistical details and
recommendations in the accompanying proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The record date for the Annual Meeting is April&nbsp;11, 2022. Only stockholders of record at the
close of business on that date may vote at the Annual Meeting or any adjournment thereof. A complete list of stockholders entitled to vote at the Annual Meeting may be accessed electronically, upon request, starting ten days prior to the Annual
Meeting by contacting Vaxcyte investor relations via email at investors@vaxcyte.com. In addition, such stockholder list will be posted on the virtual meeting website during the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning on or about April&nbsp;20, 2022, a Notice of Internet Availability of Proxy Materials will be mailed to our stockholders of record as of
April&nbsp;11, 2022. We have elected to take advantage of Securities and Exchange Commission rules that allow companies to furnish proxy materials to their stockholders by providing access to these documents on the internet instead of mailing
printed copies. Those rules allow a company to provide its stockholders with the information they need, while lowering the costs of delivery and reducing the environmental impact of the Annual Meeting. The proxy statement, the accompanying proxy or
voting instruction card and our annual report are available at www.proxyvote.com. As more fully described in the notice, all stockholders may choose to access these materials online or may request printed or emailed copies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your vote is important. Whether or not you expect to attend our Annual Meeting, please vote as soon as possible. We appreciate your continued support of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By the order of the Board of Directors, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
Mikhail Eydelman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President, General Counsel and Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Carlos, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;20, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy
Materials for the</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annual Meeting of Stockholders to Be Held on Wednesday, June&nbsp;1, 2022 at 8:30 a.m. Pacific Time at</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>www.virtualshareholdermeeting.com/PCVX2022. The proxy statement and our annual report are available at</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>www.proxyvote.com.</B></P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_1">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND
VOTING</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_2">PROPOSAL NO. 1 ELECTION OF DIRECTORS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_3">CORPORATE GOVERNANCE AND BOARD MATTERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_4">DIRECTOR COMPENSATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_5">PROPOSAL NO. 2 APPROVAL, ON A <FONT STYLE="white-space:nowrap">NON-BINDING,
</FONT> ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>22</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_6">EXECUTIVE OFFICERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_7">EXECUTIVE COMPENSATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_8">PROPOSAL NO. 3 APPROVAL, ON A <FONT STYLE="white-space:nowrap">NON-BINDING,
</FONT> ADVISORY BASIS, OF THE FREQUENCY OF FUTURE <FONT STYLE="white-space:nowrap">NON-BINDING,</FONT> ADVISORY VOTES TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>44</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_9">PROPOSAL NO. 4 RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_10">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>47</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_11">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>50</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_12">HOUSEHOLDING OF PROXY MATERIALS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>51</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx305886_13">OTHER MATTERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>52</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than
statements of historical facts contained in this report, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking
statements. In some cases, you can identify forward-looking statements because they contain words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; or &#147;would,&#148; or the
negative of these words or other similar terms or expressions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actual events or results may differ from those expressed in forward-looking statements.
You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this proxy statement primarily on our current expectations and projections about future events and trends
that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled
&#147;Risk Factors&#148; in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 filed with the Securities and Exchange Commission and other subsequent documents we file with
the Securities and Exchange Commission. The Company expressly disclaims any obligation to update or alter any statements as a result of new information, future events or otherwise, except as required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g305886g02m02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VAXCYTE, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>825 Industrial Road </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 300 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Carlos,
California 94070 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE 2022 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON WEDNESDAY, JUNE&nbsp;1, 2022 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_1"></A>QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why did I receive a notice regarding the availability of proxy materials on the internet? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to rules adopted by the Securities and Exchange Commission (the &#147;SEC&#148;), we have elected to provide access to our proxy materials over the
internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) because the Board of Directors of Vaxcyte, Inc. (sometimes referred to as the &#147;Company&#148; or &#147;Vaxcyte&#148;), is
soliciting your proxy to vote at the 2022 Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;), including at any adjournments or postponements of the Annual Meeting. All stockholders will have the ability to access the proxy materials on
the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to mail the Notice on or about April&nbsp;20, 2022 to all stockholders of record entitled to vote at the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Will I receive any other proxy materials by mail? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No,
you will not receive any other proxy materials by mail unless you request a paper copy of proxy materials. To request that a full set of the proxy materials be sent to your specified postal address, please go to www.proxyvote.com or call <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-579-1639.</FONT></FONT></FONT> Please have your proxy card in hand when you access the website or call and follow the instructions provided. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I attend the Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This year&#146;s
Annual Meeting will be accessible through the internet via a live webcast. We adopted a virtual format for our Annual Meeting in light of the ongoing health risks related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and in the
best interests of public health and the health and safety of our stockholders, directors and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are entitled to participate in the Annual
Meeting if you were a stockholder as of the close of business on our record date of April&nbsp;11, 2022 or hold a valid proxy for the meeting. We have structured our virtual Annual Meeting to provide stockholders the same rights as if the meeting
were held in person, including the ability to vote shares electronically during the meeting and ask questions in accordance with the rules of conduct for the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be able to attend the virtual Annual Meeting as well as vote during the meeting by visiting www.virtualshareholdermeeting.com/PCVX2022 and entering
the <FONT STYLE="white-space:nowrap">16-digit</FONT> number included in your proxy card. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial stockholders who do not have a control number may
gain access to the meeting by logging into their broker, brokerage firm, bank or other nominee&#146;s website and selecting the stockholder communications mailbox to link through to the Annual Meeting; instructions should also be provided on the
voting instruction card provided by your broker, bank or other nominee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any technical difficulties or any questions regarding the virtual meeting website, please call
the support team at the numbers listed on the <FONT STYLE="white-space:nowrap">log-in</FONT> screen. If there are any technical issues in convening or hosting the meeting, we will promptly post information to the Investors&nbsp;&amp; Media section
of our website, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">http://investors.vaxcyte.com, including information on when the meeting will be reconvened. Please note that participation in the meeting
is limited due to the capacity of the host platform and access to the meeting will be accepted on a first-come, first-served basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide our
stockholders the opportunity to ask questions and make statements about a proposal during the formal business of the meeting. Questions and comments of a general nature will be held until after the conclusion of the formal business of the Annual
Meeting. Instructions for submitting questions and making statements will be posted on the virtual meeting website. This live question and answer session will be conducted in accordance with certain Rules of Conduct. These Rules of Conduct will be
posted on our Investors&nbsp;&amp; Media website prior to the date of the Annual Meeting, and may include certain procedural requirements, such as limiting repetitive or <FONT STYLE="white-space:nowrap">follow-up</FONT> questions, so that more
stockholders will have an opportunity to ask questions. Out of consideration for other stockholders, we request that stockholders limit questions and comments to one and time to two minutes or less. This will allow every stockholder who wishes to
speak an opportunity to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who can vote at the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close of business on April&nbsp;11, 2022 will be entitled to vote at the Annual Meeting. On this record date, there were
58,052,119 shares of our common stock outstanding and entitled to vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholders of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If on April&nbsp;11, 2022 your shares were registered directly in your name with our transfer agent, American Stock Transfer&nbsp;&amp; Trust Company, LLC,
then you are a stockholder of record. As a stockholder of record, you may vote at the Annual Meeting if you attend online, vote by proxy through the internet or by telephone or vote by proxy using a proxy card that you may request or that we may
elect to deliver at a later time. Whether or not you plan to attend the Annual Meeting, we encourage you to vote by proxy through the internet or by telephone as instructed below, or by completing a proxy card that you may request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owners: Shares Registered in the Name of a Broker or Bank </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If on April&nbsp;11, 2022 your shares were held in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial
owner of shares held in &#147;street name&#148; and the Notice is being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a
beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. As a beneficial owner, you are also invited to attend the Annual Meeting. However, since you are not the stockholder of
record, you may not vote your shares online at the Annual Meeting unless you request and obtain a valid proxy from your broker, bank, dealer or other agent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the quorum requirement? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum of stockholders
is necessary to hold a valid meeting. A quorum will be present if the holders of a majority of the voting power of the outstanding shares entitled to vote are electronically present online at the meeting or represented by proxy. On the record date,
there were 58,052,119 shares of common stock outstanding and entitled to vote.<B> Thus, the holders of 29,026,060 shares must be present online or represented by proxy at the Annual Meeting to have a quorum.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other agent) or if
you attend the Annual Meeting. Abstentions and broker </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares electronically present online at the
Annual Meeting or represented by proxy may adjourn the meeting to another date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What am I voting on? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are four proposals scheduled for a vote at the Annual Meeting: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.&nbsp;1: To elect the two nominees for Class&nbsp;II director named herein to hold office until our 2025 Annual Meeting of Stockholders and
until their successors have been duly elected and qualified. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;2: </I>Advisory approval of the compensation of our
named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;3: </I>Advisory indication of the preferred frequency of shareholder advisory votes on the
compensation of our named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;4: </I>To ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as
our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if another matter is properly brought before
the meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not aware of any other matters that will be presented for stockholder action at the Annual Meeting. If other matters are properly
introduced, the persons named in the accompanying proxy will vote the shares of our common stock they represent according to their judgment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I
vote? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Proposal No.&nbsp;1, election of Class&nbsp;II directors, you may either vote &#147;For&#148; the nominees to the Board of Directors or you
may &#147;Withhold&#148; your vote for any nominee you specify. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Proposal No.&nbsp;2, advisory approval of the compensation of our named executive
officers, you may vote &#147;For&#148; or &#147;Against&#148; or &#147;Abstain&#148; from voting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Proposal No.&nbsp;3, advisory indication of the
preferred frequency of shareholder advisory votes on the compensation of our named executive officers, you may vote for &#147;One Year,&#148; &#147;Two Years,&#148; &#147;Three Years,&#148; or &#147;Abstain&#148; from voting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Proposal No.&nbsp;4, to ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm, you may vote
&#147;For&#148; or &#147;Against&#148; or &#147;Abstain&#148; from voting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholders of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, there are several ways for you to vote your shares. Whether or not you plan to attend the Annual Meeting, we urge you to
vote by proxy to ensure that your vote is counted. You may still attend the Annual Meeting and vote electronically during the meeting even if you have already voted by proxy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>By Telephone</U>: To vote over the telephone, dial toll-free <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-690-6903</FONT></FONT></FONT> using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the Notice. Your
telephone vote must be received by 11:59 p.m. EST on May&nbsp;31, 2022 to be counted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>By Internet</U>:<I> </I>To vote through the internet, go to www.proxyvote.com to complete an electronic proxy
card. You will be asked to provide the company number and control number from the Notice. Your internet vote must be received by 11:59 p.m. EST on May&nbsp;31, 2022 to be counted. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>By Mail</U>: If you requested printed copies of the proxy materials by mail, you may vote using the proxy
card. Simply complete, sign and date the proxy card that may be delivered and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>At the Annual Meeting</U>: To vote at the Annual Meeting, you must be present via live webcast. To vote
through the internet during the meeting, log into the Annual Meeting website at www.virtualshareholdermeeting.com/PCVX2022 and following the instructions provided on the website. We encourage you to vote your proxy by internet, telephone or mail
prior to the meeting, even if you plan to attend the Annual Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owners: Shares Registered in the Name of Broker or
Bank </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a Notice containing
voting instructions from that organization rather than directly from us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>By Method Listed on Voting Instruction Card</U>: Please refer to your voting instruction card or other
information provided by your bank, broker or other agent to determine whether you may vote by telephone, electronically on the internet or by mail using the proxy card provided by your bank, broker or other agent. Simply follow the instructions in
the notice provided by your broker, bank or other agent to ensure that your vote is counted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>By Mail</U>: You may vote by signing, dating and returning your voting instruction card in the <FONT
STYLE="white-space:nowrap">pre-addressed</FONT> envelope provided by your broker, bank or other agent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>At the Annual Meeting</U>: To vote online during the Annual Meeting, you must obtain a valid proxy from your
broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form. We encourage you to vote your proxy by internet,
telephone or mail prior to the meeting, even if you plan to attend the Annual Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regarding internet proxy voting, please be
aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and cellular companies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I change my vote after submitting my proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy
in any one of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may submit another properly completed proxy card with a later date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may grant a subsequent proxy by telephone or through the internet (only the latest proxy submitted prior to
the Annual Meeting will be counted). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may send a timely written notice that you are revoking your proxy to our Corporate Secretary at 825
Industrial Road, Suite 300, San Carlos, California 94070. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may attend, and vote online during, the Annual Meeting. Simply attending the virtual Annual Meeting will not,
by itself, revoke your proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Your most current proxy card or telephone or internet proxy is the one that is
counted</I></B><I>. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of Broker or Bank </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker, bank or other agent, you should follow the instructions provided by your broker, bank or other agent to change your
vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes do I have? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On each matter to be voted upon, each share of our common stock that you own as of April&nbsp;11, 2022 entitles you to one vote. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What does it mean if I receive more than one Notice? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on each of the Notices you receive to ensure that all of your shares are voted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If I am a stockholder of record and I do not vote, or if I return a proxy card or otherwise vote without giving specific voting instructions, what happens?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record and do not vote by completing a proxy card<B>,</B> by telephone, through the internet or online at the Annual
Meeting, your shares will not be voted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will
be voted, as applicable, &#147;For&#148; Proposal No.&nbsp;1 to elect the two nominees for director; &#147;For&#148; Proposal No.&nbsp;2 for the advisory approval of executive compensation; for &#147;One Year&#148; for Proposal No.&nbsp;3 as the
preferred frequency of advisory votes to approve executive compensation; and &#147;For&#148; Proposal No.&nbsp;4 to ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as the Company&#146;s independent registered public accounting firm. If any
other matter is properly presented at the meeting, your proxyholder will vote your shares using his or her best judgment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If I am a beneficial owner
of shares held in street name and I do not provide my broker, bank or other agent with voting instructions, what happens? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial
owner of shares held in street name and you do not instruct your broker, bank or other agent on how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion. In this regard, under the rules of the
listing requirements of the Nasdaq Global Select Market (&#147;Nasdaq&#148;), brokers, banks and other securities intermediaries that are subject to Nasdaq rules may use their discretion to vote your &#147;uninstructed&#148; shares with respect to
matters considered to be &#147;routine&#148; under Nasdaq rules, but not with respect to <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. In this regard, Proposals No.&nbsp;1 through 3 are considered to be <FONT
STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters under Nasdaq rules, meaning that your broker may not vote your shares on Proposals No.&nbsp;1 through 3 in the absence of your voting instructions. However, Proposal No.&nbsp;4, to
ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as the Company&#146;s independent registered public accounting firm, is considered to be a &#147;routine&#148; matter under Nasdaq rules, meaning that if you do not return voting instructions
to your broker by its deadline, your shares may be voted by your broker, bank or other agent in its discretion on Proposal No.&nbsp;4. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you are a
beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you<U> must</U> provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you
receive from your broker, bank or other agent. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes are needed to approve each proposal? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;1: </I>Directors will be elected by a plurality of the votes cast, meaning that the two nominees who receive the most
&#147;For&#148; votes from the holders of shares present online or represented by proxy and entitled to vote on the election of directors will be elected. Accordingly, only votes &#147;For&#148; will affect the outcome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;2: </I>This proposal, commonly referred to as the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> vote, must receive &#147;For&#148; votes from the holders of a majority shares present online or represented by proxy and entitled to vote on the
matter. Since this proposal is an advisory vote, the result will not be binding on our Board of Directors. However, our Board of Directors values our stockholders&#146; opinions, and our Board of Directors and the Compensation Committee will take
into account the outcome of the advisory vote when considering future executive compensation decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;3:</I> The option of one, two or three years that receives the highest
number of votes will be approved. Since this proposal is an advisory vote, the result will not be binding on our Board of Directors. However, our Board of Directors values our stockholders&#146; opinions, and our Board of Directors and the
Compensation Committee will take into account the outcome of the advisory vote when determining how often we should submit to stockholders future <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT>
votes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;4:</I> To ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2022, the proposal must receive &#147;For&#148; votes from the holders of a majority of shares present online or represented by proxy and entitled to vote on the matter. If you
&#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How are votes counted? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Votes will be counted by the inspector of election appointed for the meeting, who will separately count, for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal No.&nbsp;1, votes &#147;For,&#148; &#147;Withhold&#148; and broker
<FONT STYLE="white-space:nowrap">non-votes;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal No.&nbsp;2, votes &#147;For,&#148; &#147;Against,&#148; &#147;Abstain&#148; and broker <FONT
STYLE="white-space:nowrap">non-votes;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal No.&nbsp;3, votes for &#147;One Year,&#148; &#147;Two Years,&#148; &#147;Three Years,&#148;
&#147;Abstain&#148; and broker <FONT STYLE="white-space:nowrap">non-votes;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal No.&nbsp;4, votes &#147;For&#148; and &#147;Against&#148; as well as &#147;Abstain.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abstentions will be counted towards the vote total for Proposals 2 and 4, and will have the same effect as &#147;Against&#148; votes.
Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> have no effect and will not be counted towards the vote total for any proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Proposal
No.&nbsp;1, the election of directors is determined by a plurality of votes cast, so a &#147;Withhold&#148; vote will not be counted in determining the outcome of such proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Proposal No.&nbsp;2, advisory approval of the compensation of our named executive officers, abstentions will be counted towards the vote total and will
have the same effect as &#147;Against&#148; votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> have no effect and will not be counted towards the vote total for any proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Proposal No.&nbsp;3, advisory indication of the preferred frequency of shareholder advisory votes on the compensation of our named executive officers, the
option of one, two or three years that receives the highest number of votes will be approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Proposal No.&nbsp;4, to ratify of the appointment of
Deloitte&nbsp;&amp; Touche LLP as the Company&#146;s independent registered public accounting firm, abstentions will be counted towards the vote total and will have the same effect as &#147;Against&#148; votes. Broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> have no effect and will not be counted towards the vote total for any proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What are
&#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;?</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above, when a beneficial owner of shares held in street name does
not give voting instructions to his or her broker, bank or other securities intermediary holding his or her shares as to how to vote on matters deemed to be <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> under Nasdaq rules, the
broker, bank or other such agent cannot vote the shares. These unvoted shares are counted as &#147;broker <FONT STYLE="white-space:nowrap">non-votes.&#148;</FONT> Since Proposals No.&nbsp;1 through 3, are considered to be <FONT
STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters under Nasdaq rules, we expect broker <FONT STYLE="white-space:nowrap">non-votes</FONT> to exist in connection with Proposals No.&nbsp;1 through 3. Proposal No.&nbsp;4, to ratify the
appointment of Deloitte&nbsp;&amp; Touche LLP as the Company&#146;s independent registered public accounting firm, is considered to be a &#147;routine&#148; matter under Nasdaq rules, and therefore we do not expect broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> to exist in connection with Proposal No.&nbsp;4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>As a reminder, if you are a beneficial owner of shares held in street name, in order to ensure
your shares are voted in the way you would prefer, you</I></B><B></B><B><I><U> must</U></I></B><B></B><B><I> provide your voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker,
bank or other agent</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is paying for this proxy solicitation? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, or
by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial
owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I find out the results of the voting at the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business
days after the Annual Meeting, we intend to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish preliminary results and, within four business days after the final results are known to us, file an additional Form <FONT
STYLE="white-space:nowrap">8-K</FONT> to publish the final results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When are stockholder proposals and director nominations due for next year&#146;s
annual meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be considered for inclusion in our proxy materials for our 2023 Annual Meeting of Stockholders, your proposal (including any
director nominations) must be submitted in writing by December&nbsp;21, 2022 to our Corporate Secretary at 825 Industrial Road, Suite 300, San Carlos, California 94070, and you must comply with all applicable requirements of Rule <FONT
STYLE="white-space:nowrap">14a-8</FONT> promulgated under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). However, if the 2023 Annual Meeting of Stockholders is advanced by more than 30 days prior to or delayed by
more than 30 days after June&nbsp;1, 2023, then the deadline will be a reasonable time prior to the time we begin to print and send our proxy materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our Amended and Restated Bylaws (our &#147;Bylaws&#148;), if you wish to submit a proposal (including a director nomination) at the 2023 Annual
Meeting of Stockholders that is not to be included in next year&#146;s proxy materials, you must do so not later than the close of business on March&nbsp;3, 2023 and no earlier than the close of business on February&nbsp;1, 2023; provided, however,
that if next year&#146;s annual meeting is advanced by more than 30 days prior to or delayed by more than 30 days after June&nbsp;1, 2023, your proposal must be submitted not earlier than the close of business on the 120th day prior to such annual
meeting and not later than the close of business on the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such meeting is first made. You are advised to review our Bylaws, which contain additional requirements about advance notice of stockholder proposals and
director nominations. In addition, the proxy solicited by our Board of Directors for the 2023 Annual Meeting will confer discretionary voting authority with respect to (i)&nbsp;any proposal presented by a stockholder at that meeting for which the
Company has not been provided with timely notice and (ii)&nbsp;any proposal made in accordance with our Bylaws, if the 2023 proxy statement briefly describes the matter and how management proxy holders intend to vote on it, if the stockholder does
not comply with the requirements of Rule <FONT STYLE="white-space:nowrap">14a-4(c)(2)</FONT> promulgated under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to
satisfying the foregoing requirements under our Bylaws, stockholders who intend to solicit proxies in support of director nominees other than the Company&#146;s nominees must provide notice that sets forth the information required by <FONT
STYLE="white-space:nowrap">Rule&nbsp;14a-19&nbsp;under</FONT> the Exchange Act no later than April&nbsp;2, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What proxy materials are available on
the internet? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proxy statement and annual report to stockholders are available at www.proxyvote.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_2"></A>PROPOSAL NO. 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of
Directors is divided into three classes. We currently have three directors in each of Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, and each class serves for a three-year term. Vacancies on the Board of Directors may be filled only by persons
elected by a majority of the remaining directors unless the Board of Directors determines by resolution that any such vacancies will be filled by stockholders. A director elected by the Board of Directors to fill a vacancy in a class, including
vacancies created by an increase in the number of directors, will serve for the remainder of the full term of that class and until the director&#146;s successor is duly elected and qualified, or, if sooner, until the director&#146;s death,
resignation or removal. Proxies cannot be voted for a greater number of persons than the number of nominees named. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors presently has
nine directors. At the Annual Meeting, the authorized size of our Board of Directors will be reduced to eight members. The two directors in Class&nbsp;II whose terms of office expire in 2022 and who will be standing for election at the Annual
Meeting, and their ages as of April&nbsp;20, 2022, are set forth in the table below. Mr.&nbsp;von Emster, who is currently serving on our Board of Directors, is not nominated for election at the Annual Meeting and his term as a director will end at
the Annual Meeting. We thank Mr.&nbsp;von Emster for his distinguished service. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Director&nbsp;Since</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Age</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Hirth, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">September&nbsp;2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heath Lukatch, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">September 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of these directors were elected to the Board of Directors prior to our initial public offering pursuant to a voting
agreement entered into with certain of our stockholders that terminated upon completion of our initial public offering in June 2020. If elected at the Annual Meeting, these nominees would serve until the 2025 Annual Meeting of Stockholders and until
their successors have been duly elected and qualified, or, if sooner, until the director&#146;s death, resignation or removal. Following the Annual Meeting, we will have two Class&nbsp;II directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors are elected by a plurality of the votes of the holders of shares present at the Annual Meeting or represented by proxy and entitled to vote on the
election of directors. Accordingly, the nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of each of the nominees
named below. If any nominee becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for that nominee instead will be voted for the election of a substitute nominee proposed by the Company. Each
person nominated for election has consented to being named as a nominee in this proxy statement and has agreed to serve if elected. We have no reason to believe that any nominee will be unable to serve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our policy is to encourage directors and nominees for director to attend the Annual Meeting. All of our directors attended the 2021 Annual Meeting, which was
held virtually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following includes a brief biography of each nominee for Class&nbsp;II director and each of our Class&nbsp;I and Class&nbsp;III
directors continuing to serve on the Board of Directors, including their respective ages, as of December&nbsp;31, 2021. Each biography includes information regarding the specific experience, qualifications, attributes or skills that led the
Nominating and Corporate Governance Committee and the Board of Directors to determine that the applicable nominee or other current director should serve as a member of the Board of Directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;II director Nominees for Election for a Three-Year Term Expiring at the 2025 Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Peter Hirth, Ph.D.</I></B> Dr.&nbsp;Hirth, 70, has served on our Board of Directors since September 2016. In 2001, Dr.&nbsp;Hirth founded Plexxikon,
Inc., a pharmaceutical company, and served as its Chief Executive Officer until April 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&nbsp;Hirth currently serves on the board of directors of Aligos Therapeutics, a biopharmaceutical company, as well as the boards of directors of several private life sciences companies.
Dr.&nbsp;Hirth holds a Ph.D. in Molecular Genetics from Heidelberg University, Germany. Dr.&nbsp;Hirth was selected to serve on our Board of Directors because of his extensive experience as a drug developer, entrepreneur, operator, and investor in
and advisor to many life sciences companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Heath Lukatch, Ph.D.</I></B> Dr.&nbsp;Lukatch, 54, has served on our Board of Directors since May
2018. Since 2020, Dr.&nbsp;Lukatch has served as Founder and Managing Partner of Red Tree Venture Capital, a life sciences venture capital firm. From 2015 to 2020, Dr.&nbsp;Lukatch worked at TPG where he was Partner, Managing Director and Life
Sciences Investment Team Leader in TPG&#146;s Biotech, Growth and RISE platforms. In 2006, Dr.&nbsp;Lukatch <FONT STYLE="white-space:nowrap">co-founded</FONT> Novo Ventures&#146; San Francisco office, where he was a Partner through 2015. Prior to
joining Novo Ventures, Dr.&nbsp;Lukatch was a Managing Director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners. Dr.&nbsp;Lukatch currently serves as Chairman of Satsuma Pharmaceuticals, where he
has been a board member since 2016, and is a board member at Acrigen, Excellergy, Magnus Medical and Virsti. Previously, Dr.&nbsp;Lukatch was Chairman of Cianna Medical (acquired by Merit Medical), Engage Therapeutics (acquired by UCB), Inogen, and
Spinifex (acquired by Novartis), and served on multiple life sciences company boards, including: Amira (acquired by BMS), AnaptysBio, Elevation Pharma (acquired by Sunovion), Flexion Therapeutics, FoldRx (acquired by Pfizer), InSound Medical
(acquired by Sonova) and Synosia Therapeutics (acquired by BioTie). Dr.&nbsp;Lukatch is currently a board observer at Ceribell and Syncopation and he previously was a board observer at Alios BioPharma (acquired by J&amp;J), Dynavax, Fluidigm and <FONT
STYLE="white-space:nowrap">SI-Bone.</FONT> Prior to becoming an investor, Dr.&nbsp;Lukatch worked as a strategy consultant with McKinsey&nbsp;&amp; Company and was <FONT STYLE="white-space:nowrap">co-founder</FONT> and CEO of AutoMate Scientific, a
biotechnology instrumentation company. In addition, he was a bench scientist at Chiron, Roche Bioscience and Cetus, doing molecular biology, electrophysiology and protein chemistry, respectively. Dr.&nbsp;Lukatch holds a B.A. with high honors in
Biochemistry from the University of California at Berkeley and a Ph.D. in Neuroscience from Stanford University where he was a DOD USAF Fellow. Dr.&nbsp;Lukatch was selected to serve on our Board of Directors because of his extensive industry
experience, his experience with venture capital investments and his experience of serving on the board of directors for several biopharmaceutical and healthcare companies. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A VOTE &#147;FOR&#148; EACH OF OUR NOMINEES NAMED ABOVE. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;III Directors Continuing in Office Until the 2023 Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Halley Gilbert, J.D.</I></B> Ms.&nbsp;Gilbert, 52, has served on our Board of Directors since April 2020. Ms.&nbsp;Gilbert currently serves as Chief
Legal Officer of Neogenomics, Inc., a cancer diagnostics company. From June 2020 to August 2021, Ms.&nbsp;Gilbert served as Chief Operating Officer and Chief Business Officer at Adagio Therapeutics, Inc. From 2008 to February 2020, Ms.&nbsp;Gilbert
served in various roles at Ironwood Pharmaceuticals, Inc., a biopharmaceutical company, including as Senior Vice President, Corporate Development and Chief Administrative Officer from March 2019 to February 2020, as Senior Vice President, Chief
Legal Officer and Corporate Secretary from 2014 to March 2019 and as Vice President, General Counsel and Corporate Secretary from 2008 to 2014. Ms.&nbsp;Gilbert also currently serves on the boards of directors of Arcutis Biotherapeutics, a medical
dermatology company, and CytomX Therapeutics, a life sciences company. From November 2019 to February 2020, Ms.&nbsp;Gilbert served on the board of directors of Dermira, Inc., a medical dermatology company. From January 2017 to April 2019,
Ms.&nbsp;Gilbert served on the board of directors of Achaogen, Inc., a biopharmaceutical company. Ms.&nbsp;Gilbert holds a B.A. from Tufts University and a J.D. from Northwestern University School of Law. Ms.&nbsp;Gilbert was selected to serve on
our Board of Directors because of the depth of her biotechnology industry management and operations expertise and public company board of directors experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant E. Pickering, M.B.A.</I></B> Mr.&nbsp;Pickering, 54, is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief
Executive Officer and as a member of our Board of Directors since November 2013. Mr.&nbsp;Pickering also served as our President </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from November 2013 until December 2020. From May 2013 to April 2015, Mr.&nbsp;Pickering served as Strategic Advisor at Atreca, Inc., a biotechnology company. Prior to joining Vaxcyte, he was
Chief Executive Officer of Mymetics Corporation, a developer of virosomal vaccines for infectious diseases. Prior to that, Mr.&nbsp;Pickering was an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Executive-in-Residence</FONT></FONT> at Kleiner Perkins, a venture capital firm, and Senior Vice President of Operations of Dendreon Corporation, a biopharmaceutical company. Since
March 2008, Mr.&nbsp;Pickering has served as a Director of Juvaris BioTherapeutics, Inc., a biopharmaceutical company. Mr.&nbsp;Pickering holds a B.S. in Marketing from Penn State University and an M.B.A. from Georgetown University.
Mr.&nbsp;Pickering was selected to serve on our Board of Directors because of the perspective and experience he brings as our Chief Executive Officer and his operating and management experience in the healthcare industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael E. Kamarck, Ph.D. </I></B>Dr.&nbsp;Kamarck, 71, has served on our Board of Directors since October 2021. Dr.&nbsp;Kamarck also currently serves
as Chairman of the Sanofi Biotech Advisory Council, providing strategic guidance to advance Sanofi&#146;s biologicals business. From June 2017 to July 2021, Dr.&nbsp;Kamarck served as Chief Technology Officer for Vir Biotechnology, Inc. From
December 2009 to March 2012, Dr.&nbsp;Kamarck served as Senior Vice President of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures. From 2001 to 2009, Dr.&nbsp;Kamarck held numerous senior executive positions at Wyeth
Pharmaceuticals, including President, Technical Operations and Product Supply as a member of the Wyeth Management Team. Dr.&nbsp;Kamarck also spent 16 years at Bayer AG serving in numerous roles, including Senior Vice President of Operations for
Bayer Biologicals. Dr.&nbsp;Kamarck holds a B.A. from Oberlin College and a Ph.D. from Massachusetts Institute of Technology. Dr.&nbsp;Kamarck was selected to serve on our Board of Directors because of the depth of his biotechnology industry
management and operations expertise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;I Directors Continuing in Office Until the 2024 Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annie Drapeau</I></B><B>.</B> Ms.&nbsp;Drapeau, 55, has served on our Board of Directors since September 2021. Ms.&nbsp;Drapeau currently serves as Chief
People Officer of Toast, Inc. since May 2019. From October 2016 to May 2019, Ms.&nbsp;Drapeau served as Chief People Officer of Moderna Therapeutics, Inc. From April 215 to October 2016 Ms.&nbsp;Drapeau served as Operating Partner of Bain Capital.
From March 2010 to March 215, Ms.&nbsp;Drapeau served as Executive Vice President, Strategy and Talent for Iron Mountain. Additionally, she served as Chief People Officer at VistaPrint and Digitas, and started her career in finance roles at JP
Morgan and PepsiCo. Ms.&nbsp;Drapeau holds a B.S. in Chemical Engineering from Bucknell University and an M.B.A. from the Tuck School of Business at Dartmouth College. Ms.&nbsp;Drapeau was selected to serve on our Board of Directors because of the
depth of her life sciences industry and operations expertise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teri Loxam</I></B><B>.</B> Ms.&nbsp;Loxam, 50, has served on our Board of Directors
since September 2021. Ms.&nbsp;Loxam currently serves as Chief Financial Officer and Chief Operating Officer of Kira Pharmaceuticals since November 2021. Previously, Ms.&nbsp;Loxam served as Chief Financial Officer for SQZ Biotechnologies from
September 2019 to November 2021. From August 2015 to August 2019, Ms.&nbsp;Loxam was at Merck&nbsp;&amp; Co., Inc., a global healthcare company, where she served as Senior Vice President of Investor Relations and Global Communications. Before that,
from July 2012 to August 2015, Ms.&nbsp;Loxam served as Vice President of Investor Relations at IMAX, an entertainment technology company. From June 2001 to July 2012, Ms.&nbsp;Loxam had a number of roles of increasing responsibility across
Strategy, Treasury and Investor Relations at Bristol-Myers Squibb, a global healthcare company. Ms.&nbsp;Loxam holds an M.B.A. from the University of California, Irvine, Paul Merage School of Business, and a B.Sc. from the University of Victoria.
Ms.&nbsp;Loxam was selected to serve on our Board of Directors because of the depth of her life sciences industry, investor relations and financial expertise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Carlos Paya, M.D., Ph.D.</I></B> Dr.&nbsp;Paya, 63, has served as a member of our Board of Directors since October 2021. Dr.&nbsp;Paya currently serves
as Senior Advisor to Abingworth LLP. Dr.&nbsp;Paya has also served on the board of directors of Fluidigm Corporation since March 2017. From May 2011, Dr.&nbsp;Paya served as president, chief executive officer and director of Immune Design Corp until
its sale to Merck. He previously served as president of Elan Corporation, a pharmaceutical corporation, which was acquired by Perrigo Company, from November 2008 to April 2011. Before joining Elan Corporation, Dr.&nbsp;Paya was at Eli
Lilly&nbsp;&amp; Company, a pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation, from September 2001 to November 2008, as vice president, Lilly Research Laboratories. From January 1991 to August 2001, Dr.&nbsp;Paya was professor of medicine, immunology, and
pathology, and vice dean of the clinical investigation program at the Mayo Clinic in Rochester, Minnesota. Dr.&nbsp;Paya holds M.D. and Ph.D. degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur, Paris,
France. Dr.&nbsp;Paya was selected to serve on our Board of Directors because of his experience in the life sciences industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_3"></A>CORPORATE GOVERNANCE AND BOARD MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are committed to exercising good corporate
governance practices. In furtherance of this commitment, we regularly monitor developments in the area of corporate governance and review our processes, policies and procedures in light of such developments. Key information regarding our corporate
governance initiatives can be found on the Investors&nbsp;&amp; Media section of our website, http://investors.vaxcyte.com, including our Corporate Governance Guidelines, our Code of Business Conduct and Ethics and the charters for our Audit,
Compensation and Nominating and Corporate Governance Committees. We believe that our corporate governance policies and practices, including the substantial percentage of independent directors on our Board of Directors, empower our independent
directors to effectively oversee our management&#151;including the performance of our Chief Executive Officer&#151;and provide an effective and appropriately balanced board governance structure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Independence of the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required under
the Nasdaq listing standards, a majority of the members of a listed company&#146;s board of directors must qualify as &#147;independent,&#148; as affirmatively determined by its board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has undertaken a review of the independence of each director. Based on information provided by each director concerning his or her
background, employment and affiliations, our Board of Directors has determined that Annie Drapeau, Kurt von Emster, Halley Gilbert, Peter Hirth, Michael Kamarck, Teri Loxam, Heath Lukatch, Carlos Paya and former directors Patrick Heron and Rob
Hopfner (who each resigned in September 2021) and Moncef Slaoui (who resigned in March 2021), do not have relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each
of these directors is &#147;independent&#148; as that term is defined under applicable Nasdaq listing standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our Board of Directors has
determined that each member of the Audit, Compensation and Nominating and Corporate Governance Committees meets the applicable Nasdaq and SEC rules and regulations regarding &#147;independence&#148; and that each member is free of any relationship
that would interfere with his or her individual exercise of independent judgment with regard to the Company. In making these determinations, our Board of Directors considered the current and prior relationships that each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director has with the Company and all other facts and circumstances our Board of Directors deemed relevant in determining their independence, including the beneficial ownership of our shares held by
each <FONT STYLE="white-space:nowrap">non-employee</FONT> director and the transactions described in the section entitled &#147;Certain Relationships and Related Person Transactions.&#148; Mr.&nbsp;Pickering is not considered independent because he
currently serves as our Chief Executive Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors is currently led by our Chairman, Carlos Paya. Our Board of Directors recognizes that it is important to determine an optimal board
leadership structure to ensure the independent oversight of management as the company continues to grow. We separate the roles of Chief Executive Officer and Chairman in recognition of the differences between the two roles. Our Chief Executive
Officer is responsible for setting the strategic direction for the Company and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> leadership and performance of the Company, while our chairman provides
guidance to our Chief Executive Officer and presides over meetings of the full Board of Directors. We believe that this separation of responsibilities provides a balanced approach to managing our Board of Directors and overseeing the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has concluded that our current leadership structure is appropriate at this time. However, our Board of Directors will continue to
periodically review our leadership structure and may make such changes in the future as it deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board of Directors in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has responsibility to oversee the Company&#146;s risk management processes. Our Board of Directors believes that risk management is an
important part of establishing, updating and executing on our business strategy. Our Board of Directors, as a whole and at the committee level, regularly discusses with management major risks that could affect the corporate strategy, business
objectives, compliance, operations and the financial condition and performance of the Company. Our Board of Directors focuses its oversight on the most significant risks facing the Company and on its processes to identify, prioritize, assess, manage
and mitigate those risks. Our Board of Directors and its committees receive regular reports from members of the Company&#146;s senior management on areas of material risk to the Company, including strategic, operational, financial, legal, regulatory
and reputational risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee is responsible for overseeing our financial reporting process on behalf of our Board of Directors. Our Audit
Committee oversees and monitors risk management and reviews with management and our independent registered public accounting firm, as appropriate, our significant risk exposures and the actions management has taken to limit, monitor or control such
exposures. Periodically, the Audit Committee reviews our policies, processes and controls with respect to risk assessment, risk management, loss prevention and regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee is responsible for overseeing our practices and policies regarding talent acquisition, retention, development and compensation as
they relate to risk management and risk-taking incentives to determine whether such policies and practices encourage excessive or inappropriate risk taking by employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee oversees the management of risks associated with our overall compliance and corporate governance practices
and the independence and composition of our Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While each committee is responsible for evaluating certain risks and overseeing the
management of such risks, the entire Board of Directors is regularly informed through committee reports about such risks. Matters of significant strategic risk are considered by our Board of Directors as a whole. While our Board of Directors and its
committees have an oversight role, management is principally tasked with direct responsibility for management and assessment of risks and the implementation of processes and controls to mitigate their effects on the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Meetings of the Board of Directors and its Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides
membership and meeting information for 2021 for the Board of Directors and each of its committees: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Audit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nominating<BR>and<BR>Corporate<BR>Governance</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total number of committee meetings during 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>4</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>5</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>2</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annie Drapeau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#10003;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kurt von Emster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Halley Gilbert</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">C</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Hirth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#10003;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Kamarck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teri Loxam</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heath Lukatch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carlos Paya</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chair</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Member</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors met five times during 2021. Each current director attended 75% or more of the
aggregate number of meetings of the Board of Directors and of the committees on which he or she served, held during the portion of 2021 for which he or she was a director or committee member. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Regarding the Demographics of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is a matrix containing the demographic composition of our Board of Directors as of April&nbsp;20, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Number of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Female</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Male</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part I: Gender Identity</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B></B>&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part II: Demographic Background</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">African American or Black</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alaskan Native or Native American</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hispanic or Latinx</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Native Hawaiian or Pacific Islander</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or More Races or Ethnicities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Did Not Disclose Demographic Background</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Regarding Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is a description of our Audit, Compensation Committee and Nominating and Corporate Governance Committees. The written charters of our committees are
available to stockholders on the Investors&nbsp;&amp; Media section of our website at http://investors.vaxcyte.com. Each of the committees has authority to engage legal counsel, consultants or other experts, as it deems appropriate to carry out its
responsibilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit
Committee currently consists of Kurt von Emster, Teri Loxam and Halley Gilbert, and effective upon the Annual Meeting, Michael Kamarck, each of whom our Board of Directors has determined satisfies the independence requirements under the Nasdaq
listing standards and Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Exchange Act. Effective upon the Annual Meeting, the chair of our Audit Committee will be Teri Loxam and Kurt von Emster will step off the Audit Committee. Our
Board of Directors has determined that Ms.&nbsp;Loxam is an &#147;audit committee financial expert&#148; within the meaning of SEC regulations. Kurt von Emster was the chair of our Audit Committee in 2021 and during 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of our Audit Committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these
determinations, our Board of Directors has examined each Audit Committee member&#146;s scope of experience and the nature of her or his employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
primary purpose of the Audit Committee is to discharge the responsibilities of our Board of Directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits, and to
oversee our independent registered public accounting firm. Specific responsibilities of our Audit Committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our Board of Directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as
the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent registered public accounting firm, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing with management and the independent registered public accounting firm the results of our annual audit
and reviewing any reports or other disclosure required by the applicable rules and regulations of the SEC to be included in our annual proxy statement and periodic reports; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our
critical accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and reviewing a report by the Company&#146;s independent registered public accounting firm at least
annually that describes our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing, at least annually, the performance of the Audit Committee and adequacy of its charter.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report of the Audit Committee of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December&nbsp;31, 2021 with management of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has discussed with Deloitte&nbsp;&amp; Touche, LLP, the Company&#146;s independent registered public accounting firm, the
matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (the &#147;PCAOB&#148;) and the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Audit Committee has also received the written disclosures and the letter from Deloitte&nbsp;&amp; Touche, LLP required by applicable requirements of the PCAOB regarding the independent registered public accounting firm&#146;s communications with the
Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the firm&#146;s independence. Based on the foregoing, the Audit Committee has recommended to the Board of Directors that the audited
financial statements be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This report of the Audit Committee is not &#147;soliciting material,&#148; shall not be deemed &#147;filed&#148; with the SEC and shall not be incorporated
by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and
irrespective of any general incorporation language in any such filing, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing report has been furnished by the Audit Committee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right">Respectfully submitted,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right">The Audit Committee of the Board of Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right">Kurt von Emster (Chairperson)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right">Halley Gilbert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right">Teri Loxam</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee currently consists of Heath Lukatch, Annie Drapeau and Peter Hirth. Effective upon the Annual Meeting, the chair of our Compensation
Committee will be Annie Drapeau. Heath Lukatch was the chair of our Compensation Committee in 2021 and during 2022. Our Board of Directors has determined that each member of the Compensation Committee is independent under the listing standards of
Nasdaq and a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary purpose of our Compensation Committee is to discharge the responsibilities of our Board of Directors in overseeing our compensation policies,
plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. Specific responsibilities of our Compensation Committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our Board of Directors the compensation of our Chief Executive Officer and other
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our Board of Directors the compensation of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans and other benefit programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, adopting, amending and terminating incentive compensation and equity-based plans, severance
agreements, profit sharing plans, bonus plans, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and any other compensatory arrangements for our executive officers and other senior
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing general policies relating to compensation and benefits of our employees, including our
overall compensation philosophy; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing, at least annually, the performance of the Compensation Committee and adequacy of its
charter. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the members of the Compensation Committee is currently or has been at any time one of our officers or employees. None of our executive officers
currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board of Directors or Compensation Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report of the Compensation Committee of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee has reviewed and discussed the section of this proxy statement titled &#147;Compensation Discussion and Analysis&#148; with
management. Based on such review and discussion, the Compensation Committee has recommended to the Board of Directors that the section titled &#147;Compensation Discussion and Analysis&#148; be included in this proxy statement and incorporated into
our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Respectfully submitted by the
members of the Compensation Committee of the Board of Directors: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Compensation Committee </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heath Lukatch (Chairperson) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Hirth </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annie Drapeau </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee consists of Halley Gilbert, Annie Drapeau and Peter Hirth. The chair of our Nominating and Corporate
Governance Committee is Halley Gilbert. Our Board of Directors has determined that each member of the Nominating and Corporate Governance Committee is independent under the applicable Nasdaq listing standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specific responsibilities of our Nominating and Corporate Governance Committee include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and
nominees recommended by stockholders, to serve on our Board of Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and making recommendations to our Board of Directors regarding the composition and chairmanship of
the committees of our Board of Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and making recommendations to our Board of Directors regarding corporate governance guidelines and
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing periodic evaluations of our Board of Directors&#146; performance, including committees of our Board of
Directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing, at least annually, the performance of the Nominating and Corporate Governance Committee
and adequacy of its charter. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Nomination Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Qualifications </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate
Governance Committee is responsible for reviewing with our Board of Directors, on an annual basis, the appropriate characteristics, skills and experience required for the Board of Directors as a whole and for its individual members. In evaluating
the suitability of individual candidates (both new candidates and current members), the Board of Directors will take into account many factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personal and professional integrity, ethics and values; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience relevant to our business industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience in corporate management, such as serving as an officer or former officer of a publicly-held company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience as a board member or executive officer of another publicly-held company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strong finance experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversity of expertise and experience in substantive matters pertaining to our business relative to other members
of our Board of Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place
of residence and specialized experience; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relevant academic expertise or other proficiency in an area of our business operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee also will consider such factors as the ability to offer advice and guidance to management, having sufficient
time to devote to the affairs of the Company, demonstrated excellence in his or her field, the ability to exercise sound business judgment and the commitment to rigorously represent the long-term interests of our stockholders. However, the
Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board of Directors and the long-term
interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other factors as it deems appropriate, given the current needs of the Board of Directors
and Vaxcyte, to maintain a balance of knowledge, experience and capability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Identification and Evaluation of Nominees for Director </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee identifies nominees for director by first evaluating for
<FONT STYLE="white-space:nowrap">re-nomination</FONT> the current members of our Board of Directors whose terms of office are set to expire and are willing to continue in service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of potential nominees, the Nominating and Corporate Governance Committee uses its network of
contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and
qualifications of possible candidates after considering the function and needs of the Board of Directors. The Nominating and Corporate Governance Committee interviews potential nominees and meets to discuss and consider the candidates&#146;
qualifications and then selects a nominee for recommendation to the Board of Directors by majority vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of incumbent directors whose terms
of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#146; service to Vaxcyte during their terms, including the number of meetings attended, level of participation, quality of performance and any
other relationships and transactions that might impair the directors&#146; independence, as well as the overall composition of the Board of Directors, balancing the value of continuity of service by existing members of our Board of Directors with
the value of obtaining new skill sets and expertise in light of the Company&#146;s recent transition from a private to a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of
all director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and
regulations and the advice of counsel, if necessary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Nominations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders. The Nominating and Corporate Governance
Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals
for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board of Directors may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee at the following
address: 825 Industrial Road, Suite 300, San Carlos, California 94070, Attn: Corporate Secretary. Submissions must include the full name of the proposed nominee, a description of the proposed nominee&#146;s business experience for at least the
previous five years, complete biographical information, a description of the proposed nominee&#146;s qualifications as a director and a representation that the nominating stockholder is a beneficial or record holder of our common stock. Any such
submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Communications with the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors believes that stockholders should have an opportunity to communicate with the Board of Directors, and efforts have been made to ensure
that the views of stockholders are heard by the Board of Directors or individual directors, as applicable, and that appropriate responses are provided to stockholders in a timely manner. Stockholders wishing to communicate with the Board of
Directors or an individual director may send a written communication to the Board of Directors or such director c/o Vaxcyte, Inc., 825 Industrial Road, Suite 300, San Carlos, California 94070, Attn: Corporate Secretary. The Corporate Secretary will
review each communication. The Corporate Secretary will forward such communication to the Board of Directors or to any individual director to whom the communication is addressed unless the communication contains advertisements or solicitations or is
unduly hostile, threatening or similarly inappropriate, in which case the Corporate Secretary shall discard the communication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business
Conduct and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Business Conduct and Ethics (the &#147;Code of Conduct&#148;), that applies to our directors, officers
and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. Our Code of Conduct is available under the Corporate Governance section of our
website at http://investors.vaxcyte.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the Code of Conduct.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prohibition Against Pledging and Hedging </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain an Insider Trading Policy that prohibits our officers, directors and employees from pledging our stock as collateral to secure loans and from
engaging in hedging transactions, including prepaid variable forwards, equity swaps, collars and exchange funds. It further prohibits margin purchases of our stock, short sales of our stock and any transactions in put options, call options or other
derivative securities involving our stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance Guidelines </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our Board of Directors commitment to enhancing stockholder value over the long term, our Board of Directors has adopted a set of Corporate
Governance Guidelines to provide the framework for the governance of the Company and to assist our Board of Directors in the exercise of its responsibilities. Our Corporate Governance Guidelines cover, among other topics, board composition and
selection, director independence, board membership criteria, committees of the Board of Directors, board and board committee assessments, board access to management and use of outside advisors and director orientation and education. The Corporate
Governance Guidelines, as well as the charters for each committee of the Board of Directors, may be viewed under the Corporate Governance section of our website at http://investors.vaxcyte.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_4"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation for 2021 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets
forth information regarding the compensation earned by or paid to our directors during the year ended December&nbsp;31, 2021, other than Grant E. Pickering, our Chief Executive Officer, who is also a member of our Board of Directors but did not
receive any additional compensation for service as a director. The compensation of Mr.&nbsp;Pickering as a named executive officer is set forth below in the subsection entitled &#147;&#151;Executive Compensation&#151;2021 Summary Compensation
Table.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid in Cash<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carlos Paya</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;457,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;469,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annie Drapeau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">529,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">543,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kurt von Emster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Halley Gilbert</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Hirth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Kamarck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">464,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teri Loxam</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">529,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">542,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heath Lukatch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Moncef Slaoui<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Newell<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rob Hopfner<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Heron<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the aggregate grant date fair value of stock options granted during fiscal year
2021 under our 2020 Equity Incentive Plan (the &#147;2020 Plan&#148;), computed in accordance with Financial Accounting Standard Board Accounting Standards Codification, Topic 718 (&#147;ASC Topic 718&#148;). The assumptions used in calculating the
grant date fair value of stock awards and stock options reported in this column are set forth in Note 10 to our financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2021. This amount may not reflect the actual economic value that may be realized by the <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The aggregate number of shares subject to stock options outstanding at December&nbsp;31, 2021 for each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director was as follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="32%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Options&nbsp;Outstanding<BR>at December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carlos Paya</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annie Drapeau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kurt von Emster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Halley Gilbert</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Hirth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Kamarck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teri Loxam</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heath Lukatch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Moncef Slaoui</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Newell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rob Hopfner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Slaoui resigned as a member of our Board of Directors on March&nbsp;24, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Newell did not stand for <FONT STYLE="white-space:nowrap">re-election</FONT> at the 2021 Annual
Meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On April&nbsp;1, 2021, our Board of Directors approved the acceleration of 13,333 options to purchase shares of
the Company&#146;s common stock in recognition that Mr.&nbsp;Newell would be stepping off the board on June&nbsp;2, 2021, nine days ahead of the June&nbsp;11, 2021 vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Heron resigned as a member of our Board of Directors on September&nbsp;16, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Hopfner resigned as a member of our Board of Directors on September&nbsp;16, 2021.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we reimburse all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in attending Board of Directors and committee meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person who is elected or
appointed as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director for the first time will automatically, upon the date of his or her initial election or appointment, receive a nonstatutory stock option to purchase 50,000 shares of our
common stock (the &#147;Initial Grant&#148;). The Initial Grant will vest over 36 months, 1/3 of which will vest on the anniversary date on which the <FONT STYLE="white-space:nowrap">non-employee</FONT> director was appointed to our Board of
Directors and 1/36 of which will vest monthly thereafter, subject to the director&#146;s continuous service to us through each such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the date of
each annual meeting of stockholders, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive a nonstatutory stock option to purchase 18,750 shares of our common stock (the &#147;Annual Option Grant&#148;) and 3,125 restricted
stock units (the &#147;Annual RSU Grant&#148; and together with the Annual Option Grant, the &#147;Annual Grant&#148;). The Annual Option Grant will vest monthly and fully vest on the earlier of the first anniversary of the grant date or the day
prior to the next annual meeting of stockholders and the Annual RSU Grant will fully vest on the earlier of the first anniversary of the grant date or the day prior to the next annual meeting of stockholders, subject to the director&#146;s
continuous service to us through each such date. Both the Initial Grant and the Annual Grant would become fully vested upon a change in control, subject to the director&#146;s continuous service to us through such date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director is entitled to receive the following cash compensation for services on our Board of Directors and its committees as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$40,000 annual cash retainer for service as a board member, or in lieu of such retainer, an annual cash retainer
of $70,000 for the chair of our Board of Directors, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$15,000 annual cash retainer for service as chair of the Audit Committee and $7,500 per year for service as a
member of the Audit Committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$10,000 annual cash retainer for service as chair of the Compensation Committee and $5,000 per year for service
as a member of the Compensation Committee; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$8,000 annual cash retainer for service as chair of the Nominating and Corporate Governance Committee and $4,000
per year for service as a member of the Nominating and Corporate Governance Committee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual cash compensation amounts are payable
in equal quarterly installments, in arrears no later than 30 days following the end of each quarter in which the service occurred, <FONT STYLE="white-space:nowrap">pro-rated</FONT> for any partial quarter of service. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will reimburse each eligible <FONT
STYLE="white-space:nowrap">non-employee</FONT> director for ordinary, necessary and reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses to cover
<FONT STYLE="white-space:nowrap">in-person</FONT> attendance at and participation in meetings of our Board of Directors and any committee of the board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL NO. 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_5"></A>APPROVAL, ON A <FONT STYLE="white-space:nowrap">NON-BINDING,</FONT> ADVISORY BASIS OF THE COMPENSATION OF OUR NAMED
EXECUTIVE OFFICERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the requirements of Section&nbsp;14A of the Exchange Act, we are providing our stockholders the opportunity to
vote to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation of our named executive officers (as disclosed under &#147;Executive Compensation&#151;Compensation Discussion and Analysis,&#148; the tables
included under the heading &#147;Executive Compensation&#148; and the accompanying narrative). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are encouraged to review the section titled
&#147;Executive Compensation&#148; and, in particular, the section titled &#147;Executive Compensation&#151;Compensation Discussion and Analysis&#148; in this proxy statement, which provide a comprehensive review of our executive compensation
program and its elements, objectives and rationale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vote on this resolution is not intended to address any specific element of compensation, rather
the vote relates to the compensation of our named executive officers in its totality, as described in this proxy statement in accordance with the compensation disclosure rules of the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Section&nbsp;14A of the Exchange Act rules, stockholders are asked to approve the following
<FONT STYLE="white-space:nowrap">non-binding</FONT> resolution: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the Company&#146;s stockholders hereby approve, on a <FONT
STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in the Company&#146;s proxy statement for the 2022 Annual Meeting of Stockholders, pursuant to the
compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the compensation tables and the accompanying narrative.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of this <FONT STYLE="white-space:nowrap">non-binding</FONT> proposal requires the affirmative vote of a majority of the voting power of the
shares of our common stock present at the meeting (by virtual attendance) or by proxy and entitled to vote thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since this proposal is an advisory
vote, the result will not be binding on our Board of Directors or our Compensation Committee. However, our Board of Directors values our stockholders&#146; opinions, and our Board of Directors and the Compensation Committee will take into account
the outcome of the advisory vote when considering future executive compensation decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE FOR
THE APPROVAL OF THE NON-BINDING RESOLUTION ON NAMED EXECUTIVE OFFICER COMPENSATION</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_6"></A>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information for our executive officers as of April&nbsp;11, 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Position</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew&nbsp;Guggenhime</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Wassil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Executive Vice President and Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Sauer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Senior Vice President, Process Development and Manufacturing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harp Dhaliwal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Senior Vice President, Commercial Manufacturing and Supply Chain</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mikhail Eydelman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Senior Vice President, General Counsel and Corporate Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Fairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vice President, Research</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant E. Pickering, M.B.A.</I></B> Mr.&nbsp;Pickering is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has
served as our Chief Executive Officer and as a member of our Board of Directors since November 2013. Mr.&nbsp;Pickering also served as our President from November 2013 until December 2020. From May 2013 to April 2015, Mr.&nbsp;Pickering served as
Strategic Advisor at Atreca, Inc., a biotechnology company. Prior to joining Vaxcyte, he was Chief Executive Officer of Mymetics Corporation, a developer of virosomal vaccines for infectious diseases. Prior to that, Mr.&nbsp;Pickering was an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Executive-in-Residence</FONT></FONT> at Kleiner Perkins, a venture capital firm, and Senior Vice President of Operations of Dendreon Corporation, a biopharmaceutical company. Since March
2008, Mr.&nbsp;Pickering has served as Chief Executive Officer of Juvaris BioTherapeutics, Inc., a biopharmaceutical company. Mr.&nbsp;Pickering has also served as a Director for Athira Pharma, Inc. since January 2022. Mr.&nbsp;Pickering holds a
B.S. in Marketing from Penn State University and an M.B.A. from Georgetown University. Mr.&nbsp;Pickering was selected to serve on our Board of Directors because of the perspective and experience he brings as our Chief Executive Officer and his
operating and management experience in the healthcare industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Andrew Guggenhime, M.B.A</I></B><B>.</B> Mr.&nbsp;Guggenhime has served as our
President since December 2020 and our Chief Financial Officer since May 2020. From April 2014 to May 2020, Mr.&nbsp;Guggenhime served as Chief Financial Officer at Dermira, Inc., a biopharmaceutical company, until its acquisition by Eli Lilly and
Company, and from April 2014 to May 2018, he also served as Chief Operating Officer at Dermira. From September 2011 to April 2014, Mr.&nbsp;Guggenhime served as Chief Financial Officer of CardioDx, Inc., a molecular diagnostics life sciences
company, and as a member of the CardioDx board of directors from April 2014 until July 2016. Prior to that, Mr.&nbsp;Guggenhime served as Chief Financial Officer at Calistoga Pharmaceuticals, Inc., a biotechnology company that was acquired by Gilead
Sciences, Inc. Mr.&nbsp;Guggenhime also previously served as Senior Vice President and Chief Financial Officer at Facet Biotech Corporation, a biotechnology company, Chief Financial Officer at PDL BioPharma, Inc. a biotechnology company, and Vice
President, Corporate Development and then Senior Vice President and Chief Financial Officer at Neoforma, Inc., a provider of supply-chain management solutions for the healthcare industry. Mr.&nbsp;Guggenhime currently serves on the board of
directors of Metacrine, Inc. and Caribou Biosciences, Inc., publicly traded biotechnology companies. Mr.&nbsp;Guggenhime holds a B.A. in International Politics and Economics from Middlebury College and an M.B.A. from the J.L. Kellogg Graduate School
of Management at Northwestern University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Jim Wassil, M.S., M.B.A.</I></B> Mr.&nbsp;Wassil has served as our Chief Operating Officer since December
2019 and as Executive Vice President since March 2022. From May 2015 to December 2019, Mr.&nbsp;Wassil served as Vice President and Global Health and Value Business Unit Lead, Vaccines at Pfizer Inc., a multinational pharmaceutical company. From
August 2008 to May 2015, Mr.&nbsp;Wassil served as Head, Global Product Development Meningococcal Vaccines and Head, U.S. Marketing for Meningococcal Vaccines at Novartis AG, a multinational pharmaceutical company. Prior to joining Novartis,
Mr.&nbsp;Wassil served as Senior Director, International Marketing at Merck&nbsp;&amp; Co., Inc., a multinational pharmaceutical company. Mr.&nbsp;Wassil is a member of the Infectious Diseases Society of America. Mr.&nbsp;Wassil holds a B.S. in
Chemistry/Biology from the University of Notre Dame and a M.S. in BioOrganic Chemistry and an M.B.A. from Lehigh University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Paul Sauer, M.B.A.</I></B> Mr.&nbsp;Sauer has served as our Senior Vice President, Process Development
and Manufacturing since April 2016. From January 2015 to March 2016, Mr.&nbsp;Sauer served as a Principal at Sauer Biotech Consulting, a development and manufacturing consulting services firm. From July 2011 to December 2014, Mr.&nbsp;Sauer served
as Vice President, Process Sciences and Manufacturing at Igenica Biotherapeutics, Inc., a biotechnology company. Mr.&nbsp;Sauer holds a B.S. in Genetics and a B.A. in Psychology from the University of California, Davis and an M.B.A. from Santa Clara
University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Harp Dhaliwal, M.B.A.</I></B> Mr.&nbsp;Dhaliwal has served as Vaxcyte&#146;s Senior Vice President of Commercial Manufacturing and
Supply Chain. From January 2018 to July 2021, Mr.&nbsp;Dhaliwal served as Senior Vice President of Supply Chain, Manufacturing and Procurement at Dermira and transitioned to Eli Lilly following the company&#146;s acquisition. From September 2014 to
September 2016, Mr.&nbsp;Dhaliwal was the Head of Manufacturing and Supply Chain at Medivation, an oncology-focused company. Following Pfizer&#146;s acquisition of Medivation in September 2016, Mr.&nbsp;Dhaliwal led the operations integration.
Mr.&nbsp;Dhaliwal has an M.B.A. in Science and Technology from Queen&#146;s University and a Bachelor of Chemical Engineering from the University of British Columbia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mikhail Eydelman, J.D. </I></B>Mr.&nbsp;Eydelman has served as our Senior Vice President, General Counsel and Corporate Secretary since April 2022. From
2017 to April 2022, Mr.&nbsp;Eydelman served as General Counsel and Board Secretary at Sagent Pharmaceuticals, Inc., a U.S. subsidiary of a publicly-traded Japanese pharmaceutical company. From 2016 to 2017, Mr.&nbsp;Eydelman served as Assistant
General Counsel at Integrated DNA Technologies., a supplier of custom nucleic acids acquired by Danaher Corporation. From 2012 to 2016, Mr.&nbsp;Eydelman served in roles of increasing responsibility at Akorn, Inc., a publicly-traded specialty
pharmaceutical company. Mr.&nbsp;Eydelman has also served as an attorney at the law firms Latham&nbsp;&amp; Watkins, Allen&nbsp;&amp; Overy and Bryan Cave. Mr.&nbsp;Eydelman holds a B.A. in Economics from Brandeis University and a J.D. from New York
University School of Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Jeff Fairman, Ph.D.</I></B> Dr.&nbsp;Fairman is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as
our Vice President, Research since December 2013. From July 2011 to December 2013, Dr.&nbsp;Fairman served as Vice President, Research at Colby Pharmaceuticals, a biopharmaceutical company. Dr.&nbsp;Fairman also founded Juvaris BioTherapeutics,
Inc., a biopharmaceutical company, and served as its Vice President, Research from February 2002 to September 2011. Dr.&nbsp;Fairman is a member of the American Association of Immunologists and the Infectious Diseases Society of America.
Dr.&nbsp;Fairman holds a B.S. in Chemistry from Northwest Missouri State University and a Ph.D. in Chemistry from the University of Arkansas. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_7"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Discussion and Analysis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We became a public company in June 2020, and we ceased to be an emerging growth company as of December&nbsp;31, 2021. This proxy statement, therefore,
includes detail regarding executive compensation that would not have been required had we continued to be an emerging growth company, including (i)&nbsp;this Compensation Discussion and Analysis, (ii)&nbsp;the additional compensation tables titled
&#147;Grants of Plan-Based Awards,&#148; &#147;Option Exercises and Stock Vested,&#148; and &#147;Potential Payments upon Termination or Change in Control,&#148; and (iii)&nbsp;advisory votes on the compensation of our named executive officers and
the preferred frequency of future advisory votes on the compensation of our named executive officers, which are included as Proposals 2 and 3 in this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Compensation Discussion and Analysis section discusses our executive compensation policies and how and why our Compensation Committee arrived at specific
compensation decisions for the year ended December&nbsp;31, 2021 for the individuals who served as our principal executive officer and principal financial officer and our three other most highly-compensated executive officers as of December&nbsp;31,
2021, collectively referred to as our &#147;named executive officers&#148;: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Position(s)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Grant E. Pickering</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Chief Executive Officer and <FONT STYLE="white-space:nowrap">Co-Founder</FONT></I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Andrew Guggenhime</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>President and Chief Financial Officer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Jim Wassil</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Executive Vice President and Chief Operating Officer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Harpreet Dhaliwal</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Senior Vice President, Commercial Manufacturing and Supply Chain</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Paul Sauer</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Senior Vice President, Process Development and Manufacturing</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Highlights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Business </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage vaccine innovation
company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are <FONT
STYLE="white-space:nowrap">re-engineering</FONT> the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro
Biopharma, Inc. Unlike conventional cell-based approaches, our system for producing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-make</FONT></FONT> proteins and antigens is intended to accelerate our ability to
efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Our pipeline includes pneumococcal conjugate vaccine, or PCV, candidates that we believe are among the most broad-spectrum PCV candidates currently in
development, targeting the approximately $7&nbsp;billion global pneumococcal vaccine market. Our lead vaccine candidate, <FONT STYLE="white-space:nowrap">VAX-24,</FONT> is a <FONT STYLE="white-space:nowrap">24-valent,</FONT> broad-spectrum
investigational PCV being developed for the prevention of invasive pneumococcal disease, or IPD, and pneumonia. On January&nbsp;6, 2022, we announced that the U.S. Food and Drug Administration, or FDA, cleared our investigational new drug, or IND,
application for <FONT STYLE="white-space:nowrap">VAX-24.</FONT> On February&nbsp;23, 2022, we announced the initiation of our Phase 1/2 clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study
in adults aged 18 to 64. On April 4, 2022, we announced the dosing of the first participants in the Phase 2 portion of this study. We expect to announce topline safety, tolerability and immunogenicity results from this study by the end of 2022. We
expect to begin enrollment in a separate Phase 2 study in healthy adults aged 65 and older and to announce topline safety, tolerability and immunogenicity results from this Phase 2 study in the first half of 2023. We also anticipate submitting our
first <FONT STYLE="white-space:nowrap">VAX-24</FONT> pediatric IND application to the FDA in the first half of 2023, subject to a <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA and successful topline results from the <FONT
STYLE="white-space:nowrap">VAX-24</FONT> Phase 1/2 study in adults aged 18 to 64. Our second PCV candidate, <FONT STYLE="white-space:nowrap">VAX-XP,</FONT> leverages our scalable and modular platform and builds on the technical proof of concept
established by <FONT STYLE="white-space:nowrap">VAX-24</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition to our PCV franchise, we are developing a
novel conjugate vaccine candidate for Group A Strep and a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2021, key developments affecting our business include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Completed the Manufacture of <FONT STYLE="white-space:nowrap">VAX-24</FONT> Drug Product:</B> In the fourth
quarter of 2021, we completed all steps in the manufacturing process, including formulation, fill and finish, along with the testing and release, for the <FONT STYLE="white-space:nowrap">VAX-24</FONT> drug product. This achievement led to the
submission of the <FONT STYLE="white-space:nowrap">VAX-24</FONT> IND application to the FDA before the end of 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Dosed First Participants in <FONT STYLE="white-space:nowrap">VAX-24</FONT> Phase 1/2 Clinical Study:</B>
Following the early January 2022 clearance of the <FONT STYLE="white-space:nowrap">VAX-24</FONT> IND application, we initiated the Phase 1/2 clinical study of <FONT STYLE="white-space:nowrap">VAX-24,</FONT> a
<FONT STYLE="white-space:nowrap">24-valent</FONT> PCV candidate designed to prevent IPD and pneumonia in adults. The <FONT STYLE="white-space:nowrap">VAX-24</FONT> clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study is a randomized, observer-blind, dose-finding, controlled study designed to evaluate the safety, tolerability and immunogenicity of <FONT
STYLE="white-space:nowrap">VAX-24</FONT> in healthy adults. The Phase 1 portion of the study is evaluating the safety and tolerability of a single injection of <FONT STYLE="white-space:nowrap">VAX-24</FONT> at three dose levels and compared to
Prevnar 20 in approximately 64 healthy adults 18 to 49 years of age. In April 2022, we dosed the first participants in the Phase 2 portion of the ongoing Phase 1/2 clinical study of <FONT STYLE="white-space:nowrap">VAX-24.</FONT> The Phase 2 portion
will evaluate the safety, tolerability and immunogenicity of a single injection of <FONT STYLE="white-space:nowrap">VAX-24</FONT> at three dose levels and compared to Prevnar 20 in approximately 800 healthy adults 50 to 64 years of age. The
prespecified immunogenicity endpoints of the Phase 2 portion of the study include an assessment of the induction of antibody responses, using immunoglobulin G (IgG) and opsonophagocytic activity (OPA), at each of the
<FONT STYLE="white-space:nowrap">VAX-24</FONT> doses and compared to Prevnar 20 and, for the additional four serotypes contained in <FONT STYLE="white-space:nowrap">VAX-24</FONT> and Pneumovax 23 but not in Prevnar 20, the four-fold rise in antibody
titers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Completed Successful $115 Million <FONT STYLE="white-space:nowrap">Follow-On</FONT> Financing:</B> In the
first quarter of 2022, we completed an underwritten public offering of 3,250,000 shares of our common stock, which included the full exercise of the underwriters&#146; option to purchase additional shares, and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 2,500,000 shares of common stock. The shares of common stock were sold at a public offering price of $20.00 per share, and the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants were sold at a public offering price of $19.999 per underlying share. The aggregate gross proceeds to us from the offering were $115.0&nbsp;million, before deducting underwriting discounts and commissions and other estimated offering
expenses payable by us, and excluding the exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advanced and Presented Preclinical Data for <FONT STYLE="white-space:nowrap">VAX-XP</FONT> Program:</B> We
have continued to advance <FONT STYLE="white-space:nowrap">VAX-XP,</FONT> our PCV candidate with an expanded breadth of coverage of greater than 30 strains. During IDWeek 2021, we presented findings from a preclinical study that evaluated the
immunogenicity of <FONT STYLE="white-space:nowrap">VAX-XP,</FONT> which showed <FONT STYLE="white-space:nowrap">VAX-XP</FONT> exhibited conjugate-like immune responses for all 31 serotypes, as demonstrated by IgG immune responses 14 days after both
an initial and booster dose that were superior to polysaccharide-based vaccines and comparable to Prevnar 13. Additionally, all serotypes in <FONT STYLE="white-space:nowrap">VAX-XP</FONT> elicited a <FONT STYLE="white-space:nowrap">T-cell</FONT>
dependent immune response as demonstrated by the increase in IgG titers post-boost. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiated <FONT STYLE="white-space:nowrap">VAX-A1</FONT> <FONT STYLE="white-space:nowrap">IND-Enabling</FONT>
Activities:</B> We continue to advance development of <FONT STYLE="white-space:nowrap">VAX-A1,</FONT> a novel conjugate vaccine designed to prevent infections caused by Group A Streptococcus, or Strep, bacteria. Following the nomination of our final
<FONT STYLE="white-space:nowrap">VAX-A1</FONT> vaccine candidate in the first quarter of 2021, we initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the second half of 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strengthened Leadership Team and Board of Directors with Key Appointments:</B> During 2021, we added several
key leaders to our executive team and Board of Directors. In October 2021, Harp Dhaliwal joined as Senior Vice President of Commercial Manufacturing and Supply Chain, and we appointed Dr.&nbsp;Carlos Paya, who serves as the Board Chair, and
Dr.&nbsp;Michael Kamarck to our Board of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Directors. This followed the September 2021 board appointments of Annie Drapeau and Teri Loxam. In April 2022, Mikhail Eydelman joined as Senior Vice President, General Counsel and Corporate
Secretary. These accomplished industry leaders have deep experience across the biopharmaceutical and vaccine industries and will provide additional skills and expertise as we advance and scale our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The important features of our
executive compensation program include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>What we do</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>What we do not do</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Our Compensation Committee consists solely of independent members of our Board
of Directors.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Our
Compensation Committee has retained an independent third-party compensation consultant for guidance in making compensation decisions.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;A significant portion of our named executive officers&#146; compensation is variable, <FONT
STYLE="white-space:nowrap">at-risk</FONT> and tied directly to our measurable performance.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Our annual performance-based bonus opportunities for all of our named executive officers are
dependent upon our achievement of annual corporate objectives established each year.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Equity awards with multi-year vesting periods are an integral part of our executive compensation
program, and comprise the primary <FONT STYLE="white-space:nowrap">at-risk</FONT> portion of our named executive officer compensation package.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;We prohibit hedging and pledging of Vaxcyte stock.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;We do not provide
single-trigger vesting acceleration upon a change in control.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;We do not provide our executive officers with any excise tax
<FONT STYLE="white-space:nowrap">gross-ups</FONT> or other material perquisites.</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Objectives, Philosophy and Elements of Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation program aims to achieve the following main objectives: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, retain and reward highly-qualified executives who have the skills and leadership necessary to grow our
business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide incentives that motivate and reward for achievement of our key performance goals; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">align our executives&#146; interests with those of our stockholders by linking their long-term incentive
compensation opportunities to stockholder value creation and their cash incentives to our annual performance. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive
compensation program generally consists of the following three principal components: base salary, performance-based cash bonus and long-term equity incentive compensation. We also provide our executive officers with benefits available to all our
employees, including retirement benefits under Vaxcyte&#146;s 401(k) plan and participation in employee benefit plans. The below chart summarizes the three main elements of our executive compensation, their objectives and key features. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Element</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Objectives</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Key Features</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Base Salary</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(fixed cash)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Provides stable income for performing job responsibilities.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Attracts
highly-qualified executives.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Reviewed annually and determined by the Compensation Committee based on
a number of factors (including company and individual performance) and by reference, in part, to market data obtained from our independent compensation consultant.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Performance-Based Cash Bonus</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">(at-risk</FONT> cash)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Motivates and rewards for contributing to our key business
objectives.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Aligns
management and stockholder interests by linking pay to performance.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Target amounts reviewed annually and determined by the Compensation
Committee based upon positions that have similar impact on the organization and competitive bonus opportunities in our market.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Bonus opportunities are dependent upon achievement of specific corporate performance
objectives consistent with our long-term strategic plan, determined by the Compensation Committee and communicated at the beginning of the year.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-Term Equity Incentive</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">(at-risk</FONT> equity)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Motivates and rewards for long-term company performance.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Aligns management and
stockholder interests by linking pay to performance.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Attracts highly-qualified executives and encourages their continued employment over the
long-term.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Equity opportunities are reviewed annually and granted during the first
half of the year.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Individual awards are determined based on a number of factors, including current corporate
and individual performance and market data obtained from our independent compensation consultant.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We focus on providing a competitive compensation package to our executive officers that provides significant short and
long-term incentives for the achievement of measurable corporate objectives. We believe that this approach provides an appropriate blend of short-term and long-term incentives to maximize stockholder value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any formal policies for allocating compensation among salary, performance bonus awards and equity grants, short-term and long-term compensation
or among cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation. Instead, the Compensation Committee uses its judgment to establish a total compensation program for each named executive officer that is a mix of current, short-term
and long-term incentive compensation, and cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation, that it believes appropriate to achieve the goals of our executive compensation program and our corporate objectives. However,
historically we have structured a significant portion of the named executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officers&#146; total target compensation so that it is comprised of performance-based bonus opportunities and long-term equity awards in order to align the executive officers&#146; incentives
with the interests of our stockholders and our corporate goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How We Determine Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Role of our Compensation Committee, Management and the Board </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee is appointed by our Board of Directors and helps our Board of Directors oversee our compensation policies, plans and programs with
the goal of attracting, incentivizing, retaining and rewarding top- quality executive management and employees. The Compensation Committee is responsible for reviewing and determining all compensation paid to our executive officers, including our
named executive officers, and also reviews our compensation practices and policies as they relate to risk management and risk-taking incentives. Our Compensation Committee consists solely of independent members of the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee meets periodically throughout the year to manage and evaluate our executive compensation program, and generally determines the
principal components of compensation (base salary, performance bonus and equity awards) for our executive officers on an annual basis; however, decisions may occur at other times for new hires, promotions or other special circumstances as our
Compensation Committee determines appropriate. The Compensation Committee does not delegate authority to approve executive officer compensation. The Compensation Committee does not maintain a formal policy regarding the timing of equity awards to
our executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In fulfilling its responsibilities, the Compensation Committee considers input from an independent compensation consultant and,
as appropriate, management. The Chief Executive Officer evaluates and provides to the Compensation Committee performance assessments and compensation recommendations. While the Chief Executive Officer discusses his recommendations with the
Compensation Committee, he does not participate in the deliberations concerning, or the determination of, his own performance and compensation. The Compensation Committee discusses and makes final determinations with respect to executive
compensation matters without the Chief Executive Officer present during discussions of the Chief Executive Officer&#146;s compensation. From time to time, various other members of management and other employees as well as outside advisors or
consultants may be invited by the Compensation Committee to make presentations, provide financial or other background information or advice or otherwise participate in the Compensation Committee meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Role of Compensation Consultant </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation
Committee has the sole authority to retain compensation consultants to assist in its evaluation of executive compensation, including the authority to approve the consultant&#146;s reasonable fees and other retention terms. The Compensation Committee
retained Radford (Aon plc) as its independent compensation consultant for 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Radford&#146;s engagement included: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compiling a group of peer companies to use as a reference in making executive compensation decisions, evaluating
current executive pay practices and considering different compensation programs to aid making executive pay decisions for 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting market research and analysis to assist the Compensation Committee in developing executive compensation
levels, including appropriate salaries, target bonus amounts and equity awards for our executives, including the named executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing market and peer group equity usage metrics to assist with understanding of our equity budget relative
to market; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting a review of our director compensation policies and practices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee has analyzed whether the work of Radford as compensation consultant raises any conflict of interest, taking into account relevant
factors in accordance with SEC guidelines. Based on its analysis, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Compensation Committee determined that the work of Radford and the individual compensation advisors employed by Radford does not create any conflict of interest pursuant to the SEC rules and
stock exchange listing standards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Competitive Market Compensation Data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee believes that it is important when making its compensation decisions to be informed as to the current practices of comparable public
companies with which we compete for top talent. To this end, the Compensation Committee directed its independent compensation consultant to develop a proposed peer group list of the publicly-traded companies to be used in connection with assessing
our compensation practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The independent compensation consultant proposed, and the Compensation Committee approved, a group of public companies that
are reasonably comparable to Vaxcyte in terms of industry and financial characteristics to provide management and the Compensation Committee with relevant compensation information to support compensation decision-making. The executive compensation
peer group was intended to reflect companies with executive positions of similar scope and complexity to Vaxcyte. In determining the peer group, the independent compensation consultant considered companies that were (i)&nbsp;U.S.-headquartered in a
biotech &#147;hub&#148; location; <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-clinical</FONT> and early clinical-stage with an emphasis on vaccines/immunotherapy; (iii) 0.3x to 3x Vaxcyte&#146;s then-current
<FONT STYLE="white-space:nowrap">30-day</FONT> valuation of $1.3&nbsp;billion; and (iv)&nbsp;less than 200 employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The independent compensation
consultant also considered several secondary factors, including whether a potential peer company had recently completed an initial public offering. The peer group with respect to 2021 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Akero Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Editas Medicine</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nurix Therapeutics</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alector</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gossamer Bio</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ORIC Pharmaceuticals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aligos Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IDEAYA Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Poseida Therapeutics</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Allakos</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IGM Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stoke Therapeutics</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Allogene Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Immunovant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Turning Point Therapeutics</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annexon</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Karuna Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Y-mAbs Therapeutics</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arcus Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mersana Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Avidity Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">NGM Biopharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cortexyme</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nkarta</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee reviews our peer group at least annually and makes adjustments to its composition, if warranted,
taking into account changes in both our business and the businesses of the companies in the peer group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using data compiled from the peer companies, the
independent compensation consultant completed an assessment of our executive compensation to inform the Compensation Committee&#146;s determinations regarding executive compensation for 2021. The independent compensation consultant prepared, and the
Compensation Committee reviewed, a range of market data reference points (generally at the 25th, 50th and 75th percentiles of the market data) with respect to base salary, performance bonuses, equity compensation (valued based both on an </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">approximation of grant date fair value and as well as ownership percentage), total target cash compensation (base salary and the annual target performance
bonus) and total direct compensation (total target cash compensation and equity compensation) with respect to each of the named executive officers. The Compensation Committee generally targeted between the 50<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of the market data and reviewed these market data reference points as a helpful reference point in making 2021 compensation
decisions. Market data is only one of the factors that the Compensation Committee considers in making compensation decisions. The Compensation Committee considers other factors as described below under &#147;Factors Used in Determining Executive
Compensation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Factors Used in Determining Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee sets the compensation of our named executive officers at levels determined to be competitive and appropriate for each named
executive officer, using their professional experience and judgment. Pay decisions are not made by use of a formulaic approach or benchmark; the Compensation Committee believes that executive pay decisions require consideration of a multitude of
relevant factors which may vary from year to year. In making executive compensation decisions, the Compensation Committee generally takes into consideration the factors listed below. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Company and individual performance </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Existing business needs and criticality for future business needs and performance </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Scope of job function and skill set </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Relative pay among our executive officers </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Need to attract new talent and retain existing talent in a highly-competitive industry </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Value of existing equity holdings, including the potential value of unvested equity awards </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Range of market data reference points, as described above under &#147;Use of Competitive Market Compensation
Data&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recommendations from the independent compensation consultant </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2021 Executive Compensation Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salary
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Base salary represents the fixed portion of the compensation of our executive officers, and is an important element of compensation intended to
attract and retain highly-talented individuals. In February 2021, the Compensation Committee reviewed the base salaries of our executive officers, taking into consideration the competitive market analysis prepared by its compensation consultant and
the recommendations of our Chief Executive Officer, as well as the other factors described in the section above. Following this review, the Compensation Committee approved base salary increases for our executive officers, including our Chief
Executive Officer, effective January&nbsp;1, 2021, to bring their base salaries to levels that were more aligned to the range of those of similarly-situated executives at the companies in our peer group. The base salaries approved for our executive
officers, effective as of January&nbsp;1, 2021, were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>Base Salary</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$574,800,&nbsp;increased&nbsp;from&nbsp;$515,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Guggenhime</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$472,400,&nbsp;increased&nbsp;from&nbsp;$415,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Wassil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$451,800,&nbsp;increased&nbsp;from&nbsp;$385,400</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Dhaliwal<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$375,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Sauer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$375,000,&nbsp;increased&nbsp;from&nbsp;$310,500</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Dhaliwal commenced his employment on October&nbsp;1, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Performance-Based Cash Bonus </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our annual
performance-based cash bonus awards provide incentive compensation that is specifically designed to motivate our executive officers to achieve <FONT STYLE="white-space:nowrap">pre-established,</FONT> company-wide priorities set by the Compensation
Committee and to reward them for results and achievements in a given year. The annual target bonus opportunities for our named executive officers are generally determined by the Compensation Committee in the first quarter of each year and expressed
as a percentage of each individual&#146;s annual base salary, with a potential cash bonus opportunity. The target bonus opportunities approved for and amounts earned by our executive officers for 2021 were as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Target&nbsp;Bonus&nbsp;Opportunity<BR>(% of Base Salary)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target&nbsp;Bonus<BR>Opportunity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual&nbsp;Bonus<BR>Earned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">55%,&nbsp;increased&nbsp;from&nbsp;50%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">363,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Guggenhime</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>45%,&nbsp;increased&nbsp;from&nbsp;40%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Wassil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>40%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Dhaliwal<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>35%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,813</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,734</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Sauer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>35%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Dhaliwal commenced his employment on October&nbsp;1, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Dhaliwal&#146;s target bonus opportunity and actual bonus earned for 2021 were <FONT
STYLE="white-space:nowrap">pro-rated</FONT> based on his employment commencement date of October&nbsp;1, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Executive Bonus Goal
Setting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee approved the performance metrics for 2021 performance-based cash bonus awards in the first quarter of fiscal year
2021. The targets against which performance is measured are generated through our annual budget and strategic planning process, which was reviewed with our Board of Directors and finalized in the first quarter of fiscal year 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate goals for 2021 on which our named executive officer performance bonuses were based included base corporate goals relating to the achievement of:
(i) objectives in support of our <FONT STYLE="white-space:nowrap">VAX-24</FONT> program (total weighting of 70%), including the submission of the IND application to the FDA, the establishment of compliance procedures to support the IND application
submission, the initiation of clinical studies, and development and manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> and readiness activities to support a potential Phase 3 program; (ii)&nbsp;objectives in support of our pipeline
programs (total weighting of 10%), including activities to support IND application submissions for our <FONT STYLE="white-space:nowrap">VAX-XP</FONT> and <FONT STYLE="white-space:nowrap">VAX-A1</FONT> programs, the nomination of the final vaccine
candidate for our <FONT STYLE="white-space:nowrap">VAX-PG</FONT> program, and publishing research related to our pipeline in scientific journals; and (iii) financial and corporate objectives (total weighting of 20%), including successful
capital-raising activities, managing to the annual budget approved by our board of directors and scaling our organization and enhancing organizational effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 corporate goals also included stretch goals relating to the achievement of: (i) the <FONT STYLE="white-space:nowrap">VAX-24</FONT> IND application
submission, initial clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study initiation and manufacturing deliverables under accelerated timelines (total weighting of up to 25%); (ii) certain
pipeline program goals regarding the outcome of the <FONT STYLE="white-space:nowrap">VAX-XP</FONT> preclinical study and the publication of data regarding our programs and technology platform (total weighting of up to 7.5%); and (iii) a higher
capital-raising goal (total weighting of up to 7.5%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee and Board of Directors considered the immense progress made on the
objectives, such as submission of the IND and the $115&nbsp;million equity financing, in spite of issues related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and factors outside the control of management such as market conditions. In light of
these circumstances, the Compensation Committee recommended and the Board of Directors determined to approve a bonus payout of 115% of target for each of our named executive officers who were serving through the end of 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fiscal Year 2021 Bonus Payouts </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2022,
achievement of the corporate performance goals for fiscal year 2021 for the named executive officers was determined to be 115% of target based on the overall achievement of the corporate performance goals as described above. The amount of the
aggregate bonus that was paid with respect to fiscal year 2021 was determined in strict accordance with the terms of the annual bonus program based on performance, with no discretionary supplemental bonus paid to any named executive officer.
Mr.&nbsp;Dhaliwal&#146;s bonus payment was prorated for the period of time he was employed with us in 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We view long-term incentive compensation in the form of equity awards as a critical element of our executive compensation program. The realized value of these
equity awards bears a direct relationship to our stock price, and, therefore, these awards are an incentive for our executive officers to create value for our stockholders. Equity awards also help us retain qualified executive officers in a
competitive market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term incentive compensation opportunities in the form of equity awards are granted to our Chief Executive Officer and our other
executive officers by the Compensation Committee. As with other elements of compensation, the Compensation Committee determines the amount of long-term incentive compensation for our executive officers as part of its annual compensation review and
after taking into consideration the individual officer&#146;s responsibilities and performance and existing equity retention profiles, our total annual projected equity budget and the other factors described in &#147;Factors Used in Determining
Executive Compensation&#148; above. For awards to executive officers other than the Chief Executive Officer, the Compensation Committee also takes into account the recommendations of the Chief Executive Officer with respect to appropriate grants and
any particular individual circumstances. The amounts of the equity awards are intended to provide <FONT STYLE="white-space:nowrap">competitively-sized</FONT> awards and resulting target total direct compensation opportunities that the Compensation
Committee believes are reasonable and appropriate taking into consideration the factors described herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Equity Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2021, the Compensation Committee approved the following annual stock option grants for our named executive officers serving at such time, which
were granted in April 2021. These stock options vest monthly over a four-year period and have an exercise price of $20.93 per share: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Option<BR>Grant&nbsp;(#&nbsp;shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Guggenhime</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Wassil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Dhaliwal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Sauer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Dhaliwal&#146;s stock option grant in the table above was approved by the Compensation Committee in November 2021
following commencement of his employment in October 2021. These options vest 25% on the first anniversary of his start date and equal monthly installments over the following three years and have an exercise price of $25.06. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment, Severance and Change in Control Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into
employment agreements or offer letters with each of our named executive officers. We designed these agreements to be part of a competitive compensation package and to keep our named executive officers focused on our business goals and objectives.
These agreements or offer letters provide for base salaries and incentive compensation, and each component reflects the scope of each named executive officer&#146;s anticipated responsibilities and the individual experience they bring to the
Company. Each named executive officer is also eligible to participate in our employee benefit plans on the same terms as other regular, full-time employees. In addition, each of our named executive officers has executed our standard proprietary
information and invention assignment agreement. The key terms of the offer letters or employment agreements are described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant E. Pickering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an employment agreement with Mr.&nbsp;Pickering, our Chief Executive Officer, dated January&nbsp;21, 2016, which sets forth the initial terms
and conditions of his employment with us. Mr.&nbsp;Pickering&#146;s employment is at will and may be terminated at any time, with or without cause. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Andrew Guggenhime </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an offer letter
with Mr.&nbsp;Guggenhime, our President and Chief Financial Officer on April&nbsp;17, 2020, which sets forth the initial terms and conditions of his employment with us. Mr.&nbsp;Guggenhime&#146;s employment is at will and may be terminated at any
time, with or without cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Jim Wassil </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
entered into an offer letter with Mr.&nbsp;Wassil, our Executive Vice President and Chief Operating Officer, dated November&nbsp;15, 2019, which sets forth the initial terms and conditions of his employment with us. Mr.&nbsp;Wassil&#146;s employment
is at will and may be terminated at any time, with or without cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Harpreet Dhaliwal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an offer letter with Mr.&nbsp;Dhaliwal, our Senior Vice President, Commercial Manufacturing and Supply Chain, dated September&nbsp;29, 2021,
which sets forth the initial terms and conditions of his employment with us. Mr.&nbsp;Dhaliwal&#146;s employment is at will and may be terminated at any time, with or without cause. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Paul Sauer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an offer letter with
Mr.&nbsp;Sauer, our Senior Vice President, Process Development and Manufacturing, dated April&nbsp;12, 2016, which sets forth the initial terms and conditions of his employment with us. Mr.&nbsp;Sauer&#146;s employment is at will and may be
terminated at any time, with or without cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Change in Control and Severance Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into Executive Change in Control and Severance Agreements with each of our named executive officers. The agreements provide for severance
benefits upon a termination of employment by the Company without &#147;cause&#148; or by the executive for &#147;good reason,&#148; each as defined in the agreements, each of which we refer to as a qualifying termination. The severance benefits vary
depending on whether the qualifying termination occurs during the period three months prior to and 12 months after a &#147;change in control,&#148; as defined in the agreements, which we refer to as the change in control period, or at a time other
than during the change in control period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a qualifying termination other than during the change in control period, the executive will
receive a lump sum severance payment equal to the sum of (i)&nbsp;a number of months of base salary (12 months in the case of Mr.&nbsp;Pickering, nine months in the case of Messrs. Guggenhime and Wassil, six months in the case of Messrs. Dhaliwal
and Sauer), (ii) a pro rata target bonus for the year of termination and (iii)&nbsp;any bonus earned but not yet paid with respect to the year preceding the qualifying termination. The executive will also receive payment of COBRA premiums for the
number of months in the severance period. Receipt of severance benefits is contingent upon the executive entering into a release of claims and allowing it to become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a qualifying termination during the change in control period, the executive will receive a lump sum severance payment equal to the sum of
(i)&nbsp;a number of months of base salary (18 months in the case of Mr.&nbsp;Pickering, 12 months in the case of Messrs. Guggenhime and Wassil, and nine months in the case of Messrs. Dhaliwal and Sauer), (ii) a multiple of the executive&#146;s
target bonus for the year of termination (150% in the case </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Mr.&nbsp;Pickering, 100% in the case of Messrs. Guggenhime and Wassil, and 75% in the case of Messrs. Dhaliwal and Sauer) and (iii)&nbsp;any bonus earned but not yet paid with respect to the
year preceding the qualifying termination. The executive will also receive payment of COBRA premiums for the number of months in the severance period and full vesting of all time-based equity awards. The vesting of performance-based equity awards
will be based on the provisions of such awards, and we have not yet granted any performance-based equity awards. Receipt of severance benefits is contingent upon the executive entering into a release of claims and allowing it to become effective.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Elements of Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Health, Welfare
and Retirement Benefits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in all of our employee benefit plans, such as medical, dental,
vision, group life, short and long-term disability plans, in each case on the same basis as other employees, subject to applicable laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>401(k) Plan
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a 401(k) plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible
employees are able to defer eligible compensation up to certain Code limits, which are updated annually. We have the ability to make matching and discretionary safe harbor contributions to the 401(k) plan. Beginning January&nbsp;1, 2022, an employee
who contributes 5% of compensation or more will receive a matching contribution equal to 4% of compensation, subject to the maximum annual employer contribution limit. In 2021, we did not make matching contributions or discretionary contributions to
the 401(k) plan. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code, with the related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT>
retirement plan, contributions to the 401(k) plan are deductible by us when made, and contributions and earnings on those amounts are not generally taxable to the employees until withdrawn or distributed from the 401(k) plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Perquisites and Other Personal Benefits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not
provide perquisites or other personal benefits to our named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Tax <FONT STYLE="white-space:nowrap">Gross-Ups</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020 and 2021, we did not make <FONT STYLE="white-space:nowrap">gross-up</FONT> payments to cover our named executive officers&#146; personal income taxes
that pertained to any of the compensation or perquisites paid or provided by the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clawbacks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, if we are required to restate our financial results due to our material noncompliance with any financial reporting requirements under the
federal securities laws as a result of misconduct, the Chief Executive Officer and Chief Financial Officer may be legally required to reimburse Vaxcyte for any bonus or other incentive-based or equity-based compensation they receive in accordance
with the provisions of section 304 of the Sarbanes-Oxley Act of 2002. Additionally, we intend to implement a Dodd-Frank Wall Street Reform and Consumer Protection <FONT STYLE="white-space:nowrap">Act-compliant</FONT> clawback policy to the extent
that the requirements of such clawbacks are finalized by the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy Prohibiting Hedging and Pledging </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our insider trading policy prohibits all directors, officers, other employees and designated consultants from purchasing our stock on margin or holding our
stock in a margin account, pledging our stock as collateral or engaging in hedging, derivative or similar transactions with respect to our stock, such as prepaid variable forwards, equity swaps, collars, exchange funds, puts, calls and short sales.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax and Accounting Implications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Financial Accounting Standard Board ASC Topic 718, or ASC 718, we are required to estimate and record an expense for each award of equity compensation
over the vesting period of the award. We record share-based compensation expense on an ongoing basis according to ASC 718. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;162(m) of
the Internal Revenue Code (&#147;Section&nbsp;162(m)&#148;), compensation paid to each of our &#147;covered employees&#148; that exceeds $1&nbsp;million per taxable year is generally <FONT STYLE="white-space:nowrap">non-deductible.</FONT> Although
the Compensation Committee will continue to consider tax implications as one factor in determining executive compensation, the Compensation Committee also looks at other factors in making its decisions and retains the flexibility to provide
compensation for the our named executive officers in a manner consistent with the goals of our executive compensation program and the best interests of the Company and its stockholders, which may include providing for compensation that is not
deductible due to the deduction limit under Section&nbsp;162(m). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation Tables </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Summary Compensation Table </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
presents all of the compensation awarded to, earned by or paid to our named executive officers during the fiscal year ended December&nbsp;31, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">574,800</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4,353,113</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">363,561</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5,291,474</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">481,042</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2,623,695</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">269,883</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">3,374,620</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">426,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">170,400</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">596,400</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Guggenhime<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">472,400</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2,036,134</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">244,467</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2,753,001</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">274,792</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5,246,757</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">128,523</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5,650,072</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Wassil<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">451,800</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,310,708</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">207,828</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,970,336</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President and Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">369,643</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">586,489</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">161,417</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,357,548</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">29,167</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">443,385</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">8,750</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">481,302</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Dhaliwal<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">93,750</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,697,710</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">37,734</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,844,194</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President, Commercial Manufacturing</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Sauer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">375,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">561,692</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">150,938</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,087,630</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President, Process Development and Manufacturing</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">310,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">469,608</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">124,410</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">904,518</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">41,705</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">431,705</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent the aggregate grant date fair value of the stock options granted to our named
executive officers during fiscal year 2021 under our 2020 Plan, computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options are set forth in Note 10 to our audited financial
statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, which was filed with the SEC on February&nbsp;28, 2021. This amount may not reflect the actual economic value
that may be realized by the named executive officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The dollar amounts reported in this column represent the annual performance-based cash bonus awards earned
under the annual performance-based cash bonus plan for the indicated fiscal year. For more information regarding the annual performance-based cash bonus awards for fiscal 2021, see &#147;Compensation Discussion and Analysis &#151; 2021 Executive
Compensation Program &#151; Annual Performance-Based Cash Bonus&#148; above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Guggenhime commenced his employment on May&nbsp;1, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Wassil commenced his employment on December&nbsp;1, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of a $240,000 <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus pursuant to our offer letter to
Mr.&nbsp;Wassil, $120,000 of which he was entitled to following the commencement of his employment and $120,000 of which was paid following the first anniversary of his hire date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Dhaliwal commenced his employment on October&nbsp;1, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of a $15,000 <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus pursuant to our offer letter to Mr.
Dhaliwal. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grants of Plan-Based Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information regarding each plan-based award granted to our named executive officers during the fiscal year ended December&nbsp;31,
2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Award Type</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Future<BR>Payouts&nbsp;Under</B><br><B><FONT STYLE="white-space:nowrap">Non-&nbsp;Equity</FONT><BR>Incentive Plan<BR>Awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other&nbsp;Option<BR>Awards:&nbsp;Number&nbsp;of<BR>Securities&nbsp;Underlying<BR>Options (#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise&nbsp;or<BR>Base&nbsp;Price&nbsp;of<BR>Option&nbsp;Awards<BR>($/Sh)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date&nbsp;Fair<BR>Value&nbsp;of&nbsp;Stock&nbsp;and<BR>Option&nbsp;Awards&nbsp;($)(3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target ($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Grant E. Pickering</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Annual Option</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/1/2021<B></B></TD>
<TD NOWRAP VALIGN="top"><B><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">310,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20.93</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4,353,113</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Performance-<BR>Bonus</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">316,140</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Andrew Guggenhime</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>President and Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Annual&nbsp;Option</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/1/2021<B></B></TD>
<TD NOWRAP VALIGN="top"><B><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">145,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20.93</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2,036,134</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Performance-<BR>Bonus</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">212,580</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jim Wassil</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Executive Vice President and Chief Operating Office</I>r</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Annual Option</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/1/2021<B></B></TD>
<TD NOWRAP VALIGN="top"><B><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">93,340</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20.93</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,310,708</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Performance-<BR>Bonus</I> <P STYLE="font-size:16pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">180,720</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Harpreet Dhaliwal</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Senior Vice President, Commercial Manufacturing</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Annual Option</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">11/8/2021<B></B></TD>
<TD NOWRAP VALIGN="top"><B><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">25.06</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,697,710</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Performance-<BR>Bonus</I> <P STYLE="font-size:16pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">32,813</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Paul Sauer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Senior Vice President, Process Development and Manufacturing</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Annual Option</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/1/2021<B></B></TD>
<TD NOWRAP VALIGN="top"><B><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20.93</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">561,692</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><I>Performance-<BR>Bonus</I> <P STYLE="font-size:16pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">131,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in this column represent the target performance-based bonus opportunity for each named executive
officer for 2021. For a description of the 2021 performance bonus program, see &#147;Compensation Discussion and Analysis-Annual Performance-Based Cash Bonus&#148; above. The amount actually earned by each named executive officer was 115% of the
target performance-based bonus opportunity and is reported in the Summary Compensation Table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The 2021 performance-based bonus program did not include threshold or maximum bonus amounts.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in this column reflect the aggregate grant date fair value of the option awards granted during 2021,
computed in accordance with ASC 718. Assumptions used in the calculation of these amounts are included in Note 10 to the Financial Statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2021. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying
such stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Options were granted under the terms of our 2020 plan, with an exercise price per share equal to the closing
price of our common stock on the April&nbsp;1, 2021 grant date, and vest over a four-year period. For a description of our 2020 plan, see &#147;Equity Compensation Arrangements-2020 Equity Incentive Plan&#148; below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Options were granted under the terms of our 2020 plan, with an exercise price per share equal to the closing
price of our common stock on the November&nbsp;8, 2021 grant date, and vest 25% on the first anniversary of his start date and equal monthly installments over the following three years. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Outstanding Equity Awards as of December&nbsp;31, 2021 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding outstanding equity awards granted to our named executive officers that remain outstanding as of
December&nbsp;31, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;Per<BR>Share<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/24/2015</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/23/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/18/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/17/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/24/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">507,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/23/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/18/2020</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/17/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2021</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Guggenhime</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/12/2020</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">518,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/12/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2021</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/31/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Wassil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/17/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/16/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President and Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/18/2020</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/17/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2021</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Dhaliwal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/8/2021</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/8/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President, Commercial Manufacturing</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Sauer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/20/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/19/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President, Process Development and Manufacturing</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/18/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/17/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/24/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/23/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/21/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/20/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/18/2020</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/17/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2021</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Option awards granted prior to June 2020 were granted under the 2014 Plan. Option awards granted from June 2020
onwards were granted under the 2020 Plan. The terms of both the 2014 Plan and the 2020 Plan are described below in the subsection entitled &#147;&#151;Equity Compensation Plans.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fully vested and exercisable as of December&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/4 of the shares subject to the option vested on July&nbsp;24, 2019, and 1/48 of the shares vest monthly
thereafter, subject to continued service to us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/4 of the shares subject to the option vest on March&nbsp;20, 2021, and 1/48 of the shares vest monthly
thereafter, subject to continued service to us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/48 of the shares vest monthly, subject to continued service to us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/4 of the shares subject to the option vest on May&nbsp;1, 2021, and 1/48 of the shares vest monthly
thereafter, subject to continued service to us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/4 of the shares subject to the option vested on December&nbsp;1, 2020, and 1/48 of the shares vest monthly
thereafter, subject to continued service to us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/4 of the shares subject to the option vested on October&nbsp;1, 2022, and 1/48 of the shares vest monthly
thereafter, subject to continued service to us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">1/4 of the shares subject to the option vested on January 1, 2019 and 1/48 of the shares vest monthly
thereafter, subject to continued service to us. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Option Exercises and Stock Vested </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding any option exercises and stock vested during the fiscal year ended December&nbsp;31, 2021 with
respect to our named executive officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired on<BR>Exercise (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized<BR>on Exercise<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,116,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Guggenhime</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">6,200</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">150,423</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Wassil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">156,798</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President and Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Dhaliwal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President, Commercial Manufacturing</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Sauer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">194,659</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President, Process Development and Manufacturing</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value realized on exercise is based on the difference between the closing price of our common stock on the
date of exercise and the applicable exercise price of those options, and does not represent actual amounts received by the named executive officers as a result of the option exercises. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential Payments Upon Termination or Change in Control </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below provides information with respect to potential payments and benefits to which our named executive officers would be entitled under the
arrangements set forth in their respective offer letters or employment agreement, as described below under the section titled, &#147;Executive Change in Control and Severance Agreements,&#148; assuming their employment was terminated as of
December&nbsp;31, 2021, including in connection with a change in control as of December&nbsp;31, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type&nbsp;of&nbsp;Termination</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base<BR>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting of<BR>Equity<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)<BR></SUP>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Continuation<BR>of Insurance<BR>Coverage<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">574,800</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">316,140</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">42,119</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">933,059</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason in connection with a CIC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">862,200</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">474,210</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">6,441,807</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">63,179</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">7,841,396</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Andrew Guggenhime</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">354,300</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">159,435</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">31,590</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">545,325</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason in connection with a CIC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">472,400</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">212,580</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">6,190,272</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">42,119</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">6,917,371</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jim Wassil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">338,850</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">135,540</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">31,590</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">505,980</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason in connection with a CIC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">451,800</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">180,720</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">3,924,885</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">42,119</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4,599,524</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Harpreet Dhaliwal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason in connection with a CIC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">281,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">98,438</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2,347</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">382,035</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Paul Sauer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">187,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">65,625</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">21,060</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">274,185</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination without Cause or with Good Reason in connection with a CIC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">281,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">98,438</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,174,759</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">31,590</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,586,037</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount shown in this column for each named executive officer consists of the value of the portions of the
unvested <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> options held by the named executive officer for which vesting is accelerated upon the triggering event. The value of each such portion of such
equity awards is calculated by multiplying (x)&nbsp;the closing stock price of our common stock of $23.79 per share on December&nbsp;31, 2021, as reported on the Nasdaq Global Select Market (less the exercise price per share of the option) by
(y)&nbsp;the number of shares covered by such portion of the equity award. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents change in control severance benefits based on a double-trigger arrangement, which assumes the
executive officer is terminated without &#147;cause&#148; or resigns for &#147;good reason&#148; (as such terms are defined in the executive officer&#146;s executive severance agreements) in connection with, or within three months prior to or 12
months following, a change of control of Vaxcyte. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As December&nbsp;31, 2021, Mr.&nbsp;Dhaliwal would have no unvested <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> options for which vesting is accelerated upon the triggering event. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment
and Benefit Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into offer letters and severance agreements with each of our named executive officers. For more information
regarding these arrangements, see the section titled &#147;Employment, Severance and Change in Control Arrangements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted equity awards to our executive officers. For a description of these equity awards, see the
section titled &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution retirement plan that provides eligible employees with an
opportunity to save for retirement on a tax advantaged basis. See the section titled &#147;Other Elements of Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of
Liability and Indemnification Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation contains provisions that limit the liability of our
current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as
directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies
such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation authorizes us to indemnify our directors, officers,
employees and other agents to the fullest extent permitted by Delaware law. Our amended and restated bylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law and provide that we may indemnify our
other employees and agents. Our amended and restated bylaws also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and
permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the
provisions of Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by the Board of Directors. With certain exceptions, these agreements provide
for indemnification for related expenses including attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these amended and restated certificate of
incorporation and amended and restated bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#146; and officers&#146; liability
insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated
bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if
successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these
indemnification provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for directors, executive
officers or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plans at December&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows certain information with respect to all of our equity compensation plans in effect as of December&nbsp;31, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities&nbsp;to<BR>be<BR>issued upon<BR>exercise of<BR>outstanding<BR>stock&nbsp;options<BR>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average<BR>exercise<BR>price of<BR>outstanding<BR>stock<BR>options (b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>remaining<BR>available for<BR>issuance&nbsp;under<BR>equity<BR>compensation<BR>plans<BR>(excluding<BR>securities<BR>reflected
in<BR>column (a))</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>2020 Plan</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,637,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,104,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>2014 Plan<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,657,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>2020 ESPP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,070,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,357,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,175,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares remaining available for future issuance under the 2020 Plan automatically increases on
January 1st each year, through and including January&nbsp;1, 2030, in an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding on such December 31st of the preceding calendar year or (ii)&nbsp;a number of
shares as determined by the Board of Directors prior to the beginning of each year. On January&nbsp;1, 2022, the number of shares available for issuance under the 2020 Plan automatically increased by 2,651,598 shares. The number of shares remaining
available for future issuance under the ESPP automatically increases on January&nbsp;1st of each year, through and including January&nbsp;1, 2030, in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding
on such December 31st of the preceding calendar year, (ii) 1,500,000 shares of common stock or (iii)&nbsp;a number of shares as determined by the Board of Directors prior to the beginning of each year, which shall be the lesser of (i)&nbsp;or (ii)
above. On January&nbsp;1, 2022, the number of shares available for issuance under the ESPP automatically increased by 530,319 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 62,382 shares granted outside of the 2020 Plan and 2014 Plan.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL NO. 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_8"></A>APPROVAL, ON A <FONT STYLE="white-space:nowrap">NON-BINDING,</FONT> ADVISORY BASIS, OF THE FREQUENCY OF FUTURE <FONT
STYLE="white-space:nowrap">NON-BINDING,</FONT> ADVISORY VOTES TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;14A of the
Exchange Act provides that every six years we must provide stockholders an opportunity to vote, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, for their preference on how frequently we should seek future <FONT
STYLE="white-space:nowrap">non-binding,</FONT> advisory votes to approve the compensation of our named executive officers (such as the one described in Proposal No.&nbsp;2 above). Specifically, stockholders may indicate whether they would prefer
these advisory resolutions on named executive officer compensation to be presented for stockholder approval every one, two or three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of
Directors believes at this time that an annual frequency is appropriate for Vaxcyte. The Board of Directors believes that an annual vote on named executive officer compensation provides stockholders with the opportunity to provide timely and direct
input to the Board of Directors and the compensation committee about our executive compensation philosophy, policies and practices as disclosed in the proxy statement each year. The Board of Directors believes that an annual vote is therefore
consistent with our efforts to engage in an ongoing dialogue with our stockholders on executive compensation and corporate governance matters. The Board of Directors will continue to evaluate the appropriate frequency for the stockholder executive
compensation vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that stockholders are not voting to approve or disapprove the recommendation of the Board of Directors with respect to
this proposal. Instead, the proxy card provides four choices: a one, two or three year frequency or stockholders may abstain from voting on the proposal. The option that receives the highest number of votes of the holders of shares of common stock
present at the meeting (by virtual attendance) or by proxy and entitled to vote thereon will be deemed to be the frequency preferred by our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since this proposal is an advisory vote, the result will not be binding on our Board of Directors. As such, the results of the vote will not be construed to
create or imply any change to the fiduciary duties of our Board of Directors. Our Board of Directors may decide that it is in the best interests of Vaxcyte and our stockholders to hold a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory
vote on our named executive officer compensation more or less frequently than the option approved by our stockholders. However, our Board of Directors values our stockholders&#146; opinions, and our Board of Directors and the compensation committee
will take into account the outcome of the advisory vote when determining how often we should submit to stockholders future <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes. We expect that
the next stockholder vote on the frequency of <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory votes on named executive officer compensation will occur at our 2028 annual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>UR</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> A V<SMALL>OTE</SMALL>
F<SMALL>OR</SMALL> <SMALL>A</SMALL> <FONT STYLE="white-space:nowrap">&#147;ONE-YEAR&#148;</FONT> F<SMALL>REQUENCY</SMALL> <SMALL>FOR</SMALL> F<SMALL>UTURE</SMALL> A<SMALL>DVISORY</SMALL> V<SMALL>OTES</SMALL> <SMALL>ON</SMALL> N<SMALL>AMED</SMALL>
E<SMALL>XECUTIVE</SMALL> O<SMALL>FFICER</SMALL> C<SMALL>OMPENSATION</SMALL>. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL NO. 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_9"></A>RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee of the Board of Directors has selected Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm for the year
ending December&nbsp;31, 2021 and has further directed that management submit the appointment of its independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. Deloitte&nbsp;&amp; Touche LLP has served
as the Company&#146;s independent registered public accounting firm since 2017. Representatives of Deloitte&nbsp;&amp; Touche LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire
and will be available to respond to appropriate questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither our bylaws nor other governing documents or Delaware law require stockholder
ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm. However, the Audit Committee of the Board of Directors is submitting the appointment of Deloitte&nbsp;&amp; Touche LLP to the
stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the appointment, the Audit Committee will reconsider whether or not to retain that firm. Even if the appointment is ratified, the Audit
Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of the Company and its stockholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares electronically present online or represented by proxy and entitled to vote on the matter
at the Annual Meeting will be required to approve this Proposal No.&nbsp;4. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE
RATIFICATION OF DELOITTE&nbsp;&amp; TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Accountant Fees and Services
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table represents aggregate fees billed to us for the years ended December&nbsp;31, 2021 and 2020 by Deloitte&nbsp;&amp; Touche LLP, our
independent registered public accounting firm. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,061,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">919,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,061,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">919,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit Fees consist of fees billed for professional services performed by Deloitte&nbsp;&amp; Touche LLP for the
audit of our annual financial statements, the review of interim financial statements, and related services that are normally provided in connection with registration statements, including the registration statement for our initial public offering.
Included in the 2021 Audit Fees are amounts billed in connection with the audit of internal controls over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All fees
incurred subsequent to our initial public offering in June 2020 were <FONT STYLE="white-space:nowrap">pre-approved</FONT> by our Audit Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Pre-Approval</FONT> Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has procedures in place for the
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services rendered by the Company&#146;s independent registered public accounting firm, Deloitte&nbsp;&amp; Touche LLP. The Audit
Committee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generally <FONT STYLE="white-space:nowrap">pre-approves</FONT> specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. <FONT
STYLE="white-space:nowrap">Pre-approval</FONT> may also be given as part of the Audit Committee&#146;s approval of the scope of the engagement of the independent registered public accounting firm or on an individual, explicit, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis before the independent registered public accounting firm is engaged to provide each service. The <FONT STYLE="white-space:nowrap">pre-approval</FONT> of
services may be delegated to one or more of the Audit Committee&#146;s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has determined that the rendering of services other than audit services by Deloitte&nbsp;&amp; Touche LLP is compatible with maintaining
the independent registered public accounting firm&#146;s independence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_10"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding the ownership of our common stock as of April&nbsp;11, 2022 (unless noted otherwise) by:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each director and nominee for director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the executive officers named in the Summary Compensation Table under &#147;Executive Compensation&#148;
below (referred to throughout this proxy statement as our named executive officers); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all current executive officers and directors as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all those known by us to be beneficial owners of more than five percent of our outstanding common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This table is based upon information supplied by officers and directors as well as Schedules 13G or 13D filed with the SEC by
beneficial owners of more than five percent of our common stock. Unless otherwise indicated in the footnotes to this table and subject to community property laws, where applicable, we believe that each of the stockholders named in this table has
sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 58,052,119 shares outstanding on April&nbsp;11, 2022, adjusted as required by rules promulgated by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address for persons listed in the table is c/o Vaxcyte, Inc., 825 Industrial Road, Suite 300, San Carlos, California 94070.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FMR LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Group plc<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,246,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abingworth Bioventures VI, LP<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,183,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TPG Growth IV Switcheroo, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,149,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Management<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,865,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,134,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Named Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering<SUP STYLE="font-size:85%; vertical-align:top">(7)(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,229,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Guggenhime<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">606,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Wassil<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Dhaliwal<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Sauer<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carlos Paya<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annie Drapeau<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kurt von Emster<SUP STYLE="font-size:85%; vertical-align:top">(3)(7)(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,224,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Halley Gilbert<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Hirth<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Kamarck<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teri Loxam<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heath Lukatch<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (14 persons)<SUP
STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,282,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information provided in the Schedule 13G filed with the SEC on February&nbsp;9, 2022, by FMR
LLC (&#147;FMR&#148;) and Abigail P. Johnson. As of December&nbsp;31, 2021, FMR and Abigail P. Johnson reported </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
having sole voting power over 1,220,395 shares and sole dispositive power over 7,874,350 shares of our common stock. The address for each of these reporting persons is 245 Summer Street, Boston,
Massachusetts 02210. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information provided in the Schedule 13G/A filed with the SEC on February&nbsp;10, 2022, by
Janus Henderson Group plc (&#147;Janus Henderson&#148;). Janus Henderson has an indirect 97% ownership stake in Intech Investment Management LLC (&#147;Intech&#148;) and a 100% ownership stake in Janus Capital Management LLC (&#147;JCM&#148;),
Perkins Investment Management LLC, Henderson Global Investors Limited and Janus Henderson Investors Australia Institutional Funds Management Limited which act as investment advisers to various fund, individual and/or institutional clients
(&#147;Managed Portfolios&#148;). JCM does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. As of
December&nbsp;31, 2021, Janus Henderson, together with its affiliated entities, reported shared voting and investment power over 4,246,664 shares of the Company&#146;s common stock. The address of the principal business office of Janus Henderson is
201 Bishopsgate EC2M 3AE, United Kingdom. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information provided in the Schedule 13G/A filed with the SEC on February&nbsp;14, 2022, by
Abingworth LLP (&#147;Abingworth&#148;) and Abingworth Bioventures VI, LP (&#147;ABV VI&#148;). As of December&nbsp;31, 2021, Abingworth reported beneficial ownership of 4,183,716 shares of our common stock held by ABV VI, as a result of serving as
an investment manager to ABV VI. Abingworth and ABV VI reported having shared voting and dispositive power over 4,183,716 shares of our common stock. Excludes options to purchase up to 14,998 shares of the Company&#146;s common stock that were
issued to Kurt von Emster as a director of the Company (the &#147;Options&#148;). Mr.&nbsp;von Emster is a member of Abingworth. Under an agreement between Mr.&nbsp;von Emster and Abingworth, Mr.&nbsp;von Emster is deemed to hold the Options, and
any common stock issuable upon exercise of the Options, for the benefit of ABV VI and must exercise the Options solely upon the direction of Abingworth, as a result of which ABV VI and Abingworth may be deemed to beneficially own any Options and
common stock issuable upon exercise of the Options owned by Mr.&nbsp;von Emster. The address for each of Abingworth and ABV VI is 38 Jermyn Street, London, England SW1Y 6DN. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information provided in the Schedule 13G filed with the SEC on January&nbsp;18, 2022, by TPG
Group Holdings (SBS) Advisors, Inc., a Delaware corporation, David Bonderman and James G. Coulter (&#147;TPG Reporting Persons&#148;). As of December&nbsp;31, 2021, the TPG Reporting Persons reported having shared voting and shared dispositive power
over 4,149,544 shares held by TPG Growth IV Switcheroo, L.P. (&#147;TPGGIV&#148;). Group Advisors is the sole member of TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Group Holdings
(SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings <FONT STYLE="white-space:nowrap">I-A,</FONT> LLC, a Delaware limited liability company, which is the general partner of TPG Holdings I, L.P., a Delaware limited
partnership, which is the sole member of TPG Growth GenPar IV Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Growth GenPar IV, L.P., a Delaware limited partnership, which is the general partner of TPGGIV.
David Bonderman and James G. Coulter are sole stockholders of Group Advisors and may therefore be deemed to be the beneficial owners of the shares of Common Stock held TPGGIV. Messrs. Bonderman and Coulter disclaim beneficial ownership of the shares
held by TPGGIV except to the extent of their pecuniary interest therein. The address for each of the TPG Reporting Persons is c/o TPG Global, LLC 301 Commerce Street, Suite 3300, Fort Worth, TX 76102. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information provided in the Schedule 13G/A filed with the SEC on March&nbsp;30, 2021, by RA
Capital Management, L.P. (&#147;RA Capital&#148;), Peter Kolchinsky and Rajeev Shah. As of March&nbsp;30, 2021, the reporting persons reported shared voting and shared dispositive power over 3,865,808 shares including 2,616,973 shares held by RA
Capital Healthcare Fund, L.P. (the &#147;Fund&#148;), 947,125 shares held by RA Capital Nexus Fund, L.P. (the &#147;Nexus Fund&#148;) and 301,710 shares held in a separately managed account (the &#147;Account&#148;). This amount excludes <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 2,500,000 shares of our common stock held by RA Capital, the exercise of which is currently limited pursuant to an ownership limitation, and therefore the shares of our capital stock
issuable upon exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are not deemed to be beneficially owned within 60 days of April&nbsp;11, 2022. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund and RA
Capital Nexus Fund GP, LLC is the general partner of the Nexus Fund. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr.&nbsp;Kolchinsky and Mr.&nbsp;Shah are the controlling persons. RA Capital serves as investment adviser for the
Fund, the Nexus Fund, and the Account and may be deemed to beneficially own any of the Company&#146;s securities held by the Fund, the Nexus Fund and the Account. RA Capital, Dr.&nbsp;Kolchinsky, and Mr.&nbsp;Shah disclaim beneficial ownership of
the shares. The address for each of these reporting persons is c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information provided in the Schedule 13G filed with the SEC on February&nbsp;10, 2022, by The
Vanguard Group (&#147;Vanguard&#148;). As of December&nbsp;31, 2021, Vanguard reported having sole voting power over 0 shares of our common stock, shared voting power over 40,087 shares of our common stock, sole dispositive power over 3,074,028
shares of our common stock, and shared dispositive power over 60,258 shares of our common stock. The address of the principal business office of Vanguard is 100 Vanguard Blvd., Malvern, PA 19355. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes shares of our common stock issuable upon exercise of outstanding stock options that are exercisable
within 60 days of April&nbsp;11, 2022, as described below: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Held by</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"># Stock<BR>Options</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant E. Pickering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,169,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Guggenhime</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">565,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Wassil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Dhaliwal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Sauer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carlos Paya</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annie Drapeau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kurt von Emster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Halley Gilbert</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Hirth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mike Kamarck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teri Loxam</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heath Lukatch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (14 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,510,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 355,660 shares of common stock held by trusts for the benefit of Mr.&nbsp;Pickering&#146;s children.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 4,183,716 shares owned by Abingworth and (ii) 40,555 shares issuable upon exercise of
outstanding stock options exercisable within 60 days of April&nbsp;11, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 7,113 shares of common stock held by Hirth Enterprises, LLC and (ii) 81,668 shares issuable
upon exercise of outstanding stock options exercisable within 60 days of April&nbsp;11, 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_11"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below we describe transactions since January&nbsp;1, 2021 and each currently proposed transaction in which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have been or are to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any
immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Rights Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to an amended and
restated investor rights agreement (&#147;IRA&#148;), with certain holders of our capital stock, including the holders of more than 5% of our outstanding capital stock. The IRA provides the holders of shares of our common stock issued upon
conversion of our redeemable convertible preferred stock with certain registration rights, including the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise
filing. The IRA also provided these stockholders with information rights and a right of first refusal with regard to certain issuances of our capital stock, which terminated upon the closing of our initial public offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation contains provisions limiting the liability of directors, and our amended and restated bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our
amended and restated certificate of incorporation and amended and restated bylaws also provide our Board of Directors with discretion to indemnify our employees and other agents when determined appropriate by the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered and expect to continue to enter into agreements to indemnify our directors and executive officers. With certain exceptions, these agreements
provide for indemnification for related expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in connection with any action, proceeding or investigation. We believe that these amended
and restated certificate of incorporation and amended and restated bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#146; and
officers&#146; liability insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has adopted a Related Person Transaction Policy setting forth the policies and procedures for the identification, review and approval or
ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, any transaction, arrangement or relationship, or any
series of similar transactions, arrangements or relationships, in which we and a related person were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or from the related person or entities
in which the related person has a material interest, indebtedness and guarantees of indebtedness. In reviewing and approving any such transactions, our Audit Committee will consider all relevant facts and circumstances as appropriate, such as the
purpose of the transaction, the availability of other sources of comparable products or services, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction, management&#146;s recommendation
with respect to the proposed related person transaction, and the extent of the related person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_12"></A>HOUSEHOLDING OF PROXY MATERIALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability
of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials addressed to those
stockholders. This process, which is commonly referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This year, a number of brokers with account holders who are Vaxcyte stockholders will be &#147;householding&#148; our proxy materials. A single Notice of
Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be
&#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#147;householding&#148; and
would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify your broker, notify our Corporate Secretary at (650) <FONT STYLE="white-space:nowrap">837-0111</FONT> or send a written request to: Corporate
Secretary, Vaxcyte, Inc., 825 Industrial Road, Suite 300, San Carlos, California 94070. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request
&#147;householding&#148; of their communications should contact their brokers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx305886_13"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delinquent Section&nbsp;16(a) Reports </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a)
of the Exchange Act requires that our executive officers and directors, and persons who own more than 10% of our common stock, file reports of ownership and changes of ownership with the SEC. Such directors, executive officers and 10% stockholders
are required by SEC regulation to furnish us with copies of all Section&nbsp;16(a) forms they file. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEC regulations require us to identify in this proxy
statement anyone who filed a required report late during the most recent fiscal year. Based on our review of forms we received, or written representations from reporting persons stating that they were not required to file these forms, we believe
that during our fiscal year ended December&nbsp;31, 2021, all Section&nbsp;16(a) filing requirements were satisfied on a timely basis, with the exception of one late Form 4 for each of Messrs. Dhaliwal, Guggenhime, Pickering, Sauer and Wassil, two
late Form 4 filings for Mr.&nbsp;Fairman and one late Form 4 filing for Ms.&nbsp;Drapeau, each for the granting of stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * *
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly
brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Mikhail Eydelman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mikhail Eydelman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President, General Counsel and
Corporate Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;20, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A copy of
our Annual Report to the SEC on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 is available without charge upon written request to: Corporate Secretary, Vaxcyte, Inc., 825 Industrial Road, Suite 300, San
Carlos, California 94070. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g305886g50d01.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">SCAN TO VIEW MATERIALS&nbsp;&amp; VOTE w VAXCYTE, INC. 825 INDUSTRIAL ROAD VOTE BY INTERNET SUITE 300 Before The Meeting&#151;Go to
www.proxyvote.com or scan the QR Barcode above SAN CARLOS, CA 94070 Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 8:59 P.M. PT / 11:59 P.M. ET on May&nbsp;31, 2022. Have your proxy card in
hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting&#151;Go to www.virtualshareholdermeeting.com/PCVX2022 You may attend the meeting via the
Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE&#151;1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions.
Vote by 8:59 P.M. PT / 11:59 P.M. ET on May&nbsp;31, 2022. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or
return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: D79070-P70361 KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.
DETACH AND RETURN THIS PORTION ONLY VAXCYTE, INC. For Withhold For All To withhold authority to vote for any individual All All Except nominee(s), mark &#147;For All Except&#148; and write the The Board of Directors recommends you vote FOR number(s)
of the nominee(s) on the line below. the following: 1. Election of Class II Directors ! ! ! Nominees would serve until the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and quali?ed, or, if sooner, until the
director&#146;s death, resignation or removal Nominees: 01) Peter Hirth, Ph.D. 02) Heath Lukatch, Ph.D. The Board of Directors recommends you vote FOR the For Against Abstain The Board of Directors recommends you vote FOR the For Against Abstain
following proposal: following proposal: 2. Approval, on a non-binding, advisory basis, of the ! ! ! 4. Rati?cation of the appointment of Deloitte&nbsp;&amp; Touche ! ! ! compensation of the Company&#146;s named executive LLP as the Company&#146;s
independent registered of?cers. public accounting firm for the fiscal year ending December&nbsp;31, 2022. One Two Three The Board of Directors recommends you vote Year Years Years Abstain NOTE: Such other business as may properly come before the One
Year on the following proposal: meeting or any adjournment thereof. 3. Approval, on a non-binding, advisory basis, of ! ! ! ! the frequency of future non-binding, advisory votes to approve the compensation of our named executive of?cers. Please sign
exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other ?duciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please
sign in full corporate or partnership name by authorized of?cer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g305886g50d02.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice and Proxy Statement and Annual Report
are available at www.proxyvote.com. D79071-P70361 VAXCYTE, INC. Annual Meeting of Stockholders June&nbsp;1, 2022 8:30 AM PT / 11:30 AM ET This proxy is solicited by the Board of Directors The stockholder(s) hereby appoint(s) Grant Pickering and
Andrew Guggenhime, or either of them, as proxies, each with the power to appoint his substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of Common Stock of VAXCYTE,
INC. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholder(s) to be held at 8:30 AM PT / 11:30 AM ET on June&nbsp;1, 2022, at the www.virtualshareholdermeeting.com/PCVX2022, and any adjournment or postponement thereof.
This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors&#146; recommendations. Continued and to be signed on reverse side
</FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g305886g02m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305886g02m02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1044&AO=&]S:&]P(#,N,  X0DE-! 0
M    $_B^41(X0DE-! 0      %H< 5H  QLE1QP"   "-%@< E  "')R,CDT
M-C$Y' (% #E-:6-R;W-O9G0@5V]R9" M(%9A>&-Y=&4@,C R,B!0<F]X>2!$
M<F%F="!#;V]L97D@0V]M;65N=',X0DE-!"4      !!9N/%.POHO'6W^ A>-
MI1IA.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            >P   K$          0                         !
M          *Q    >P                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    >P    !29VAT;&]N9P   K$    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   'L
M    4F=H=&QO;F<   *Q     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      F      0   *     =   !X
M-F    ED !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M"  = * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P !
M @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"
M! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P$  P            @)!PH !08# @0+_\0 /Q   00" 0,# @$("0$)
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M,JJ)),0![ZZM^RQ"JX).@$'7WBI7VCN#6NEJ&%D^T<LK\.H;"U#1P[.R%-*
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M&4\\PV^&QYCPIRW$/=#-]<?-=;"/*%(OY%0VDR]K'-\PY=CZI5WCBB156/\
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MZ&'1UAT=5="K*"!\7A,/CL-?P>*MB[A\3;:U>MG3,C"#!&JLIAD=89'"LI#
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M.7_X@K0<:MB6G>[I8ASZJM9QD\[:DC(X\W#'E*[S+/HQ(6;1,[D<:C9+@,0
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M..PBL<X+_!''ZQL.F6XCR1VE"AED@@B2XD&=.SIMPI<,)=1\R,L @J22&'D
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<LR$C9CME/]DUO9L74S9V!F([1.TSN/#^P*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g305886g50d01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305886g50d01.jpg
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M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4 9,
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M P(% P,$ @,!      $1 B$Q$D%1\&$B Q.A,E)Q@3.1L<'AT?%"@D-B_]H
M# ,!  (1 Q$ /P#^_C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# BKHO=^'\@E#(76NR<JY=--,/R@T3HO0Z
MC291:-%<0U*D#(]E,#'9[$9UQ*7%M:6E"E:UO>M[UA8B9V1Q_78\,_[6_C'^
M?OE?WUX..7:3^NQX9_VM_&/\_?*_OKP<<NTLPHWDKXY=0/MU3FG?^)]$M+T6
M3.9K5&ZK1;:?=A0DZ7,F-A@!X@17%B(5K;KFF]H;UOU5O6"8F-X39A# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# ^-N-I5I"EHTM7^BG:M:5OU^C7HG>_7?KO6!]X'QIQO:MHTM&UZ^G:-*
MUM6M?1].T^OKK]W _=K0G:4J4E.U;]$ZVK6MJWKT]=)UO?KO?TX'U@1WTCHP
M_F].*W20)+64<#;1**0ZSJ#,)QAVUZ1()_#29L-+L.#[6E/;2O:D-^JO3>D[
M] @OEOF'2.O6^'3:G3[YN;(CR9TR?.A!6!0<9$1[4@D4E-FWE,1DK4AM/HE2
MENN)2G6][^@-LVWV7O:]R\T[[/I[7NW$+]GU]?3VO9WOT]?3Z,"FFE!@S2%$
M2,$>EU7LMJFRX\33BO\ Y%&WW&]+5_Z-8%4EUI;>GD.-K94GVTNI6E3:D;UZ
MZ7I>M[3M.]?Y?7TP/I*T+UZH4E>O7T]4JTK7K_F]=;WKUP"UH;U[2UI0GU]/
M5:M)UZ_YO7>]:]?HP/C;[*?3VGFM>NM*UZN(UZIW^YO7KOZ=;P/SXB/_ /7V
M?_LJ/_JL#[VZVE.E[<1I"OW%;6G2=^O^96]^F\#X^(C_ /U]G_[*C_ZK ]$J
M2O7M(4E2?\Z=Z5KZ/_3KUU@?6 P& P& P& P& P& P& P& P& P& P& P& P
M/X1?GX>!W>_F,_.7J?"/'F'2BE[K_@;3NAKC]"LZJP#C5@/UWH DI\$0V+,^
MS.<)62+O3*64Z<UM2MJU[/TQZ/;RC#V[GNU%YO\ JSOS,Z'/K<P[XR^!76F0
M)VP&)P[I/9.BKA6R(;K\4)#K=D^Q,BER% :O-CJ*#]0EPY>B+SFY#\B/[$=%
MI9]W&>LPJ.S?JTGS,.K&PY>K>+?@%P"(+$K&2:[Q?LG2FPAZ2N:[+T<,ZZ;+
MZ23V6;:<U'3\+)C1_<H3ZM;7ZKVHCW<8ZS*J\#_E.>6ORQ_FV_+(-^2HSF(A
MCL?6.M@Z<[S:\*M<E]VI<4M<NPL%]) @U08CD2P1](U[3J7O56MZU[/TREG/
M'/"8CL_T8LKRF P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P&!R=^:OSZR1:#SOR6H,B?"N/ [@+(3GH$F4REZL
MDBL!QA^:VRZAM^.(LT2(I6E)WK3$E_U^C>\#>X+WRFE/'>'Y&N26V:>[S7?1
M)GHYK2HS48.L@0%>TO\ _K8LYER'[/[NWT^S@:#_ "LZ;9;4)Z_Y97]V<_:.
M[74PD&W+DRG6859'%I,H@N RZYN.U%FV!Y<9'L)U_J1C?I]&!I5YDV[K'D-W
M?MW4N/EIS%+\&AE;1"E#I4U+$^QP+2S)LL^%J&ZF-*DPR$.2\[M>E)4/$>G_
M ,?7J'>7@W60_<^/\^ZL$4WJ-<:Y!(RHJ%:5]6F4)W%/"7/I5O3@LS'?8WZ_
M3OW?K_EP/Y.?F@\)ZS\JSS1I/S#_ !LT6G</Z)<):K]S^3/)R:4(MEDT^Y?.
M:'1JWGQ\2A]A$ZDR!N_=Z2/+(<2UI/L14J"W_,V[\2.5W@/A3X15>Z,V'SVJ
M_,>\6![;BAUKGT/ICSDOE/#!DV"][P:!%SH4J?8)/M^PF+%2E;BF=O>@=IZ'
MS.O_ ">_EV*%@Y:;KUN2Y =LUO,/3I[=T[9<FFHT@B\N:^Y,34JI$B+3 B>T
MC6AX].MZ2Z\ZO88EQ/Y;SGD/3A7;?+WJ/3[7?NCC8UFA!!M@8'L5D27:3-$M
M/N2X!-M$Q<%Y#GPD1N+#AI5IE*%;1M6PVP\7O"FU^.%NZ(*=[;8K_P #LU?^
MJP'+K*UJ7N--)*6V7DEW7M.0H^H\!/P[>QJ8B9B'U[D-ZVVCV@U.X\4,?+X\
MP2? ;>5)2/'7R"GH+<JL)R>_+C5H^^^F&-@R2,YU:6%1GW4")_JI&E)W E*]
M-*7@>EKE%/F*^8S5%#3R+?BUXT3U/6XB,ERHD&^6S4A3$F"B5#>:U*:,S(2X
M3'[[>D"XTI]/IN2CU#;?R$^7ES'R)Z&GHMAO_4:G,17 M9:"4HR+%@F( /<O
MX5;$20'F+;?4B7M*MZ5[/HE/IK7I@<GO!_PGI?D^WVU5RZ+U0'OF?0M5$-]F
M;%'8U-'[T2W\02^LH)+:YGK#3]+>VT?3O][^YZ!MC\SBB1N.^&'#.;UTY8)@
MZE]$JM:A%R)%:3D^'!J-K90\3F0=0T/R'-:UM>])2G:M>OI@78=\K_Q<ECX$
MM[R"ZJT]*A1)+K>NH576D.OQVW7$IUL1O>DI6K?IK?KOTP.DWCKQ2J>/_+1/
M.:58K!:J[$G%C,(W92D4R3E[.S7"+O\ [0A1HL=^*VMWT:]E'T(]/IW^[@3E
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#^?;7_P"DVJ_^E(__ )Q:<G5T
M_P#E_P"S^@G*YF!P<^9Y_BA_(6__ "@_+3_Z'X?DETP^W+]'>/*YF P.*7ST
M?F:=+^6)XL4SH_'*-6[9TWK?58')ZP:O;!*3S^AJD5JPV<A9['"$S1LPM*1"
M *9@P_BHS;CJU.N+4AA3+IT]O",YUV1;\NGO/S=[1<:Y>O+#HGR[?(GPGL=&
MM]JL/D)XK79Z45YL6#5Y1P,.D)1)&!#0EUY"H\[;,.4]$]/;6XC6M^L,HPVB
MXR:;<_\ F;_."^:U?>HG/E/<P\=N)^(G,+E.I(GO_E!'-%#/3#$!EF5ZP1@Y
M)1N"[-&R&)JA\01+^K(TQA,LAJ0YIA)J<,,/OOD[;_+VM/S')U%Z8%^9?1>%
M57H-*ML.'0[[P<Q(D4CIU#?!,3I=FFCR9>=/KQ,69T_&>;?CCM*;2E>F-)W[
M:JYY</\ PM_.]R;]8W\B+5\P*MHM]%YN.^5QTSR[O/B;SSL;=3-CK1HP,&"X
ME5/D;O(M\H([ZS[$'-D6OJIM" I-6D+]N.M>1UGVHX__ +JW1#Y^OS4?)KY8
MC7AP2\<JOS:X_AGNW3AEZK=_K=A/2S8RBQ>=3AH6K2J[8 \H(2+ZLLMA3_N)
MZM*6VI#*MHVE=9]O",[M;?+7YX$,C\G(S\R/P5F4N7=Q=NY?3;#0^HBY%F<Y
MC;[';00.ZT6[@@AVNRE&!4,IMR#*;D-QYL9QB8SI;+J=8,?;]?')VEX#T3H'
M8O$7BG65_9QCJ?4_'#G'1%:W$F1*BST"\<R#67?K!3)FD(M<;L1/_P"5:>>>
M1%U[/MK5KVMG.8K*8Z6_EU\S?F#_ *P-X(WGQ5YUVDE\MDS8O+OI2>3\V?YY
M2^T%Q0RTZ,4D$Y)M[YP]7)(T-N=?(:M.16IKOND.[]WZI2E<U=L</;RNKT;7
M^1?S-_F/_+!X*3(^>-5\4N^>4?D!T>L\S\'.3^*[/3Q80Z41"DHOAOJCMOBM
M%WA8@J8!LP8HOV94^5.;B^TQ[W<ADD88YSZ;KJB#K/E;^LG>%W*YGF5Y&<K\
M(^N\-JD2+:^P\"YMNP"^D\TH[CS&RTM-@BRY$?;M?CO_ /BY42;:&X24J?<8
M?CMNN):D8^UE/&+M_1MX?^4G-_-7QJY%Y0<F7.31^NU9JP0!Q9#39FODXTN4
M'LE6-MLK<808J]D&RX$G;:E-+=C[6VI3:DJW7+*)QFIW;)X0P.5/SAN^^0WC
MEXK4J[^+MPKM([%8_*CQ@Y2 +W$ S9J8_&ZQU<)0R NX!U,NS9%9GLF])F*@
MJ9(M,ZVN,ZV\E"L-X1$SKM3">8_-6?Y??@/CQ\S[D>_!ON1T@D%1^HRS+MF\
M+N_$M*;;8?Y%Y /,11M8,E/;T[JM6[0HO%TM+7MR'-_2)PO7#6/J[$,O,R&6
MI$=UM]A]M#S+S*TNLO,NITMMUIQ&U(<;<0K6TJUO>MZWZZPP],!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8E?J6$Z/2;90;+'3* W&O%JV69VE*
MM[A%X3T)YQO2M;UI]C3OMMJ_=2M.MZ^G6!_,7^$/J +BUC^6FADB[T69Y)1:
M*/EITXJ*NC32NB,N'I7^2),M3+!#6M?O=CY+F_\ 1U@=R.\72N^$'AG/^S"F
M8CE#HXOGW/FMZTVN=;IT-(<3.4C]]IR1J8ITG)_^22RZK YB^,=6\_\ C?&B
M%1I'BQSRY57JOQULL9V\V6$U8[;$N(AAC;1J.W=1BH[&PZ](2PXRAU'O5[<U
M[:E8$S?*YMURX_>NM>&76Q+M4M()UOH]0KTJ='G)AQR<:$JQB!\Z/(EQY\54
M65!GL*:=6E6ER%;W[6EX%N^<!VX+<J(_X.5L0S<K1V)D3#O8^-$9)3PXLA/C
M.U,(';VAY4:Z'S33$B,XG278D=I+FMZV\VK0:B==Y-?O 7R-\(/)ZPU^%;D\
MS\1N0>,4YQIEF7"8F4408@]('0Y;K:DC+.<#EDN#)2-I2M$9U&M[0IY.PZ;_
M #"Z^WY0^#J+YR)]=L&#I-<ZV)T+;7)DE*S"AD89U+,-G2W=D! TJ^\]'WKW
MK:XCC>]>WK>L"9O#SRTY%VCB=(?9N5:"6^MU8*#N53+&AXTH)*!AT>!)FM1I
MKT=<H&0W']_&DM:6SMIS2=JTXE:=!+%&\J.#]*ZI8>-T3H0>T7BM!TFY\80M
M4T3(BID?#3FA1UC2Q1:8'<6U\6W'=<VQI]'KOU]O2 UT^:'0*M;O$2_6,V.1
M(-\X="VJHDD;TW+%DWSHH)-2A[V=KW#(C"3K3[7KI+G[Q7^DA&]!E?RY*)6*
M5XA\CEUX:W#F7<$F[6B;_IRB]A,N+U(ERGMZ]I26(S#4=E'^BTPTE.O\N]AO
M)@<;_E%?_*O+/\MFO_W3F!?/G)__ (NO/M?Y-]E":W_ZMU:VZW]/^3Z,"P#O
MEN_+UEC8$B5T BW(DP8C\A&NV D:2\]';<=3I.T;VG6EJW]'^3 ZF\DK](J'
M.*A3.<EF#5,I@2#504Y@S%/JW"!QVX+3,DK#4IF5,90WK3F_HW[7[NM8$C8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# _GVU_^DVJ_^E(__G%IR=73_P"7
M_L_H)RN9@<'/F>?XH?R%O_R@_+3_ .A^'Y)=,/MR_1WCRN9@,#E#\X:\5^G>
M+HJ-T?P&N'S#>'6OH@L!VSE'/A+QZ[42F) V(O$ZW6Q$.&^4?(U>QC(<=+L-
M\=)C?&^]1,8]G>U&\(N=)J7\L7RKO&J7T+YGEB<^7QPWSE\<OEN]#X7U.A^4
MPSRA@$J^(=?NW.KO7&J\#=DRYL2S$!UK*A9(!$B:4.PG(LQU]YN&I2-QVSGT
M>NIRML1\OORK\F_U?D#TOP0\S/!WR.ZSQ^#U.T7CBOD1XST-[H *V1+$R.BR
M6][=>&!)< UH4Q.::<(13 I^0]$E0U)0TYHF41[GJQF+;X>5GS5/+#N?RO\
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MT?GT&PM4ZTS(R'69FS"DQH[GMJ]Y[/ILF6%1?^&._/*__%4X1_\ 3#_E^?\
MT3U"R2>WO/Z2[ V&Q5^H@RUGM9T/6*T!@22IRPV$G""@PHR&VIZ81+%B3\:
M.@164[6X\\XAM"=;VK>M96'&"P?,Q[7YA&R_+OE$\@%]F'PITH#;?/3MK!ZI
M^%G.Y;"TQB"N?O1VHEQ\G+6)<6KV8=;0V&2[I"GB"F=JPZ<(QB\_Z=4S^-'R
MK^:\UZH-\JO*/H5J\XO-N,TG</R%[9"&H$\PTIV5)V"\<^0C-;HG$*Q"?FN[
MCZ@,OE=;6M2YRMNKULDYS,5&F+JAA@P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MK)(H D^_:@FH3'-(<I<.2VI2/>,/,R&%[2ZRXAU"%:-9>[AEC.,WJV.^8_\
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M,!@,!@,!@,!@,!@,!@,!@,!@,!@<O"_D]Y&4*<7C%Z>_8X_-9-JYG821>JF
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M=ESX.0CXI>MKW&]IL3$5HQVR'/+(W<>T3Q]^N%*YU7O(;D7-J6T#JW.R!J:
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MQ<G[25QT>MHAIM/N]*=;U["-ZWZF9B(V;)X0P& P& P& P& P& P& P& P&
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MECB0'1ET%2Y_U#*39([4A^Q5:1 4U/<:VAO>WV]>Y:WK?MDF(Z-D<(8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# Y#L^1_E2#=62 >.T2G5BNRK^ ;I 2N'OJ>L.E^K<U%
MN67H(0=%@Z+2*C7R!$TS(#SHC)QLG+<TTTU$7*=-U'=($WR6\JGP0:S)H5?
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M[DEU@:(@Q1L!EV;*>G3'&8<-IF.VY+FR7'G=Z3K;CKBEJ]5*WO87+ 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# _%)2I.TJUI25:VE25:
MUM*D[UZ;UO6_HWK>L"S *W7:F-:"U8 %K0=EQYYD2 %P0PUIV0YMV0ZU!',1
MHK;C[JMJ6K2-;4K?KOUW@7K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8',JO>077PIRNW5\7U"UTBP&NMO]7"
MF.;V%V-S."Q:+"2XT!HX\/3X%G(6@C4*\H5*C:V0C?'S83LE3+DAGWYNH>C'
MD/Y>3MUT@]R04(=GUCI=GG#OL/TB;$ #Z@/M*!@DNPF?&DGK?;CU#6D;'8<A
M>XAF8J_8EK6G2A6*0^8^173.EG.K K+46ZO#H_*B5HL%>K8NU(Z-2K5,MEX
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M#$CI=^X4ZU0*L2B<09CFAH]M@T4-$Y1E4K;6VH\3WTPQE%1YNM&&# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M)&85Z;3[3+#32O9WO6]I]I"$[]-[UZ[U@5. P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M\2>G=)ZQRGHE@MQ$E8IL&YS0=*,DZ[6*TZ9@1N94">5^$33BI"NEA8_II([
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MC,;EQW=--H0E.&9:"+C>9E2@3'(C-YFIITN=QP&1A*K-VL5RK=' 6PW0NMO
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M'YI6M^OIO6_3>T[]-ZWZ;U^[K?I^YO6!^X# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MMEADMXUYO;[%>=M@@EV2-QE5"=7N<6L+7Y8BQT.0U<^H0^:,@:U<9C2ZI.^
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M?)UN,PJ2A7PT@D5>NS!R%/\ .%)LO-^T9$FTS;XTYP6.LE+$5.WLZNQI\+&
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M[-DM-2=,K00AZ5RB<O\ +8KY O6XR?/!:TLJD(7.CC/,G SW.$=%N%J'UVA
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M]P*WZJ;FV&?87=A#//N<P9VVU$9LV0&B_:X04]S 2I#$9KV?<MH:4A.B2YI
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M*\\IUIYAQ*&$%],MXN*F+U/I\,;TL6=BWL-!!JMI,E"&109*R60".MQ@=39
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MZV@;?6%.T"G#X]BJ<5AQHFZN=%@QG8[KZIOMO;)$1<VQ8%Y87>S<G?,.WNI
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MON P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M2,3C#GGI(^.08G1WVIK$&1)<<90YI26EN*4G6MJWO8>B*U7&FH[#=?"-LQ)
MV7%90*@(:C2@T=J('DQVTL:0S(%18[;<9:=:4PVA*4;3K6M:#[>KM?DZ(ID
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M8I"=[DZ8VYMC6O5?LX2GR6Z'0 $0#/.WFGA8-JD,1*O-+68*.B625*;2[&C
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MQ&Y(4K0V90&*[5'Q\FM!6JT\PH8@:#D"8RXK6F_894PC:=:]G6$N;OJU@_\
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MY+3=+]XXG:VV_9V/]?;6C6]ZU^[O7TZPO//O+9TGP#@![B,7QT+<LYT4\?\
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M#*#BYD<!(]H?(BO+9VTE>RQRK29IE%3YWX<^)?1[)U49\OOQPY*>X_T:[<X
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M;!<GX ^%?B6Y+^;FG?\ )L%R?@#X5^);DOYN:=_R;!<GX ^%?B6Y+^;FG?\
M)L%R?@#X5^);DOYN:=_R;!<GX ^%?B6Y+^;FG?\ )L%R?@#X5^);DOYN:=_R
M;!<GX ^%?B6Y+^;FG?\ )L%R?@#X5^);DOYN:=_R;!<GX ^%?B6Y+^;FG?\
M)L%R?@#X5^);DOYN:=_R;!<GX ^%?B6Y+^;FG?\ )L%R?@#X5^);DOYN:=_R
M;!<GX ^%?B6Y+^;FG?\ )L%R?@#X5^);DOYN:=_R;!<GX ^%?B6Y+^;FG?\
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MD\0NCR;1<;+Y V@L8YQTL@9Z%(O_ $'DS,N.>H5\Y[41-F*BV:V@;2A!(WQ
M,R-)"60DLD/>VPZZMN5MG1;RC2G1SFU<K=/YY1:I39RB=1K=0K@.KDE3XY51
M"O"Q$.$&G;)Q4HBD?BQS+;GOV]:;=]KVD_1O6&)UEFN P& P& P& P& P& P
M& P& P& P."WZS)_@S^57\8<5_3?S[#I[7\D.T/'/YH>5_DWH_W,"\,3NDC"
M& P&!PJ_64O\&'S"_P!CQK]/7,<DNGM??#KUP'^8GBGY).<?<<&RL3NEO".;
MWS%+EWR@0?&8AP_O!#C7X1_*7B_C];F(W/N:WAHH#[-;8@"2=BJOM>-NC[#6
M(\=Q4!+*M175OJ^(9>TE&DFL:F[CHTUJ?S3>D\;,>4@KNM!)]:K/.K]\Q,GR
MJWTTU7HUR,5SPFD<VE3^=%>=AZ6*A#(S@B_ITP>V2G2=N1)*Y41IA++KAKA$
MU7E]71_Q;\IS/DSP2X]8E\YD<N,5D]=:PT-=.ZM@,TJN!H!<;;:P8D@JJ6GU
MPK'+-:2D@)&3&Y#+[:F-MI;>=,S%33BMX/\ S=NZ$^8ME^Y'J=V.V= &^#J*
M'+M)_C_)*51K+Y.TKJYBXG>L=6XHCI5,YOR6,=YBY$KPTR,_"&F:ZU%(#=?6
M$%S(WEA'3;5N_3/G#T>[7?Q*J0_EBV->2KG/!-BCN7M3EEYB;ZG8>N5:BDH4
M'[%-5/H_.[.3X[/DCC, Y&DSP\AF>B EI2$N5GA.ODU:[9\Y3JI7Q[X[9:+R
MZK<)NG?JGR_L51L-D['6K')@<LL7EAQSAFA=2 '.9-">F=*L\&UDY!$)&6Q]
MGP#T2;\8Y.?3"8EM1[<7Y?Z==/,+RQ_JM#N1-0ZK5CY[LW1B'.P!3I?387%.
M0U:2'YW=NESR70^L$:W;XU81/$4:1"%,)'27B160RPGW:-N.HK&./)K%X9^7
M?9/+3RLN1I<35&\;$>#WB/V^@<Q(216[G'M7DL2ZB6E&[VRY1/K5TA"A\UD#
MX6H-A0)1 9:EICS'"7M#2Y8QC'G<M=^P><O=N>^8?9:L!\@.>D8E"\U_#CQL
MHWAD5IE.EW'J?..^\TX*<Z7::F=%2(/4X=NHZ^FF[(@D]N;7XHP \S+CI;]J
M0T6,8G';I.K[ ?-Z/5#E4.SD>-V?K8ZL^,O6?)V_7*;T"J#[6R JGDMT#Q]K
M5:@UFE<K&A2[LVP@X3TB>VP.BB0#<N5)W)E14MSQ.&M1O;8;EWS,3W5+KPOF
M4/A]:H=XZ]"[<5??ZIVM%+I$H=Q^^5GGD&-R,ZKFI*Q]7M-Z*6^%.8#.A0)$
M<+2^[+;0ZEEE\DX5%VUIH/SH+' X)XSW_K/'Z 5O75^42^N]%A<^ZH^(%,"F
M.YUCAKE#XB"LM4(&NJ=\%FK6W*)TA4F Z.8C>[42=DRHS*S7QZS'1.EJ^:B;
MJ#I4^=X"%"<F%^;/0_#J3T\OVG3C0S?,[I*H!?I1ZE5SF5CN48=8[B] $B8(
M^*4]B=)<65DBX2&)DHS&%]=:MNAY.^2ECX/:?&JDT_E[/4+-Y']B*\K'19-U
M12HM8B5WD_1>Q6.T/O:K5IF'50*MS2<A@;%CZDS)3C3:%)]K>]$B+OR<Z.??
M.?\ PD<Y 7D=XY(IJ>A=4Y!SGG!GJ?88E"Y:Q'Z]6>HVV,1Z[T.=SZ5+YB;J
M,#E,J"0'LAS4>4<)CX ^;,6\^N,:GVZFK95U?YPP+EUP\CZZOB>K!$X-4_)T
MG$9A=3&Q[V=L'BQR6I]:M,RWT%RH.R.;<?Z$/M2(-2M[TT@@I*2RIV#&;FQ%
M.",+B)89;_G*6SFL#K4SHGBF-%N<L;\N &XM>\@8=A</=(\2:!0^IV*O-N2^
M5 &1M4M5-Z!&;C&'%+DQBT9]AT?N+[F<\.$3M/;ZJP]\Y$]SQOIDCJ/BNZ+8
MYW_6\KNFZ#V5KH!$UT7P_*\RB7,9J [S&JJ&T$T.ZI"DH.K4Y+@_ 3MR!FF&
MF)$@<+Z]OJJK?\X.TU6A"+OOQ2=DH&\E\G.X=,BS^SQ04<-S7Q=ZCQ_GEEL'
M/)$WFSA&^*N4'L$6>'C$H59?0]$=B3=1=^CV#XXVOM]6)7OYJ74)/EBY1^<<
M^"$:9R@/\PX8<XY$ZOSQKKG:[CXI1^7":VY9P=LKH9?! 1VQ'ILFNS7C,MHV
M)E-R7VD*7&C+$81QN?+ZNBU7\N9O0O!B7YC<MH(_J!1'*+CT@/S&J6:Q1&K4
M4HVSC9JD ;+;>=5FP:,N3:[*@L*EUV-[R>G3?L>[5I[9GC67&6C=Q^<]5Q?.
M078*;R$,?YA<ZIY)=AYM;KGV<5S*#U;A7C25HM9+EN:;+THHBT=GZ99;7+U5
M*5I3*B T;J8\2CIDM-Z-<-:3YS3YF-5Z-Y2 /%EKG[82Y&>R>0W,9<4C>82;
M>  <-Y#S3K R^'.?N@8QL=#OC'1VX+49YQM,1R,I>GY/M^P@DXU%LU[)YW.<
M>\K*'XFS>1D3UTZ^Y0C7'YXVS*]F[<]2UT(GY&6[0Q-:D.0IGCI7Z)'E2AZ'
MI"S#ED#L-NQERM[02,;BVCTKYP]ZO7$2?2^3\BY&#*B+OX&$B4N]]N=L'/Z]
MQOS3["[SAF)TBU5&DL)Y=WKG[(US[3UN8B9&K#4YB<J422WN&\:X:U/G]&Y7
MB_\ ,&WY+^2'8^%0>)V6I >7%.M@XO1)YWXKZP,\:Z6/YB>@6*KRZ\%>KF[5
M,G_6@!R',,-21#?O)BH+[K$=TS.-1=ZM8.H^7?ES1^P_-9M%1@6F_P#./"OE
MK<[D=!@U?DCW.)=]D^+?*>PM"[O+@S4>21VQ-GK=-)::&1]!G0Z51MOHE^ZU
MHU&,3$=Y_P"6NO0O/3R@J]<Z91N1>35:\M'(1[Y<SU6\@N'\YXG]?,6#RT[J
M7YOT?@E<$&#B>'%KI+IP>&<JFBTB-(&Q3C""S[_M,2W"QC'6*W^CL7X"=ANO
MD!X9^.G9NCV*HVJ^=#YJ'L%M-4@=*# G3KSDEB?!="R][="6,,]'W"-0D_ZF
M&9CRF6M::0C6&,HK*8C9M]AEKKY7^.H?RRX->/'FT6JQ5&D].^H O0955<1&
M.'^?1K*(*W6B1R6UMO!HG0ZX/D!)DQC>I4>%/>6QM+VD+26)XS<;M#S7R@^:
MS8EXKXGMW7X=,M5B\CK4(!68HKHYFJ&?*'Q2G>+W2EL7J]33-O/Q'-3-VB,V
M1E/J:+J<:]O<9SV$FN<]NWT=4J15V*12ZA2XLM^?&J%7 5>/.DH;;DS6  F(
M*9ER&V=::;?DMQ-+6E.O9TI6]:^C##*,#F5W3Y9%%[QVR[^11_LG8@/6R-E\
M<3W*RE;LY,;4^1Q?&:QM7>EA&^=QB;--Z-#)WDD=(S7+!$F.I^OI#4;;"4-[
MPW&<Q%=$C^&7@E4_#,MU$M6;_9;JOJ ^G#YL<^,#CV0[=.MG7K9%7 V+;0MW
M<Q_KLAE>G-[TEN$UM/[Y2_4F64Y;M[L,M:?,'QL$>7OCATSQT/6674!7280"
M+)L,,((LC@]5=MP"WQM/UX\AP,;'S9=?;CRHLE.V7XSKB%?1O"XSQFVI4CY8
ME=,7_P 8.F'>IM#[)XK58]1Z,)YCQ_G/):#+J717[J/["'>IM4CZ9#:NU,L\
M,:.='R8RZS*&;(0/23/G>^-<])CNB\1\FZ@Q)'!7+!VBSW2%X_4>D<;JX8Q3
M:\%$%N)\JO=?Z+RNM&QE*F5@7*OU3LP#3SUF7'<^L7'$ONP-2H\=]LO.?ZHZ
M\=/DZF:KXX5ZJ=:[7+']QA\J\7*2$+4:IT>32^3SO&#O$GR8JD<?"W7 6^L,
M3>KSGM3IQMMF9*$*W'3MAYR1)>A.>NFSNVPEU#+*'W=/OH:;2\\EO3*7G4HU
MIQU+6E+TUIQ>M[TGUW[/KZ>N\KF]<#0"!XM\Y^O:F7H/:!\2^\G,%OL^^B+4
M;'"'VFS7+IUZF,VJKL3(BR+\L9T4W';C[?B2D>QJ:TZEYM:E&KFO)B0OP_\
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M&OO-K=@RGA\UYA3C6TK4RZM&]^RI6MD8H[R_FCX^R"'^=T5X5<9VBEO&.U(
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M&3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M# X5?K*7^##YA?['C7Z>N8Y)=/:^^'7K@/\ ,3Q3\DG./N.#96)W2WA# 8#
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MKF.273VOOAUZX#_,3Q3\DG./N.#96)W2WA# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'!;]9D_P9_*K^,.*_IOY
M]AT]K^2':'CG\T/*_P F]'^Y@7AB=TD80P& P.%7ZRE_@P^87^QXU^GKF.27
M3VOOAUZX#_,3Q3\DG./N.#96)W2WA&NG>_+7QU\7UU)OO?4 _-U7N8^-J'UN
M/L$M-@*,/0H_U4/6&$$T.%I#Y!E$>+O>I$E:_1E"]Z5Z%B)G9(O+NM\Z[36Y
MEOYA9XEMKD"U7"D3"D.,1B-Q[50;(2J-P#.,E(<&5J2#L@B3$=W['NU.-;VA
M2D^BMB8F-WKU7JO.^(<^L_5NLVT31.=TR"V2M%L...M"PT)Z9&'LO2E,M/O;
M]_.F-,H2A"EK<<2G6M[WK"1%Z0I.1]EY;WFE1.B<>O 'H%,F$"X=!P!)4\U&
M-5\C($'@9.*^VQ/$' A2*Y'EPI;3,J,ZC:7&T[PLQ,:2DS"(_3U.@*ZFYQ--
MEB;ZFSS]GJ;E/]Q.^/10)%CD5)FR[D_"_5OPCEBBN1=-^_\ ?^VGU]CV/16%
MJ:OHK>B]$I/(Z%<.H=)L@VG4"@5PM;;C:3#BVAH&O X;I H2EJ:0Z\MN-%85
MO2&T+=<5Z(0E2U)3LD1<U&Z-.F^47!N,<ZI75NK=!A\_HW125?"TPG: UE%D
M3ART 2-H"@FJP^%3:HIV2 #RY3D*1":E1FXKWOFV]MKUHL1,S4,CYSW?D/7]
M!GN67P)T(78J..Z/7[+4%2CU--TXJ:*UV(4$W8=&?J)!_1H'*CO0VIJYT9;.
M]O,H3M.]B8F-TMX19A=BKYR4=A!#H<Q,JY;0"RQ!9.$0DUX[L8.-:"G&(C[S
MHDML.8B2_AI&FWOAI3+OL^PXA2@O. P& P& P&!@?.>G4/K8"=:.=6.+: (R
MWWJA3B4-B=':CV_F=Q-\_O0139"+$?5(KUQK<Z"ZM*-M+<CJ4VM;>TKV)BF>
M8# 8%"3)C0@T@9,D((@.(@RR94J3EL0!HP; 8<E3B!"=*<:BPH,**TIQUUQ2
M6VVT[4K>M:WO ^AQ$>7'P2PF=#*"BD.*1&$QTEF:/(CYK"),.=!F1EN1Y<.7
M&=2XTZVI2'$*TI.]ZWK>! !GRW\;J[U2V\4/=?J8?I= J+M]OE?)/38<>CTU
MFNR;<Y8[A8GX:*Q6!B:Q#=G^W.FL>L5I3FM>RG>\+4U:,]_,;\'=4!_IZ?)3
MG#U)BW4-SJ24C32$J9'N=DKY2VUL&_7XPYVQM/6*JA99,>ZJ)IB:.C.265K9
M1M>B\<KJFS0WJ?-"]  =6'= ILKF-J&5LU6^@HL@A--."KDZ.CU.>,L;DM F
M7&LLDO%:@J0[OXIV2TAOVEK3K9*FZZOWGW3:)U0:?+\_L46RCJO>[WS,_*BL
M3HZ1MZYG:2=*O5=>1/BQ'5RZ[:0TJ&ZM"5,K<9WMM:T;TK8F)C=GF$,"!^R^
M2_&. EN=5_J-G*"+!UDL8"<[K]?HO0>@GK00KP]HL?U#"\[JUK)QX006^F1+
ME2&F8L9G?MN.)3K>]%B)G;HG+<F/KWGJ^SKW2TMN^KJ->Z<4E*TMN?OOWBU(
M7K>M;]-[UO6\(]/;1['O/:3[OV?;]OVM>Q['I[7M>UZ^GL^GT^O[GI@0WPSR
M&XKY+<[B]9X5T0#TCG4P[8ZS&M0-4ML>X=J9Z963XW:"46!+;?A&8+C2=J;T
MA]&T.L[<9<;<668F)J=V;72]URA5DM;#[I-T2$C0Y<]JN #UP-_#3YK$"*[#
MK53&FK"22Y(DI]?AHKOLHTI>_1"%*T2F4*EQ4)>6N3'2F/KVI"E/-I2PGVEI
M]I[>U:TUKVFU:]5>GTIW_FP,? 7>FVLE; U8M5>L):A'6ZO=QH0Q )S:C97@
MXNPM@+)&A/O.AC*P1N',U&D:;>^&E-.>S[*T[V&"77R"XSSGJ?(>)7?H0*N=
M5[VNXM\AI9!4O16\+H 9JP6Y(U;,5V%'V($OH<_\4ZQ[]2O=L^\<_>86IF+Z
M0N_*^P\Z[51V>C<WL31ZG/FKE7T%W81$/[)6@72Q<]M<=V&:B#Y["!MMJD^+
MIQ;26G],>\:4MI2%J$Q,:,@ WVD6F99QU:M]:/SZ59]TJX0PQL<2DUBX)&##
M2JL>9B2'5BK"@29B2=PWM(D:9DMJVGT6G>R5+YJUXK]P0:<#.%&_J&UV"F3T
M&Z^>K+SARLSG1Q3ZL8L8T6\:$*DLJW%(PTOCYS6O>1GG6_WV#9EV P..QSYG
MW3Z'=+W7^H^+(BL5[FWE_P -\1+(=I?9;+UNQ$;)W"KTZ_"#]3Y[6."P;'8F
M8%*O@U>H,?;D^456N$RTM*=25'3A$QI/2VV-+^8KX;="N7**%4>U"2UG[4#K
MISGT+ZAMT&//W;AUL+5:OFB1$!$&U"[6 ?0S3D4$6=A%W/JQ]/P_MZ2E1GCE
MO2$.[_,P%<-\V*-X?S.7#CV[;_5Z1(MGX51@*WHWY"W7I],@DJMR^?5'46RM
M\UWS)XE:)JCH]<$;*0XRS)<3[I98QO'DE>+\RSP[GU"TWJ!T:R3*Y4@M9MLV
M2SR'L6I9CGUSEV&!5>J4P8[0VR5ZY*>F5,DU&M =J:"=<B[1J5[3C.G"<,KI
M;;'\SKP[#HLD<3T8S;RX)FDMPX-0Y?UVV1K$:Z;R=CN7/0%=)U:A&X9XG8>2
M2-V1QF#N2Z.!1Y,Z8AB/&>6@<,DB4#S$H!7P[X9Y>]0;7SD#V?F7$KK&JHMH
MYT(VBU]Q%U==3YO4!M7 /6?H5H*62U1Q8Z,.%JF$7UIVB.GUWI(G&>7&$<<D
M\_Z7WSRJ&<!X]6B=FH2O'%/?#78R(N^UZ$Q.G=.LW+(?.X ,IS]F''L8*QT8
MS&/-ER0J8-)0G!Z8KTR-.:B"<:BYWM$AKYFQ:J]*O0JU>/3XGA]3\K"_AFQW
M&)U* 7?C]C:H@*X5@A=>9-TN(<KO.K61L# ALD+FV";%F*2M^"EE7O-%X?UJ
MV<#?FM>'D.M5V;=^D*$6F?SOC-X/A:I0NQW0'!E=NY</Z[30==L;/,!3EEEF
M**],+PXVX<0LL.+F2Y$&*F)*0P.$]%VZI\T+Q7YQ2;=>Z_/Z/VL/28O$YAV5
MQ'E-_P"@ XR/((C06>90U7<< 104'C8'I@<UH2HIHML3-9=1&6N1';>$83UT
M998/F1^&U43TUVQ=7F!X?)!]B*6\E/YSU&,+=ATJ^5SEW0=U D[3$PN@RN:]
M'MPT'98X)9&0 *2T1IR&'?:3HG')+W#_ "GXQY%F.A N3FK(;(\I,0ZUT)HQ
MSWH%,;J]MDP62$FFDGKG60#3=Q!QY+>B8O6]SACCFFY+;2_WN$F)C= <KYI'
M@Y ,+"$.RO#I3-[MO.I$HCSKIX\-&L%!OL+EMWEOGYE-9"MU.I]'*109 Y[_
M .IHQ.2AA<G2]+T@O#)?3GS(/$*O I=H(]"LJZVQ:N@52 =%\B["<&6=7)&"
M,GKEMI,D+1)Z;OS#E#8B5JR6P3\96@ZV=HDSFUJ;TL<<F,67YJ?@W4SMOKY?
MK)UV515W;=B( ^/=IL]:9A<R8J<_I9H=;JUSXM5CE=YT$O08F=(PIDB$+%DH
M\N0ZAAQ*]CAE+[F_-.\(!]B/UB7U2Q(GU@U8 IR:UQKMDFMP=4_J;/%+H?5;
MHO/'JL[2Z5U";$$&#B)BA V3.B_$2&TR&E*'#)5J^:%X1..$XPSK\RRD1]\K
MW-X@2G\VZE<;!:+1;9'18%631 %8I94Q?0=B+\FL4&&4#LS1KTP6XUI_VE->
M\'#)@O3?FK^-=7(>/L+G5@:ZC%[=9^+/$SX\9>!54YYR3ME/Z->:YT6S6]RD
MS:N)-O5KFA";&JY*8-.2XC#SR64I95ZEC"=;;1!/+OA-A\:"GEZ+L9]SQ_$4
MHUT>3=9% OL&0]0 $)XJ1N(^JS:W'MQ2OZ#,+FM2(\%U+\1.W6_:3K>\,\9O
MCU1O9OF-^'51-EP1CK+BY-=-'1-GGA:+T6S5ZIPJQ*J0RQ72W6>MU,K7JMS(
M(=O X9)M!"3'K[1-;T7<OWT26E@O#)+///*OA/5;>$H=$NNS=IL0WN!<..T
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M,X\V5]*^4]UNSB^E&A_: UM[;9NT<#N50Z]TLQ<B$"#3^/>,_-^/E-])Y.[
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M^8GBGY).<?<<&RL3NEO"- _+3Q=NO<O(#PEZO32: O\ 5RO'<+05-/VRS#4
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M;5;)+.0*[9J^?G5DBH19(04T-*RZ\63I2E"SD:#)?>$D4I3O>V)"6W=:UO\
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M"/P9I" 8$*?(P2TMH8*CHCZAN)?>FEOZL;Y/XY\H[/S=YNF=G*66/$HT3G9
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M4O\ !A\PO]CQK]/7,<DNGM??#KUP'^8GBGY).<?<<&RL3NEO"& P& P& P&
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M7W*.$G\IN3UO$'(EY=T;CUJU#!( MS>S@:=<J9=Y1T*+W0>BAK!8XS*ZX:3
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MC@V5B=TMX1HUYZ"N6R*-Q"U=>[ISW@-2Y/Y5<'[,JS='(#1HFS3.961^RMT
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MY.K#P*'3.,6NV/U=3?D^---$^J';$/B&:L:Y]XZDVGQCNVD(]XS%U\4B7M+
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MA<NR_)K0GG!1B% DR-%6Y;<=F,QZ2&U:'&>[)S'E/0Q%=M4"B^-A:9'N%V7
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M*GR7_BX22)&5'W.;;DOMOO-H6DO+M$1;HCADP& P& P& P& P& P& P& P&
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MC+<C26W65JCRF4.(WM.]H<0E6O3>M;PBMP& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MT]K[X=>N _S$\4_))SC[C@V5B=TMX0P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M%-/?#2TL1F9"$;6PWIC;2E&9W2?A# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M2*Q8N]"\ETW:L4V:&Z=!J$;RO"W,(."T?ZVKMAI)'RG[#;[[:+W>G&E3*E%
M 6@;HR%\=$:?$R&]HB3T2'%0!IOY)9MO2/+H7TWMS::^9W0@DAH)1 M5J!4B
M3<KYJ1RL=7^HUZT_@BN0$A* 2C=BE6$5IZREE0H24PP*%,>]EDB,:A&HTWY<
M=;H(@+TYCI7.^@R#OC&1"AJWRR&[47 @OJO)#/0>DV2U2J\^@9>@TJ"94]7I
M,L5$;&Q4.J%RF75>A=(G39L0:N'D4$Y;RLFY'M)>Y0>VF:O>0P*A1E7#H?.1
M-^N-4KY-J8U6SM&H+QVM1!1^=.FQ18F5&]\Q'FB%26'6R:7Y-.C';?+VIQ*A
M2A&RE;Z@4"3 ]1Y0'Y'6R=0DAX'B5:[VQ:)4U322XNX0N["M0EA=3F6DCX\=
MK</3<K4YPU43KT=.^*RND+"6T7TU\@2)5OHUP 5RRE1 L(2MM)BRV95:/S(0
M.&-"*><BS%1O?1(L9E_4;2_=I6I7J8FNB8\(8# 8# 8# 8# 8# 8# 8# 8#
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M<=Y.X\@M1LW]\6>E]#ZQS)5MZ/#J<8HZ>D113]11.B19P9(<)+6LJ&($3,@
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M7F[X2&=,1RQ(#B N97&G+Y;7 YIN9-%S4,MZ5/B0E:6B;J4R(CK"K<\S^@1
ME5*O >45NY]'I7%SE#I-FZ42BU HWTX]V=$$;$,_9 ?*&%:[5N?*+V">I$B&
MP.84AAA;S+?QHXQT>+OGS=2&SC4?FE0I8ER[W"G![MT7I0D!7ZQ(I2>O?6 K
MH\6"T9L%5MM@:Y6AX0S(A,Q9&BND>\<<A*1*'%DLWS!M//>&^.EG+"Z[83]R
M\71W<;46NEGW4U74@ JG.Y9B@\[T/ 2XUAZU=)UQ6Z/@:9C-;4VE.F]Z>_U(
MXZS^J)A_;_(D5T!\M=+)$(TMRS^1CC5?KAB0)(HW6_+GE?CY2(._C:C+BQQ=
M8JA5U:XOM.;E2I$EY;NW5M+9%17FSB%YE%V3-&,57D?/#%C[L9+NSX06^A!-
MG"CN?$JA5V.==))V9-<@1.ZMQKBMQD*X[M$- N;'TIW37OL'%N?X^]5+=?YT
M(N-B'UBOG#<?Z];JM?L+Y^2'JQ29/8JLLVY-&AYD>>9B#775)^&2PE:5MMN.
M^Z4O9F8J:3CA# 8%IF@0I$D&,SQ4"86KKLY\"2DQ67IH=XE"<&D'1LE:%.PU
MS1[RF7=HVG:VE;3OUUOTP+M@,!@,"PPZM6A\5J#" !XT-@X2LS$5H=$2PQ8S
M!4@=*G66O=>PT7(&BLF4](3K3JY$AQ>U>TM6]A4C088,\8DB1< =(L!51PX]
M"BLQW2YE< >*44(K:2E4N>H:*C,;=7ZK]U';3Z^B=:T%UP&!\K0AQ"VW$Z6A
MQ*D+0K7JE2%:VE2=Z_RZ5K?I@8A2N>TGG(Z2)HU8$5B!-F[(SF!45+&YT_<>
M/#U+G/[]J1,D-PHC+"%.K5MMAE#:?1"$IT-V8X# 8# MCH40^9@V%X9!=.C!
MI0,.,.1FE$8(DW)$33 Z+,VG;[$(G+ 077VTJTEU<1K:M;VVGT"YX# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'
M!;]9D_P9_*K^,.*_IOY]AT]K^2':'CG\T/*_R;T?[F!>&)W21A# 8# X5?K*
M7^##YA?['C7Z>N8Y)=/:^^'7K@/\Q/%/R2<X^XX-E8G=+>$4LJ#"G)93-AQ9
MB8TEF9'3*CM2$L2X^]JCRF=/(7IJ2PK?JA:?12=_N;U@62ST^M7(-]GK*)CE
M NRX$\H>XIYAA9:L6,;;@DMSX5UA;FX=B$1Y.T*WMMY3?LN)6A2DJ&RY:"AT
M[CJ2)&:5$A['Q%:@1=;BP-Z3K<&/O37JS#WI&O\ 5)]$?1KZ,"HW @J?5*5"
MB*E+:0PN3N,SM];#6GTMLJ>VCWBFFTRG=)3O?IK3BO3_ $M^H>:!0MN2Y-;&
MP$3'6XS+LM$..F2XS#WM4-IQ]+>G5MQ%;WMM.]^C>]_O?3 _(XD7$:4Q%&CX
MS*UR'%LQX<=EI2Y;VI$I:FVVTH4N3(3I;F]Z]5KU[6_7?TX%C&T:I"+-8+D.
M!PX]GM.A:3AC_6NRIB T#0P<A&GG7&H3;$'6F]I82UIS]U?M*^G R!\>/DM/
M,28,.0S(1(;D,OQF76GVY6M:E-O-N(4AU$G2=:<TK6]+UKZ?7 ^FX,)I*4M0
MXK24>GL);CLH2CV6ULI]G24:TGV675(UZ?N)5O7[F]X'PR-'1I3LV./A1YK[
M#$9^6S%8:E/1HNMZC1W9"&TNN,1]*WIM&][2CU^C6L#%C/.:8?F5V<3!L.N5
M:S-7(3'CO2H [=GBP7Q\$T4%P'XPX[,&,O\ MQ-SFI&HLA#;[6D/--.(+<LJ
M<'P'9;)!V##=GQVE,,37(S*Y;+*UI<6RS)4C;S;2G$:5M.E:UM6M;_=UA%.V
M#",LL1V0XMJ/%=<?C,-CXB&8[[K3C#KS#26=(:=<9>6A2DZUM25;UOZ-[P/=
MT8.?=COO#X3S\.0Y,B/.Q&''8LMU"FG94=Q;>UL2'&E;2I:=Z5M.]ZWOTP*:
M: !$VFF"042098TWIEF:.ARVF=-:7IK33;[+B&]-:<5[/IK7L^UOT_=P/IP&
M$>^,V\'%.[(O1I)#W@^(Y\=(A>QN&_,]IG?Q3T3W:?=*7[2F_9U[.]>FL"H>
M'#Y*8B9$&'(3 ?9E04O1F74PI,=.T,2(FG$*U&?82K>D+1[*DZW]&]8'IN)$
M5^[%C[^E>_I9;W]+KR9#F_I3^ZY(1IQ7^=>M*W].O7 HE 0:EN.J#"E..D&2
MSKBAT/:W"L=/L,$W%[9]I9!A'T(>W_K$Z^C6]8%<U%C,*4MB.PRM:&FUJ::;
M;4MMCV_<MJ4A.MJ0S[Q7LZW]"?:WZ?N[P/? 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M2Z1T&P#IXR55+:\]#F"K#9RHN2UM^*TXG:V=J0XVE2=Z5K6\*GW"& P& P&
MP& P& P& P."WZS)_@S^57\8<5_3?S[#I[7\D.T/'/YH>5_DWH_W,"\,3NDC
M"& P&!PJ_64O\&'S"_V/&OT]<QR2Z>U]\.O7 ?YB>*?DDYQ]QP;*Q.Z6\(BY
M/\]3WY+HWW62\+T_=*.$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@13U7_1YU^5
M:F?_ #6;A82MA# 8# 8$6<;_ /G*?_\ P]ZW^EBZX64IX0P& P& P& P& P&
M P&!3R__ +5D_P#W.]_\S5@8#Q[^:3EOY.:1]S(S"SND;"& P& P& P& P&
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M0GQ3!>3D^^"AY:M3G+*^DR>#:HP"@.ETIGROWS3OUHUI>]*0A*C>-5K%_O2
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M-_XG ?:^I_\ 5%=_EL;_ ,3@/M?4_P#JBN_RV-_XG ?:^I_]45W^6QO_ !.
M^U]3_P"J*[_+8W_B<!]KZG_U17?Y;&_\3@/M?4_^J*[_ "V-_P")P'VOJ?\
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L,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g305886g50d02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g305886g50d02.jpg
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M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4 9,
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MN$_H^G>:W&+&SEOZ%HY?"2)CJNSYBBMB!*HL38 MBUJ#&R A_,:2YAO8=_\
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M>I2)5<KVK3,ZU>SG 96$)<H91@D!(0;T((M!#KTQ>:'G,\?^LJ.>Y34+WSW
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MS(U<K>VYT=R')8^^2^!V,W.USR(RI(_#K-CZ)M;U3<:UV*P1Q[4&*E(2W)N
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M5)*;M:8FA;H9[6_.7);R<PS0F3G%6Q55VW7+WQK0EA1IC5$711"8M?P:W[@
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M1@%KQU@?1I:&E@;43,Q-;<RL[:0%*W-32B3-K:@3 \?(G1(491*5*0#Q^0
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M+7M@"W#?F=(XHU#JR =R35#2-W;R3AJVT+FG(&8GV< &CP $('FUK>\#*X#
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MM)V5^'TU:"BE)I<JSH,J,6$OO(ZGIK5AS;5AL9Y$@1O3S+4#_8#_ !I9&OK
M72BKZ[4!=5;F_.ID?.4.('$Y'IHV04$N)G&./]7W27'=TCOYEYRAO2SV_5T+
MH(J%&7RT1JH7B;NS.IY.L^WI55!;PF@HJR43"OIE%F9<-T2L?J$-;V4B5$&*
M2Q*!#$QGOC\VP<O7]<JEUYKDER72GEK#>50].2:=I':/0.'0R%J.?YI!F>/2
MN,JFAF;7AI"LC#NL,D?SFZ." Y6/XA*6WD%A3Z%DYQV=7TRE.L3D*TAY*I(J
M)*4I528T!Z=2G/ $TD\@XH0BSB3BQ:$$0=["(.];UOPPP^V P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P/,L1I'!(J;W!*F7(%R8]&M1
M+""E*18D4E")4I528X(R5"902,0!@&'81AWO6];UO \^V=I$<%3MK;MJ -QC
M. _:)-LX+2:,LPUK";LKSA;C!D@V(C6_2WL.M[#\FL##&P6$'N<?>CX;%3GF
M)I/@(L[&QYH,<XTA]/1/P<?7C1[5,R3TM:#Z:898/+\GAX8&?$@0C7$N@T20
M;FF2*4"=Q$F)$N(0K3DBA8B)5[!M04D5GH"!FEA%H!@R2]BUO8 [T&M.%>0!
MV;Q-#K!H>YM0GTZ4";'",LJUO%)E*DU:HD0D2E$8FV^J%B@PT:OR_$#-&(6Q
M[%O>]AD':)15_6(G!]C,?>E[8G6I&Y<[,S<XK&](Y?#_ #BE1*5B8XY(G7_"
ME>N L00F^F#S:WY=> ?%1"X<KD94P51.,J9:0WG-!$I4,+6=(R6I0$P![84]
MF)1.9;><$T6ADZ-T6+0M^(=^.\#[1J)Q:&-NV:'QJ/Q1HVI/6;:HTS-S$V[6
M*=AVI5;0M:9*E^)4;!KSC\OF'X:\=[\,#P(J^@3<<N4-\(B" ]S<#'9R/11I
MF2G.#J<O0.IKFN,(1 &K<#71J2J1'&;$8)0F*,WOSE@WH9KWNL2BK\A>FM\C
M,?>6R2;)%(FYU9FYQ0OXDQ28A.)Z2+$QR=TVG(1$@!L\)GD 4#6O#00^ >@B
M.Q]*TJ&%*Q,Z9B5E+"53*0V(B6E22XZ,TX%*&XL@*,XI=HX?K!$#>C?-OS>/
MCO ]9C:W&_-^C6]$;II/"I:M&)2!_-BD"10@ H;_ #%[^"/ A5FDZ&7Y1:*-
M&#Q\HMZV&$-@\*/=GA_.A\7.?9$T[89 ]&Q]I,=GQCV7HG;,\.(TFUCFT[)#
MH'PQXQD^77AY?#!FH\MJBXK<*2/M#^J5-D>;Y'#'N4,C,V1D)=@M-?2 J81*
M$RAR<V)R=RH<W3!(0O&E;ST0S]EC(&9\.>H*-++A*,AC4=ES2J8)6P,LG8EW
MIZ6LLA:D+TTK-%&!.*TJ;G(A2C4>D: (@^<&_*+6MZ^76$><</B1J!A:S(O'
M3&R++&]QC#<-D;!H(XX- !EM2]A2"3;3M"QL+,$%.:G"6,G0MZ!L.MX'C;X!
M V@IT(:83$6PA\"Y@>R6^-LR(IX ]#]5Y"Z%ID10' +L;]TIT=H>CQ?*/S;P
M9K\E5[ 25T<="8/#RG.'MP6B(N)4:92UT6:0%;( UQQ6%%I0R-P2-^31"811
M6@?)Y?#!FLN5'(\24G))868HE(T&1Y*44UH2RDS =HC1S&G+"1H)+0;I*5YD
MP=:)%Z8?$/W.O / =!X4H=V.0*(A%SWZ,(]M\:>SH^TFN\>0"!LO:%C<AI!+
M&E'LL6P[*3C+!Y=^'AX8&23,+$CTV:1LK2ETRDJ$[/I,W(R--)"S0 JR&S11
M(?@"502PZ,"5Y CT'7FUOPP/,ABD6;& <4;8TP-\6,(7)3(TA9FY(P#3.AB@
MYS3C9TZ8MN$0XFJS1'@V7Y3A&CV/6]BWXA\6:&0^.EH28_%(TQ%-8!EMI3,Q
M-;86W%F(TK>8!"!$E("D - A((WHO0=;)) #?W( ZT'P<(#!79.T(W6%Q-S2
M1]2>M84KA'&=:G9%BD!I:E6T$*49A3:I4%GC",PG0!#T,6M[WX[P9K-Z:&G1
MC8=IL;M&LI9A+.;I$F]1I).3A2'%-@_2\R LU*#18@E;!H1>M!W\GR8'R4L+
M$L7E.JME:53H1I'HER4MR,]>3IO-5GH-%+#21*"](3EYXR? 6O2$<9L/AL8O
M$/\ 2&)C2K/G%,S-2=P]1P.^.(;DA*SUG<2,;J;\262$[U',;<GVH%YO$[9!
M>Q^;R!\ PJZO8"Y_,OSE!X@X?1M*K0QWXZ-,JOY@1."?21>C9?71&?-:5:D#
MHHXLCTP&%Z\HM;U\F!]SH/"U#VIDJB(1<^1K4Z9*LD!T?:37M6E1E'$)$REU
M&D$O/3I25)@"P",V$ 3!:#K6A;\1]F6&SM!J%(UF-3:8V(!MIB%N&A2C0HC&
M8].J:!I$@BMITXVI4D*,3; '6R#"@"!Y=AUO08=\@D(DR5S0R2&Q60(GI4B7
M/*-\CS0[)79<V$E)VU8YIUZ-04O5-Z=.6608;H8R@ "$.]:UK6!';!S]6[#:
M$WMK3.F=91,U$*5$:>&QC6)(8?!8J.'MAD'%MK O8!JV<>PJ=@/%L>_D#L /
MN<+FXPDX,2BH)(9,@1F/AEYK>%I-E069N#)#6H(M#"V&/FDVG,;>$8=;T3LW
M9>MZ\?#"!\3BJI&RMRJ,Q]2WQM>@=8ZA/9FXY&P.C7H>FQR94QB81#6O;M&"
M] X@)9A/FWY-Z\=X'X?8=$90H;E<EBT<D2IG^-^:%+ZQMCLH:OG)/\&X_-QR
M]*H,0_'I/[H[TMA]4O[D7B'Y,#[+(O&7%M=V9PCK$N:)"(T;^U+&AO5-KX,\
MDE.>-W0GIQI7(1R=,6 >S@CV(!80[^0.M:#Z(XY'VYB+B[>Q,R"-%(#&LJ.H
MVM$E8BFPTL9)K<6TD$ 0 0&%&""(G1>B]A%O6]>&\#&H('!VIH"P-<,BC:Q!
M-;#PLB".M"-H"<RGIE+,<%M3HRT>C6E2B),2B\GB0,H @>780[T,U]U<-B#@
M^D2A?%8VMDR5*G1)I$K8VM2^IT:-<6Z)$A#N<E&X$I4KF4%266$S0 'AT9K6
MAZUO ^2N#0EP:U3(OA\66LJYJ2,2UH5Q]I4M:QD0'GJD#.J0')!I%#4B5*3#
M"4XP;)+,,$((=;%O>P\:^MJZ=429M<X#"G%N1F>LD;U\68EB)*;\6F</53)5
M" P@@SX]&2?Y@AUOUB@#_P#N"'>AFLJZQ.+/R5Y0OD:C[RAD1*9-($;JS-SB
ME?4Z/_\ 8T[RG6)CB7,E+_\ RP'Z&$'_ ..M8'K3L3&D92XVD9FI+'BF_;24
MPIVY(2REM6R-IMMA;662%"!OVFWLOT=%^GY-^7P\/DP, 56]=IV4$;(@4+)C
MI9[8J+8"HLQELH%+(:2>S* -0$(4(3V@Y,6-*/1?F3B+#L&P[#KP&:V5<U-C
MF)"-R;D#@-K7E.K8)<C3JQ-SF04>00XH1'EF;2+R2%)@ '%^4P(#!:UOP%OQ
M#P'1:,*$3PVGQQA/;I"K,7OZ YH;S$3XN.+3%'+7A*-.(AS5FE(R0B,/",8@
ME UO?@$/@,L@6UMI3BJ>"FY"4[KDB- M="TB<#BL0MQJP]O1*EP2]*5"1"<X
M*!DEC%L!0CS-AUK8Q>(8]+%HPA QEH8XPHRXR6H*C8$K0WIP1\I6G$D5%L82
M4X--):E*/91FB/3T,O>P[\=;\,"+F_GJKF^S'.T-1MJ5NJJ(5?#61E6,D?.C
ML*25*Z60ZQASA2'YI"='G@1EGKBSC23=!T200$H)?E'LPN;C"6SF-D4IWA(H
M9VL]+(?4V_ICF](:G?/60D-9WSP2,D1;GZK:E*3B];0_,06$O?W =:T1CVJ&
MP]B2(4#)%(VSH6QK5L;:B:F)K;TC>RN"@I6O9T*=(E))2-:U40 TY.7H)1A@
M B$'>]:W@1_7E*Q^O9M8U@IW1S>I'89<59/.X)6! WQ"OH"4\@@=:1%NCS,S
M)D43BRB3.B@G:C2E::H<3A&GC#HH!9;<\-Z706$.D<W#W.'15QB6Q:'N++H\
MT*XYL>E0EVA[9%",QLV+2T6SO'TO'U=['_\ =\N$>Y5&8VM-83EL>8U9T64:
M5Q@U4TH%!L<5:1F-VE+"8:G&)H4:;SAD>=/LL7HBV#Q\N]ZP,4V5U7S*G,1L
MT%AS2D-?2)2:E;(PR($YDF3'!4)I$80E0E%#?4Z@ 3 *]Z^( /6A:'K>O'!E
MZ!0:$C?'23CAT6')'QK$QO4A%'FD3X[L@@%EB9W1VVDVO<&L1900[3FF#*V$
M.M>7PUK!GL^K-#8A'4+0V1^*QMB;6 U2>PM[,QMC8A9#EI:@E8<T)$24@AM-
M5DK#0&B)"#9@31Z%XZ$+Q#Z&Q.*G(P-QT9CYK>4@=6HM":S-QB,MK?=!"]MH
M$HDVR ('D(=:5$Z#Z:C6M>IH6!FR""4Q)*9,24G3IRBR""""P%$D$E T6422
M47H("RBP!UH(=:UK6M>&L#ZX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8&,>7MFCC8K>Y"[MC"S( !
M-7NSRO2M;8B+&8 D!BM>N-(2I@#.,"#6QC#K8A:U_;O6!'?U\4=]LU4?I$B'
MWXPN*W5GF$2D+*=)&"41U\CJ?XO9[\SO;8YLI'P =B7>LZ(E)Z$OX((=[-\Q
MFO3UK[KPPC2M7S1N]:WJYZHWK>O'6]6+$-ZWK?\ 9O6_GCY=;PN*V^,3B%S8
MI8=#)?%Y<2WF%$KS8Q(&E^*0G'@$824L,:E:L"8PXL.Q!"/8=BUK>]?)A&K*
M+QI5(H/2*K?JY,J2GG)E2918$3)4)E*<P1)Z<\DQV"82>0:#81@%K0@BUO6]
M:WK"XK.QJR:[F:P]OA\^A<L7I4WQBI#&I2QOJQ,CT:61M6>F:URHXE-HXT(/
M4$'0?,+6O'QWK",<\6_4L><E;*_VC73&\(# E+VEXFT:;')$:,H!P"U:!:YD
M*DQ@B30CUH8 [V$6M_V;U@P^C';552=S3,D;LROI"\K-';2-#',XX[.:K2<D
MQ0?M,@0.2A6?HA.4(P?E!OR@#L6_#6M[P8>F1V=6T/7@:I;84'BSH8F+6%ML
MCEC"R+QHS1FE%*@(W->E4"3&&$C"$>@^78@"UK?CK>!B4=V4RXK$C>WVW6*]
M>O4D(D*%'/8JJ6+5BHT)"9(D3$.HSE"E0<,("RP!V(8MZUK6][P8K8I//8-"
M?@OIG,XG$?G+U_F[Z3R)G8/C_A?2^)^"^=5B3XKX?UP>IY/-Y/.'Q\/'6!JF
M[YHW6M[W<]4:UKY=[W8L0UK6M?V[WOYXPN*W5_F$2BC80]RB41V-LRDXA.F=
MW][;&=L4*%11AR8@A>XJ4Z0TY024(8 A'L0PAWO6MZUO"-*^OBCOMFJC](D0
M^_&%Q6Z#F,1+C>IF9*8X"'[2EK]2L;XV!C>T)I@2BEFGT2K37M*8:/00F>KY
M-BWK6M^.\(TOZ^*.^V:J/TB1#[\87%;HS3"(R-F/D4>E,<?H^FVJ"I?69[;'
M1F3B0@]1;H]S0JCT16T9?W1OF'KT]?*+PPC2]7S1N]:WJYZHWK>O'6]6+$-Z
MWK?]F];^>/EUO"XK;HQ.83-@+#89,(M+BVX9)3@9&) TOX$)B@(QIRU@VI6K
M"E&> H6P:'Y=BT'>]>/AO"-747A2J10H2*[?JY*K2'G)52918$3)4)E*<P1)
MZ=028[!,)/(-!L(P"UH01:WK>M;UA<5G(W95<S-:<VP^?PJ5N*=,):H01N5,
M3ZM(1A-*($K.2M:]4>4F"<< &S!!T#0AAUX^.]81X'BWZFCSFK97^T*[8WA
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M[9X_YELRP9(-&9(9Q/:.K66RU\&W-Z5J0#=Y"^QM<ZN(D38A)3E;.-'LL@H
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MB %$DE!"646#00ZUK6M899/ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M@E?H:OG_ *RQP?%OZ']2G[,/[8)7Z&KY_P"LL<'Q;^A_4I^S#^V"5^AJ^?\
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M@E?H:OG_ *RQP?%OZ']2G[,/[8)7Z&KY_P"LL<'Q;^A_4I^S#^V"5^AJ^?\
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MIK]?58Y*Z>U^^.O5 _D)I3\TE<?@<S96+U2WA# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'!;^9D_@S]5?ZA2OZ
M[Z^PZ>U_)':&G/R0U7^;>#_@PUX8O5)&$,!@,#A5_,I?P8>PO\&FOU]5CDKI
M[7[XZ]4#^0FE/S25Q^!S-E8O5+>$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<%OYF3^#/U5_J%*_KOK[#I[7\D
M=H:<_)#5?YMX/^##7AB]4D80P& P.%7\RE_!A["_P::_7U6.2NGM?OCKU0/Y
M":4_-)7'X',V5B]4MX0P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P&!P6_F9/X,_57^H4K^N^OL.GM?R1VAIS\D-5_
MFW@_X,->&+U21A# 8# X5?S*7\&'L+_!IK]?58Y*Z>U^^.O5 _D)I3\TE<?@
M<S96+U2WA# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# X'W==CWPC[QR6=6;84O#REVWQ?8KB%FD,K<U,"KV_^,V<^>/QT38G-P,8X
MZLF=)Z,&:6C*3F.2\K8AZ,,UK>'23RTQWE_U<>)AT+92_A#BRG+GZYE/-UO^
M\WU?977%N71+KK65\JYHY$^=5<_88Y$I9))(U)Z\8UL:011M:$*12@2'G*UI
M 0;V:9D=,?JMDS-9AT7YMMH?N1^Q5-FZ<=0N517IR\RSFM)WU+!;0=FK41M_
ME01BV)W2OFL3>BSY7!)[$&UL=W49AJI*]-SHJ^0T>PBT8L\/<Z<7\U>O;6[M
MO7LB/]C>Y7>4L<$%F</\9)8=67'C*^S)CB:QY#22RX9+U'-H!Y(XAD0NAG9'
MZ,6.-2J0-;&4>209L?IG"+OK-;-)TMZKA>UYP3 NE>:>8>_^G+QZ.O[JB[&*
M.= O\]UTG<47@<?42@TQX*JB(U5!YC'ZV:JWC[:<%H5-0VT[1PBC?,(&O( J
MIOM9;K,212M''.[D/1KA[!0K5M@^L'&U@=9).T#;3?S+I1^V@-_%(7*EP3DQ
MQ%/=6@9<A0(46]:4Z. UG&BUOX?R>$:_3CY._3'W3%W7Q- F/W1O;AJ>/7/V
M-&Z\[2E/8CI=\4CO9?2+,TJ!5E4K7-H6@A*=!8Y(8 TL[XL'Y4S5\.4,C6BA
M:V'65-=OT6XF9CLK/9<$<'/W8>S^?%M;^Y]T]5E%U1PI%JWC_+'8$Z@OU3)%
M]+M3>\2>T%;_ -"5>HE2R9!:RU1RW7SJO5JD:Q0HUZQVQF3NN9X2\2W/9_9,
MF( E3ITI8C!EIB"B ".-&<<(!)82PB-.,V(PTS80^(A"WL0M_+OY<K@_D8[V
MN:W8S97\S$6Q6M9S,DJKCCB5^K1&S6#+FI/73N\UJZK'UUK\E"[D%0IT>U!>
MC%:EMTF.4F:T(T0MZ\<.VN/T?C491CJ#H&'M'MG<-W'<L^6W]SY[I7%+8YS8
MJ82=N>NF.,;^K6=SRH)K+%H'G:R;MA8CE$4D:5:-41\[, -J?4.,UO(N)SM.
MEE_NM[P5SFR^[PGZE[![-MKH62.";K2]Z+I*EZ[Z!MNE(#S3 *9DA<9CJ9DC
M=32V':4V4YE^5>X.;G\6<=ZA0O+KS"V(FU\,:ZXZ/Z=$*0MO0HT!1B@TI$E3
MI"S59YBE4:6F) 2 Q2I-V(U0H&$&MC&+>Q#%O>]_+O*XO5@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#@M_,R?P9^JO]0I7]=]?8
M=/:_DCM#3GY(:K_-O!_P8:\,7JDC"& P&!PJ_F4OX,/87^#37Z^JQR5T]K]\
M=>J!_(32GYI*X_ YFRL7JEO"& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P&!0'W#_;<YX]S.J8E4G0JB?,[3")R5/8W):OD#;%IFWN
MF!ZC#LTEO+HP2,C4?D;(^G$+T^D^A'A 7X##L'RFM=[I<Q^B/;5Y:.Z-(Z3E
M43-L9]8N=H9R[7M<6,AB4PJ"JJKA3KIZ2DU["W6+&F-$A=UX0_&KSE:DP9(=
M%%Z*+V((AY7&/N@"?^RIR7. =21]NDMT5G5/94]IFP+]HZJY/#X=5,G74P0
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MEO)/95XF7[=E:6Y 9TMMZO9I)&!(P64&F9=$)0UQ=:CF(6Q.>2%\1F!;1AT
M(#=!$(PS=IMK)<YD0#[>7LR6E[<TNHN6T_T+#S$Z^L9'5W=4&%!GU)#NC34D
MPELBJ.VX4G%)%2B 6U7C/*--"A6?I:G=6XCTAA+$,1F5K;W)OQ9^#;*X]G^>
MP7D#VWN9SKPB#@]<+]S1GKJ12TJ$/)#78C(P6C:M@CA3*TCD1BM@=5*:Q"4V
MEIYZDD)B48_2WH80AB7W/U6^LPAJ6>RYTXJJN\N#85T_4C'[;W0_1+[>\R;'
M6K92X]4Q*-S.QFRUIO2$,EI<N*K=5&GB6MO@G?%S=MS2)CAAV4;OY-U?DF?+
M'ZY$E7[[*KY=*/W(-M]Y,D->.M[DY&OCGYP2PUP<2Z2G7(D286:(IIJG5O8M
M3=F?'!AT$[X?:0PE(?O?]Z8#7F)/<QCCI^;2IK[-/2?6,XZZLOM_I:H5<EZO
MXLB'*P6;G>JI5'HW4CU7%KL5KP>8L1E@31_<9DW%RB/ <7%*M^#&J/5G)BQ$
M)@%>!9[DUQ-9TKT0OV=;944)U=4,QBGMGTU*KOY0F_-41MCDGE64UY-ECE."
M4"9XG-FNKQ+C3OF-P"SICE$:9]%)AJ_$W:K>BR@!%WF99GB]TY]S>V?;73'&
M?/7(</(XXDR:LJ<;:MD%B=%5;84DEL!DK+ HE"F*X><'.#RMD<8/,F4;.L5Z
M3JCC"%0A) &FZ 28$TFN\FUVY=6* K!PI*BZ<IQUG$@LUTJNL(+7KC8LK'LR
M2SE=#XRVL"J5O@A'JA_.;\>@$I-T(TX>A&;T(PP6MC$8MS<I=PA@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<%OYF3^#/U5_J%*_KOK[#I[7\D=H:
M<_)#5?YMX/\ @PUX8O5)&$,!@,#A5_,I?P8>PO\ !IK]?58Y*Z>U^^.O5 _D
M)I3\TE<?@<S96+U2WA# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# Y61O
MW.X*S=-^X?4G0 H+25/\/2#DV-(+C?)0NV5,';J*)&.K4A?F\YJ*2L*HB4&)
MFQ"$@Y3\4(_0A^GOY,-W3B6=:N3.>M^:JTEEEP6>W-"(K+Z;IL70EHQYV<A$
M.4(I0*Y:V"LE^("2/X:,:7MIY7K:V+?G*%KR_)AGQM1I1ON,\.=+VF\4I0_3
M%8V?9S+&1S)1%HPZ*CS5\6(-2$+7V..BA$F8Y:WM:E<44M&U*5GP)HM@4>F,
M(M:+=-I,V</G2WN/<-=$VXYT32?2];6):K8"1&@BK$N7^+^3$%/P<L.A#VM;
MTD<L(F,J/'2\;$L<0H]:V(W8 ZWO0NNTF;.$-^ZO[@DW]N_G5TMVNN9Y_P!(
MR@EEF,C.(9O48:MKF*P%K2/4JF=RV)\,O!$64E"K"6VI24RE>\KM_#I@:V$8
MP%TU\KBW"]M(6 JMFEJAM1<V)V5;9=7P"P%C.D4F+$K2JF44:9&H;$RPXH@U
M4G0&N6R@&"+ (80:%L.M[\,,V8N$ =@S/N&)-,>,XRK+FR9&E-,S?[#D_2MI
M32 1R.)XZC:U4>9&)L@T0D;B\N4LV<MT-8J5-Z!J CT,X1FC=:"77Q_[9<RH
MC[QEN] \Y^W([<VT! R>K/<6?+B98I"K>G3^DI>LFGG ,BU<]AOTJB,>6R^4
MP_1S 6%B A0EG+M+@;$/7H#T,U=)+<W],215/?\ W3UMRXPVORISSS.P6O7\
M]Z&J+K*/=%73-V*#59:_/#ZCCZZ,P);"X(YN\S;)^,1ZY&Y+QM*=I1A+TJ]0
M0O-@NNNMQ;<,W2_=_;O:_#/-/5/&G/7.S3)+79;-<+6;^D[AFL?@L <*RD2Z
M'EHX4M@L$=WB>MT\?V-P,0N!NVQ(@0E%F*!&"'X:%UUUVLVM6R]M/L\_W .-
M:HZB7P'ZLWJ;&3)CD<03N^Y$R(I+7\VD$#?5<5D>TJ';_%'5RCIBEO5;) (2
M<W01>80-B$9WU\=L.3_._O:]!7)>O/Z%WY^HY/2/3'6MN<FQBNHA;,H>^SZ7
M<JJ')@KK-O>L%<531IFB)9$:VK<TY)Q)S4B6)S1&FZ-*T;&[[<DO-S)G[.I-
MH=5SRTZ9+L;VZI3R3;>VJUY)6=@SF^K2F$(J:!*H66Z-TL1'KH7%9 ]/,L;)
M<2C;A(=?"%!TH&;L_?D" =8DF?U9<TZ]]Z>]+>H>@FF \\58'L_HCM*X>+8(
MSN5E2-SY:<%5!-!\FM#H=FL5CC)LOE5-H&$K0$9:!&8K5KMC+ =L)6Q"-WVY
M+S?TXRZ;>W5V7(.S:AL)WL6OVRJ[PH*^;2YDON!,#\?)XLTVG4SFF1NKC#7U
M8B;7)QA\D:W)(O0"5)RE)0#Q$F:$(K9@S&^OC>.EBG?;/O$%\D=QU)S$AJ1%
M.:C3@II1U_>8Y.K;2N9DG2%AK*QI$Y<SD-"Q,Y_/;ZAVJ7>LH(TG;SBC ^.Q
MX:UT\M<]W@]RKW?)9[?O7G,E%!I!AGU1VG%6ZPKLL]7+W-F?:BKPVYX?4+W+
M&^/)V->@?43 ?-$BL_UE2;P#O>M[T'Q'H:>WY:V]W^]:>[W*:#]S#F[@ROJ5
MCMB1.RI=0<'NJV7.8N3,KJN4]#OTT!!X\T,*-C<$;\['PJ"+'C8#E2?6R1EZ
MWX!WYMB:9TNRSON9=L6WQE&>82:/JF!VW9'3O5E=\NQEDLB;O< BC2[V,R2Q
M8TOCF_1^,RQQ*3)W5@(*.T%&9Y23ACUH0@:"(FFLVMSTDRH4+W;.Y9! ^Q 1
M'C.@6JZ?;C=),+LN'S'I:3*80.'D5B=:4*E-"S&+5 O4S)=(F-C=@*VIY2,Q
M[<:2FT,T0CS D&O#7CFXO1T0]M[I+K3K*EH]??1-+4C4$#MFO*RLVCBJIMB6
MV1('B.SMD6/ZXJP6Z2U["TL5<VQ H;?2*1J'(!HSC]"&'T@[,,;367$SE(CY
MTW*#^^8%QY"(Y'W5@;^;YCT3?<O<%*_;M#&]PFK17E'QF/IT9H$&G2=OR.2*
MU/QFA;"WLF]E!UL?GT,?I\KZJC^[)[H5@>W1&(:X5YRI.;U,?7")*9G8KBH4
M0ZB:OB\FL)BKA$5(Y\4@=5#I8;[(I G*;(^B3#4#($-6>84G*WYRZ:3;OA]_
M=N]SV?\ MP5TQR>NN59W?JU>%K>99-U9ZB'T55T263>-0()TTL,M"ZG*)J^R
M*6(DS0P(DIBI2$PQ48(I.0/8AII-[S<.A,FZ$KMML8SGMBF4*7]0.]+OMV0B
MDWA^,:7J10]K7F1M/)%)I2%<:@B0YGLIN4+@E&B($+>]%CV'R[,X[WHY+5=[
MH_25?=7R+FCMFK^9MH$'*%I=:++%XUMB9VTUU1&*@V69*8A<C;-8K&%;4[.*
M?U0M2XO:<A<H*T6 G?F'LDW=)XYUSUQR_7%_NL]#7-=7(\2Z3YXK6I:N]QFF
M[*N[C=_@%A2&63!D;*W1()8;7]\-K_'&-G(F$AK-W3/:94Q''(BQ"VE$ 1F]
MC -M))<7F=5Z?<@[/<^'><0V7"J^*N&Z)[9E:4?0%-F.QK'NTK@M.4(V*/1?
MYU3I%ZE 04W?&KSC0$&>4I&+6_+H7FT9UU\KCI%2)7[N*DOV=EON=P&JV-[G
M+&Q1=OE-'/LL6-K=&;7^N2/4G8\!=I,E:%+DE^B4I7K-DFC1!-/)))$,  F^
M.B^'Z_!&LJ]ZA_9O:Z@?:C/1#.Z]+S:YS.9M<O&S)>F1M70,<G\EC%@PY9*M
M,8W72"+Q:%.CYZ_P.MB2EE>?00CV+4[97X_U^.>/5THXIZI=^K>%J,Z\=X@U
MQ!YMVET-JJX6U.ZMX:&=4L;U:[YI1O2M"@6+$H=I]:T<-.6/>A>/ERL[3&UU
M^[FSP5[C?N*=TT_%+UB_-O$$>A-DUO:$BKZ/*>L9Z;9PYI$C))'HBRR^& I8
MW3#&GN;,0"EZXI2J.1M9^E)9)P]Z)V;VTTUN+;_9F^1/<"]R+HSK.\><I1RC
MR7$&3DNTZTK_ *9EC%TA9;VYMK?9,/%.$#O4[2OI)K2S52D8O+H9+@>SZ]<7
MD\V]:\V1-M=),YO/1W<RN9@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<
M%OYF3^#/U5_J%*_KOK[#I[7\D=H:<_)#5?YMX/\ @PUX8O5)&$,!@,#A5_,I
M?P8>PO\ !IK]?58Y*Z>U^^.O5 _D)I3\TE<?@<S96+U2WA# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8&->53@A9W5<TM8GQT1MJY4VLH%:=O&[N"=*:<C
M:PKU?_M4(G!0 )6CC/[LK8_,+Y-;P/Y+K/\ ;X]POK.F?=\NJ5\XL=#7'V19
M_"\[HWFN1W% YC(5K;QBM953T@DMA156= V5?/$R 8&W8U&@ /#X'^D4(!HC
MO-M=;K,YDE_RE:TN1O<-ZSN#W(^A)9RHWT63T[[2[ER71U</EX5;+)ENU"9(
M_.J1AG;E&GHV-1]4[+'D\\I44I/;"$/P_K*0*1'D$SE)MKK),YQME-KC[;%\
MN5K^U"8S0UB@$+YW]MWHOEJ^)='Y#$R%U9V%:?/<(@,>(9FI XD.,O(3S=(X
MJ-*6W1Z8!P-GB,#ZNA[K/E,;>MJN/MO>V[T)4UD<0P+IKGWJP"_AP^6#B]W;
M[5J63\A,2E/!)-#T#_3=)-J7ZW/@+3;7 I&L85Z!L V 5#,/4G;(T$R-;[2R
MV6<_;EVZ]T6CK*Z7]O'L2@:<9$LDM*VZ(F\(@;"M>&N/I':2/3?M.W(E#V]J
MD30V%G&_)LY0<64#_P#(6LKGK<;2HYKNZ+FI*R?;MX3144ND(WSE19(NB;6,
M<W,N(T<CI> P:(M3,D=6I@=HS+)1.;!6F($R3;DCV%(F,5E^L6'>L+9+G;[H
M(]YN">XS>E?U[SEQG59TIHVU5#NF["F$0NBNZAN-36"92T$&T]63U8:DMNC8
M[/;%2XET?"TZXU,B*VG"6'1X_.72ZSG;KV5\FW-'5,4'[7'65&\ -]<R#V^E
M=\TV\\'1R_ZG?I$HY_M6NT]<LLD@%JGJF&M'22M9S$E<E"1P6D*U059FS#AJ
M CV,LNO,MZ]U09;PY[N4,XD1<VU;33<<7V[T_P!+]2>X8GK*_P"L()9<!A5S
M3UK<47,54S^:*P1\"^5P8G2.029&F6ED^D<F3@$4;LPXOEI=LWM.%H^MZN]S
MB;<&\Y\@\?<+).6:O>"9#5G25:0+JBDOK1K_ )QA9S$Q1V 5-:2\Y'#RGF\X
MRI<-N3UZ"]<VE%F / ,]6,W9-;I-KMM<W\'8C@F,R.!\NUQ6CYRFBXO15@A,
MKZ&T2AM*(7&G8X5&@DI6!\'-X240TN"N1A$8J4Z,\RW:D1AB@8S3!"V8VYN<
MY?S4\[>V%WO">L>?YV]<YG0OJ""]SSVZ>I/='2]#11SC_3'+,G?G]4XU-JK$
M#T*>+1R^)G-C00Q+V1&@9-HM'!.#ZQNRSK=];K>>,<1UYN9'=<MY8<J\MKV9
M*]O*.3:^+)*F',<!NKGK<<,AT=D/T@JR]7G<Q!#HB^O]ANZ(A<M0EF?.C0J\
M#3=G##X8<YUSY8KF;3_MO=_<_4WPQ?"*FVZ6V#QKW/TS=L&X69KM8'MSJOCS
MI*&;A"6@J^MV;.+?!G:5588G^<TA!Z\IN.+6F$EJ0C!Y11ORUML[6=?N[#>U
M#S)<W/\ 5W1MA]#QEJ@ET=A]?WCUK+:Q99$W2TFKD%EKVM%$J_729HWMC?)
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M%)H\%:;WKT-S,Q\Y2MF-83%P%C4TH3275_2N!Y!:$A8X[$$[9@AZ"3SGC/\
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MK')73VOWQUZH'\A-*?FDKC\#F;*Q>J6\(8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8'%?WN81-9S6? Z6$0V6S15'_ '6.)9:_IHC&GJ3*&**,<CE9KW*7HAD0
MKC6J-LI9P!*UZC1:1,$8=F&!UO62NGM];^%0QV)Q[#>J_>\Y@17I23K:_.[3
M[>5VER/3[&I OJ!=-OKA9"V",S5R3IPQ=R7Z0.A[@C:5Q^Q"4)B5@"MC3%F
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M%AVM$.*E*(9>M" 9O=9]SKUSQ_9W3PYF P& P& P& P& P& P& P& P& P&
MP&!P6_F9/X,_57^H4K^N^OL.GM?R1VAIS\D-5_FW@_X,->&+U21A# 8# X5?
MS*7\&'L+_!IK]?58Y*Z>U^^.O5 _D)I3\TE<?@<S96+U2WA# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# K\Q\P4S'.E9YURT1M8GO:RZOB-.3"5#D+\>
MA<8!!GAR?HTTDQD]Q,CB!0B<W8\8E1"4M2=H>@F#$$.M:+Y7Q\>RP.$,!@5
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M8>PO\&FOU]5CDKI[7[XZ]4#^0FE/S25Q^!S-E8O5+>$,!@,!@,!@:Q],8_\
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M>.08I0[;,^;FY%)82!<B:TXBO!P3G#T$0MF:V-N;6HVFO/Z6/C*]\N2Q%[+
M?>M.J.'N4$L1?&T;/'$44;FWYA2+6 Q.4:IBDF3*TZ X0AGHU*I466/Q.%K9
M9^G_ /5N3+(NSKDNZ^I17;@X(Y'2G;#;5;02^=1ND-K6)4Q")%!RU4+F/-),
M(=6>7++IJ9X5O2=Y<3SWU2O>49[<M1)R""@1,:R3\'<U"ZM;H->6V.2!Q&U+
MS6IT A6)U8VUT))3J3FU>%.89M&O*3JRC!$F>4P(#0"WKP%K>ZYN.WN.7-)
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M2W3S,)7""E:^4:;"F8,Z;T;FXM<<L@+2F*(2-P;*C2%&_P"B2"RTQ>G'P)
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M)[CJ2XGB.P2!1=L8),Y5?9L+L54U/K D1H6QP)F9,+*:EQYP#3=(C/#P'HL
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MUK!;;U>2>4%1MIR2-S&RZ>K*P)9#MD[BLDF<&C4F>X]I,N Z)@M#F\-JQ6A
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MT4%W^X<\SR?PV7I%'6P&@M.Q5@IASP6N0\W\WJV]2HD"F?RPQ8SH(LO1-Y2
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MPAB+#&HA2]8N]3U5SJJ?$S@SK[V"3&E$MM2UUS+LI4ZPM;+G5K3PDPLX@M;
M=CD0 :^?TH49;K)9JZ"5SR0IBP6R13?H[IVR;..97E',94XW3,6"'OSO)6!>
MSN[@RTM'G!OJ"%HFI4Y#5,9+<S%GM1I"<?KG&E"-,,W;[3"HL&L[IRPYG'>
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M-;W0+>6W/)C>:D.*(2&)QY9XLX;?&N&F^%V>]7C#K/>(Q<,ENYWM"4RAICB
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MK;A31&XU*7FU(5'70AK6BJAK;Y:@*&_./S>B.6J24Q CCU*0"@>-[X1*X>X
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MK<J0TI+JTF$6GJ)IM1W-;X;,G)"B9Y#\+!GHIL<0$.A?K)].;>:VGB(7!&2
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M"=K?5*4938J6&"+",MUL:5_\EG-QJEL"WHKD=VJ3S&9U=7TE;*9G:B/6=<T
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M6]?G1/FRR+'X_C'6UX.\K@2VSSH,?+3(TPQ2KHS$E\GAV@C=Y2L>35ZQQ/\
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M)2CA=+&JX'14GNB1RLOHHV?K0REKI>8W^MOI\C:BK-Q(:M9<Z+3JJCZ->6Z
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M!AF8EYZ.;3?P%:[G >]$K#6];4=_Y.<T595E9P 5KS"T'E)-ZW/NQ<X/%L6
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MB F;XQ1&Y55.R3&QY+3)7!L<=G!&0J2%%'";=?O5@Z!Y4751<E:6&P0:'55
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M 19@ F%C#L P##H0!A%KP$$01:V$01:W\NM_VX'Y))*3E )(*+()*#H!91(
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M8JQF72))"6W<>=W( Y,J8FQ0L+2"V$X:<D8PAV$.]X/&]XDFU;JJ6C6B.O\
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MDF,(XJ[OSW,'CA'A_HF==70M%./<WZ.I_E&(2LVB*];X!R/' S"TV:5W*>0
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MZ),6^4_8Q$\=+9.)<_=IE-"Z"*]VGV9Y1T7U^S=6N=F\0]17>WO/U?5W7*Z
M;L.J8^[21N0:KM&TM3W5ZY264%@5KR-N!>V]8$U0<#R@(+<>&V)CEW+]Q&WK
MN:/;[O+H/A*PHRZ6=6L,-MZ$/+&BB-F1:?1NM'@E^L6&I?BR7ME7;DD-979
M4>E%\4G7>3TAA,#O*YZR>6-NCB>O]\RT&N_WKK;<NBJSVHW1CE]%0M(.,,X'
M;?4<0XWCO6.G,R>$)/GU2E?I,L70$A"(_P"%VZI]^  FZ^2-_',>/_?\LX0U
M>70O6\KJ2Y*MZF?H7(YW87\M3=/4-JK$=3U[%9:W6G-;0<](XLFE3#'F^2H(
MI#X8]IFL;*%3\WG+D@EAI0E0MFX629XZ>2U7M4?Q,]?_ /"CVT__ .OQW3?]
MG_Y51W=@]74F;_,,].\Y=A1FA$_)W;TWN)743C6%>SE+<$@#"XH'319C[,DJ
MY_C\/E[6S 9F(EBVWJCGC2@PQ0;L!199>+XZV9S$U2GW&/=1Z?M#IYVY/C-U
MQIXYLB'-JRN*'KRL^4I#4<EE=GT9#;JDIW5DROZR(;<K)$9@;(53>RGP\DDM
MN;DNE!B@U6$P&ZGCI)/+I77GW$^KNC>6*FXLZX;%":!T^TWM2S%WI6;@PQR3
MF,].7B4VPQX? 2L9"U8Q'TO8+VB-,4MJHHI8489ZHC"0Z\#&NLVMG?LYINGN
M0=OVNRT2;!;C8*?@?N7>YC;M \LW8NK*#OQ-&<@TVU/#,POL;;W9O"U3>UNB
M97$%ZAB4R$2Y*2G/!Z)(M;!Y(WXZS.>LBH/N+7_VF]<J>ZYRC-NOW&P$? 5K
M\?Z5WI%:W@T,D][0'I!\B!I--VFOAA3.T0R;5!)?(K6K(Z2@^>TFMHUR?1)A
M@1%UFOEKM)URN9T+TS[F23K-]X5IVW^@YU+.=^/(%<9]G4#0'&:J87Y:MFR:
M6IV"4VA$;TF4)B$6HB+%MJ%D4HX46<YGK-'FGJ"=B)UNLR:8\KCF_=YG'K7W
M'>G+JE-!2VZHEP))>>O:N@?5EWP'Z 5;:#5:ETSQ!)4$Z0R!_D"J1$M=$Q<I
MH\IQD<<RER7XP(OC]F!"(N+C23,YEVPQ=$6[+Z+_ )36-W%7I<9#,8)R/)9!
M'"YC$(W847"N#<+X2 #Q#IFV.\9D2()2D6O07)3BM[\!;#XZUX.QMS[V/NRU
MI=0>XG9UL>XS#:=ZX:^>J\X<X5YJZ?A;7'*%J66/,EGLMYR=[-=8>YN,J85R
M9#73Z[118)8221M<3LY.6C/3)RC2CA)KB9F;:F'W*+BO#H?^766]1LUGKJ=F
M<RY JR[[91P=F0B#/&^8PI@52ZO6QY4G >H TO#Y(0*@N#8=IP()2Z3:&(HT
MWS5-9)[GCVRK&NJ#J&0>YA[:-9QOL-?'[=<_:>NM>_\ 3J>F:S72LB#.EH1-
MX:6.)5VK2JJS3/C20M:&H+FL2+-G(4AZ@9>UIX32RYDUMLXRT:#>Z;[@=XU'
M[<%-MLFLL%JWR[]UM]S7%S/5O.CM=5E X[LY37T>:ZRA_0\@B5$QIW?V\9;Q
M)=[]=4%*3KYO2AT89H,7PUEM[3#JW&^F>]H+[/G5EZ](QXZL>NZ!K7IY;$9*
M^,-8#<I0AK5J?G>I;1E,#A$AGE:LLG=F<*3YY92%)Z$IS2J A*"0( ,,8UN\
MD_;7/2&WK[ILWZ$Y+HU=[@*9G2]R>W O[-D$C9>::8^-H>31-KBKH5&*81K6
MD]*N0R(R5)$SBHDNGD?HA5F)0)C3$VTIJS22W'2X>NK?<<ZBZQY7]O*+Q>[^
MAV7LBX>=+DO*UV+E*F.2#M2.&UC;#A3J"W+!G'6C_&ZGK&*@?(N>(]K:-;5N
M:Q:8$.TA!)7G%UUUMZ>,O=@N;._O<0[@D7M=U#'^F6"B%?5G)W8$ZO:RHE2U
M83"0K)+S=>[E5K',X"W21*]16/R*4(64C:@L/QK$2%<J,(3&""D$6Y+KKKFX
MSBQCJB]Q7W%;V@?M?U(S]"Q6"VET+U]WOR=>=V%4U GY;*HSS%I]U'[$9H:Y
MH-QN.3S3,R&&$EIP :S'(0#%28]/H:88NNLS<<21CGOW+?<!A59+^8Q6?*+-
MN=)[Q-F>W@#IN#551R>XGFI(562&SV@47KV<.,'YZ!>DP&L$U-ZAU-2M7I%&
MCT2:I"7YQXZYS_\ 7*19IV-[O-9UU1%62=T>JFLFW?="KWE2IKCZ-JSGQQGU
M@<YVY44H>43Y;594C+I37S)8-9S)+HXP3.K:-/2=,D^Y*+/4;$)KI;GMC+H+
M[EUZ]1<;<C\@UE >@4YEXWYU#SAR!->R)Y7D*\\4(L8QW#+[E45\F2$5PWR1
MR"P"+2)!IA-B<U5OP+\0 WJLZ2;6VSB3.'"BY[)OWE.R?Y@R6K[MA71-T5-7
M?M7QI/;$SJ.KW5!(&]TL!(SD(K%JKYF6U8JG+#&Y&)&L&0VIT_QA)2PI,F4>
M&@'28OCQB<NA-U=S]\1>\/>)L>)W%'@4)[6+/&9I"*$3U)%G!RMUVL#E[4E;
M(I.9Z405)&FLX'+?5DJPQ#K;TN'X)M*B4A/IC,377&OK4:P;O+W6.?J:M'IF
MPHE>/0='%^W[9O10Y=?E>\B5VQ1KH1AC3!+($=2Z;F*SI'*IASU*&][-^*3O
M:4;LA(3D&#5E;.-T&+==+<3BY:![BD9[>-]ELKHZP/<NEEO_ %NCY+LB6QR*
M4]3,%A12*TK @!(HC!)9 6IFF+;"&)ZDR=2+:M:L/= ->TJG>DZH\G2KI=?D
MQ)ZIKZ+Z=]SHOKNP^'J7MOH&<S+E_DVL;-#8E$4#QFJD705P6@X2H]KFMQQ6
M\II"([$J*9QMR1C.004HU>)6!2<<I*%M. 5233Q\KC%OWX8R4=:^XEU%;-QT
ME)[LB/!KGS)[5U:=-W-5VX%6%G-5JW):,,DAUD(I/)GY2_C;*/B8VX2'9\:=
M"5B42LHWXX9H=9#QTDSC.=L(N=! _HZDH_2WHO\ \,8^+T!#%K>@?7.V[](1
MGAYM;\OR>;P\?_7PQV7_ /W_ *I4FG;7>'M]6%;,-L&[6CK!G![.,\[I@<1<
M*CB%>,]46[53_'(8GC$:-@R0F32*I24+MI4K+>%:YW&0D$/:K1FQC$3QUV[8
M_5A@X-V)[M%>4G;]V2M=>,VJ)W]N"\.AD=V7Q5O%<09ZQZ1BE<)+"K=WHADH
M2Q)DNG]'2Q,L,3Z0R=N5+4A@49AY^M''EX/'2W'&<_=CY1V%[G36D]NFL7J]
M[-FDX]Q:KY9U9(7OF"A^8T]C5G#HE4%;/C)SO0C7?TDC=6/9ABF5#?I,]OZA
M:\F!T8!M2E$;T26/'3G[<)@K?K3OU%>WM>U[UG#F&&6C,%_ND,4S<9A6U(JK
M"F\/HRETLMHJR"5<)<YZV4]*WQ(K*!)VF..Y"14L2'$FE[2B++U2ZZXVNO3A
M"?*O=7N0K85[-/65Q]4LEFQ#W!^A%G.EG<^)J.K.'0]FC:])922.SYHED?:D
M\T#8B=P@FEJW8%1+09ZX4Y2,LLL8CH773.VLG,C^@'N*7P^=>WGW*[0V41N8
MLQ7*74K,H<XR]-<A;"W1JJ*;HG9J.6M2E8D X-JLL1*@@0O4),#L(PZ%K>LK
MGKQM/Q?S&1"K+JETZ_E=M0CHM36S7(^29.37C2"HJZFB>JWN#\JPIWL60(AR
M9,:.6*+<CR@EI$4X^)<?"G^);_*<,6'6V8W_ !_-V4[0N'LB5>Y_S9PGSWTB
M3S?6MP<AW/<<_F#;4]>V1.&Q[KV<L+,U+X2;/&QQ;4#LJTZDI#-+"U2$",Q0
M9I/M5Z!I48UFLUNUF;ESPHSW(NZ.F:Q]L7FXV_(Y2EN]8W5W75MP=@-]80AS
M?7%IXKDCRSLK)74&DR-56+/:%NI0I]G".;E)"72<1B9-L1NP!-7366WM,<?B
MZ;>V[U/TY;;9[B%!6/,XA?%M<,WY*:.K?H(R-ML CMT&'5^CE\33V$Q1'R1M
MFET.>EP6N2": D)_#R#"269YMCK.VLF+.ECC<J]S?O>B./.TBKXO2X8C[D]%
MM_+$RL"G+>HCG!)4%81*UNE6>NWJ=<[2>MVEW;K$JJ5QE\ VA')%BEQ;SP:/
M+\!;$8&-^&MVF,>-7I[_ /=/Z!Y9ZD]P"-U>[Q2?03F/VI(STS$:W.8F5P+9
MKYE5WIH2DE<I?VPD$I4Q]MA+ZC<U#6)6!,8@!ZP= ]71N&==)9,]]E;>ZX!U
M@FY3]L22SWN '2]O7E[FO TYK>QGZHJNCU<U+)99$; 6%J(;&ZR;(T;-8 6[
MNY"Q,0[K%"DXM$$'Q  '&:T76Z^5XQ)*ZD>VS=73*SJGW)..^C+O.Z.+Y)G/
M/BZMK<>8#!Z[F+C&;[J]QG:Z-29FKII88FJU&')M]-(H)1E&B*-%H>]ZT (*
MSO)B;3C+^=GKKH?KCL3A)SZQMGIZ/)ZPD7NW5U0#+Q<36<#;6^O&.H>FF]KA
MI35825(GLY7;"4+ !W>"G!4K0*V<XP04Y @%#!'36:Z[8DY\>J[%N^X'V9 '
M?M!LHF5U3#)P1[ZM#\6PEV6TS =M@ZVMBLFS2LFP--+.V.\W="G]80H->%2K
M;V).GTG+6%E[UY3,UEQY=/'+T6UTW[L172'3/)%'VYT%;%C<-4]2NV"5UM0?
M%I;;T/;MHPYQL@VP>H&FWY[!U\*I]T//+CR!)7I&AHTR$]2>KVKT LZDFF)M
M<8OX\+6TYT-WCW'W;;5'JNA@<&,W(M$\>V!.:2AE=5+94TM:Q[WK]'8=D#?I
M-8*69I@55"W,1L<(-8#2]G#$6?\ %^H+6]DLUUUSUSERQ;)WUOSORE_,+7@M
MZD*N5\I/K1^K[Z*VG1]4RR*R:R"Y-SHD*MU;'Y$WOS6SMI<06GM*2()T_P!&
MTF_!624%06$6HUB6ZS'6.A]H]4=M7C=/N7MU4=AQSC2'>V)4572**P4RG*PF
MQ=XR&146?<SM/;?<+ 2JG-HJ9T4)OF5N3QS;8,LK>S_7$< )9AGQUDF9FU%-
M>=U>X;WM:#3&JSZ&3<:Q-Y]H2C^\W=HC]*UW8$J;+@ECQ+FQ8RQ]TLAJ=Q)(
M!*5;<2J/"L+6JM-11!:0:<X\Y3A;KIK.F;Y8=O/:OZ3L'L#V\>2ND[8TT[LJ
MUZD:7R<*&)"!L:7"2(EKBPNCNC;"M[(;@/*AHVK$G*\"21G; 7H( AUJL;R:
M[V3HO_AAP6_F9/X,_57^H4K^N^OL.GM?R1VAIS\D-5_FW@_X,->&+U21A# 8
M# X5?S*7\&'L+_!IK]?58Y*Z>U^^.O5 _D)I3\TE<?@<S96+U2WA&BV=64 N
MBO)E4]J11HG5;V''G*)S:'/Y&U3+)8V\)QI'1G=$^AE[.1+4QFP&!\VO$._[
M<#0WKF.@)$30Z=[JB(N9',#LSOO/Q2I (8*G=X_&APYE7Q#6C=? *&V,&"1%
M;WY_*1OP_P#XX7-:4]<.<CR-RE[P^T#7;HZ3ZZX+T=,EJMI&8?(KSK(E,G@-
MG.0OB-:.E45(1E!2'Z\- T#7B'>#-8:LO;_XWIV]Y5TY75"0]@OJ9*98L>K,
M-/?WQ_)4SQU.>YL9'0R)Y=FZ&_2QT4&'..F<A %7L8M&Z$'>]86[;68MX4RL
MSV<Z'Z+[FZ1ZBZFCD!O"M;HJ2B:^A]7O+-(6J0P)\J8,F(?WS4U99"VK#VN:
M(GTM.I0$>@2H((T6JT>#RAT6;V:XCHK#^6>=:^G,)LJ#4W HC.:WILCGJ!2*
M.L29H5Q*DDKPF?T]9,12+1*-OB9+TC*4A3 +UK1H-;\<,^5LQ>B#T_MC\!I>
M@]=4)^5:H)O@,N%80)P6SJ@EE6(/7W5B%132[Z%%6"(S^\^?0MNG7UO[WXCU
M/NL+Y[8QGAMBW@'C)RK9XJ)PYSK597D@N4WHEZCRAH--^<[W/=M/9MNJW4:K
M;V;80G,.C-.FU/Q>M?<:'H'W.$\KG*B3)[6D[M?J7L#K#J^P:R1V%?/-,CXN
MJ=3S+$GF+N];43(5<C+<IV]R*S%<R->;Y>&%V2(!+2TVFU"0A\A)8RS/(6;\
MY)-=>DN74NBZ)KGG>BJOYTK=F+15C4M=1NL(PT+"TQXCHW&F5.QD[=M%)TZ5
M:O=""-FK3/2 %0H-,'L.O-O6&+<W* Q>VSP8/G\/*HN4Z<WSH"=[L\-/_18C
MZ%!L':H2W<MTV:,^1ZV>/?\ >^;_ /3WZ?AZ?W.%\MLYSRGHKGJDB+5<KQ(K
M.*$VV\52EHQSGI+?HI_5U"A>3)"CKTQ0 82]1I,]&B4@("#6@F;\=;\/DPF;
MC'97.:^V)P-852U31LIY?K=16%%C>!4W'VDEYBZRL R)8I7R$B$2F+.[++HZ
MC?UBPPQ<0F7EDJQ;UZH1Z"'P+Y[2YSRE2"\8\L5DY4:\P*CH)&';FF(3"!4.
MYMK<:%?6,1L#TOINR1M4<I-/*3RL9(1KQFB--4F>(QCV,0A;)=K>O=JTZXTK
M '*_4'-5#1F)4LDZ3BE^@=ES0SGF,X+.ON-/35)[%>FPA62H<ER]X=0K%H2S
M2A'[!O0=AWO6]%FWZI;V5YXD]I#D#CZ/4[*$E*U<\=,P.BXQ4,PO1H87-O42
M5>GA+;$9_)H]'G%W<FJ&J[%VE/,<SD)1*Y>!28%4>?LPS8R[;[;?@M$MX?Y&
M<N:D7'3AS[6BWF%L1[1-5+*F H^%M!?SVKDI1[.C,&)2T.*20+CEJ=6F-*5)
MU(]F%& %\N$\ML^6?U*+]/>SC0$VX@L7CGDJ)5KS,BLVU:?LZ7R,Z-/$T'+5
ME9V1%)FN!-G!R?3);,5CHRQXQN3&.#BH E ?X:#LOS $6>Y?+RO*VU/>VYPE
M0:>WDE3<N5-%$E],YT9MU*)@$_IIO$3P*2QPAQ3R=2]$I8$ M88$MB2Z(:"@
M[UH"8.@A\"7;:]:TR!^T][=E:1"TX##N5:\00VZXDA@-FQYQ42F2-TF@C8[%
MOS="?3DTA>!,T10O)0%)3:WB2(BS@!%HO6PZ\!=]KUJR$YYZKA[?(!:+%7=>
MGWG0<)G\:YNFTL:UZQ-61\XB948<$)'S8K2.)4:>D;>D3.92<83S416PEC"/
MP%A)>W:J>^W-P1)N4)'U=?EUOM72KJ+M6XPVO<;G2\5?(G5<<1M#9MLC$)@;
M?+'1[EA[>G4*W!U7K5ZG:A>YNAPQ@UY B$:WVSB3I$U=)>W-Q)UY+FF?=%\[
M0BR9NS,0HLGEJHQ_CTB6Q0:@:L42?W>(O,?72F)_$FC'IL<QJT&A&#WHK[L7
MB2;;:]*W8SBKDX]3<"Q50%9K5-_5S&J@N(UPCB9PW/:KAT?'%HM7CR%;ZX P
MY@83-ITK>1HE,5K[O0/4UH6B>5]4+V=[4WMY7&AKIOL?EFOI 34\!;:I@AY:
MF4LCDU5<SA\C36ZYXCTA:7:20)K+\0)V=T/6-Y(-[" K01;ULLWVG=M=P>V[
MPU?<SK:Q+5YLKZ23JHV>/1ROI6F+>8P^,4:B:Q,X1F,&KXB[,)SW%V%:C+,2
MMKAM6A)%K?E*UYA>(F^TF)>&KR;VI_;JF=G3RY)7R)3\ALFS9.@FTUDSNS*U
MICO-6YY;9"5,R6LYP$R,TN4O+2G/5N:%,F7+A WI2::$8]"'GMC&>$K2WACD
M6>7LX],3&@:_D=X/=?.=52*=NK<H4J)57KPQKXRXQ:7L@E?T9ES>HC;HH;];
M<D2HT"(W9 !A+\ Z'EMCQSPTFBO;3X4YI-GIE*<UP&&ALZ%+JTFZ08G^3MKS
M6[F:(]QKPMJF#U(&UI@BXT7B:SHBDS<9X:T(G>@ZUH7;:]:C.+>T#[?%8,TD
M)HWG:'4=-7F!VC7K';, )4FV9 &:W(@NA,H^@\CEBB3;:"D[*X#T@1"+-;$(
M][V4F#H9@1E\]KUN5NN>N<JNYEYVJSEZM&;TJIJ6N&2L&%L=@I5JAS8FAJ"V
M*U<@$4F3(W%UD9FSE3B9HDLM0J4FC\@="\NC-N;E#)GML\&F\_MG*IG*E.#Y
MT9IWJSVNG]Q8CZ%(K!TJ5K?I:2V>I\CUZZX[Q-V+?B P0/#R;\N%\MLYSRE.
MP.2>:K5D\KF=B4Q!I=*9Q1;SS-+7MW:O56OU!2%UV^/54+Q%FE@'#W%VWL\Q
M-H(?$SY=;U_9A)M9Q&2K[F#GZJ9SJS*YJ:'P^>ZJ>#T5J5,K>),[:J"MM;U
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M0CL,H*O&.AZ^;(1RS,2; YXC*5I$6UU%-$^WK9,DAI'K[VW.9>Y$N\![V/\
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M/@"$ $Z0CXLSP*^77@+OM>M6MB%(5) ;(M:WX; 8['+-O(V''6[-6Q)LE]L
MVOF4^.0H<C5>H+2P4;8U)B5+X!#Y"A;U\N$S<8[*BR3VF_;@F%I2VZI/Q]3K
MW9<YE*"=2>2+V9::%?.&YV0/I,V(9/G'4>:I@H=FPDY4Z(TB=>M$'>E!IH1C
MT(OGM)C/"8W+AWD=X<) ZNE UVN<95?\6ZHD2Q0TC&<[]$0E,2CB=O+!?$:\
M\R84J< $ZC7AH 0Z^YWA/*M2Z1]N3B+KN8-=@=%<ZP>R9PT,6XJ3+59C_'Y
MX13:@:OZ)R)UB+RP+)7%-*31CTV.@UB$.S!^!6O.+Q+-MM>E?.X/;>X;OJ<U
MS9EJ\VU_)9_4S5'6" RY,6\QA\98[$ER9RC$:4+8D[,1C]&F!<C+,2-SC\6B
M(%K?E*UH0M;$VVDQ+P^<P]MCA2?3>\+&F/,M;/\ +^E(VAB5\.*U&Y?"6BQM
M[I&WI,3*V(ER*CZU=\Z1!L.,6A2@7'B1%>H</0?#8\MNF>CSW[[9W!?4<U8K
M%OSEZL;)FT?9&N,)I"[H'%&L=(PR'!4,\8EH&5R;$TZC;6<#6T[>]%N",K^P
M)>M;WK!-]M>)>$ZH>9J :["?[7;*DA+98<HJ1HH9]E+<SDH%Z^FF!2I5LE;"
M DV2D(B32H6&"3I"BP *T+P#X:UK6B9K:Z@I^L:"K6(4[3,*8JYJ^ MFV:&P
MB-)MHV*.M6U2A;M"VIA#,V21M6K,,\/-O[H>]X1)&!P6_F9/X,_57^H4K^N^
MOL.GM?R1VAIS\D-5_FW@_P"##7AB]4D80P& P.%7\RE_!A["_P &FOU]5CDK
MI[7[XZ]4#^0FE/S25Q^!S-E8O5+>$<F?<QL6 02X?:T;)K3B*U'&P/<'@$,@
MKTLL2;P4=22Y9 YVK262C;8@H(03]4VI4AJ?3,\Z,:SM*-F##YRP;T;UELN/
M1%O WN?6KV%UWT!1D[C?/E%H*@E5JQ9!SW*Y59C=VSML@$J11Z.VB[0R01!H
MKM\KB;)-G+/795JH3<$Q,$8S=&^?"[:362\_DWCL;O'J6M.TH1Q!RQ1U,V#.
M9_R78/3*6>W38\MAD2B@:[FNHXX-3PU1"(R-W>TSL0(E.C"F-3&?."TL1QA2
M8HT>$UUU\?+;.,JF\D^\MTO>LU]M^2VES/45<<[^XX"XX3 5\9M.42RW(C95
M%Q1\>9-)9(U+8DR1 BM)8[Q=<0U)RE2AT3I @4*S CWH@1K;VY,XO,>FH/>B
ML"1]C4=24L3<EV93715JV3446FW+\NOZ9.=<2&'1>6RYC5R>P)Y4,0I*T$;F
MCB1J-R!$W8\UL6F;V'2DDO9@A?;_ $YYS% >E^[>N.ZZ=]N[H1WHRLJPXYN+
MW>>9&VB)%&;3E+A>1+=7UTRR'-2FX(L='6^)&,UF?,[B,D#6X#&W&HP%J23@
M'@.#&IK-;9G]7BM38/\ ,%2",WY9Z*-UK3K_ $'3O5"GF"004,@N-;UW.$<=
MFS97L^O& Q]DK!?3Q$,BSZN/5$LKB]%NR]K;CSA&)AB++W69[?'WQ_1_3]AR
M?RJJ^G_<.M>5>_Y4E[!IS5,<_P#.$Q84[3#Y](5#C3JB2\I6!*X FJH.JFBZ
MN=DV 2;IRE"Y]7(%;.O !,@"J( $>H[>.L\;.MK<_;V[KZCKR#>UUR_?]#U2
MDH[KCA%_-HB91>TY@_VX2LYSY\89<X*+F;UT8:V!O)LZ(%Z6)"V=8K.;!+"R
MSU)IH#-:)MKK;;+S*AJJO=J>N;.&O:U::#Y\H?F"INFH/<[I]973UL7Y).7J
M,5PBS'YM:JM=[@01N8S]5,+'=5ARM,N?S4Z)"6+>M[,*!X%5;IG:YMMCOAWC
MUV^<;<#75V(T1>*V4^U)5[1/B(RFDBM-#I0H7.# A/+;I0C;UJP;(:!X&<E4
M@3B$<6$&_+KS;\#GKKY;>+GJV>Z=U[6%SPZL^K^9:6A:#H[CR\^K>9CJIM>6
MS%S97.B:^#9,CIJ]#I!#8\C+D@XTH),,=&$LYO*.%Z)>E'RF -^$LSK>EQ48
MP+WB^R[ HWD.=).3:18K3]RB91&'<.U\ZW'+CV= Q,]?NDRN^XNB)"DA'JL4
M,9M(B5$;9V(A<\.#>H#M2(@_^[P7366S/3JE!=[J76<3J7O]DEG,51/'7_MJ
M.%<3"[JYAUKR$NI;9Y]GD:43[ZRJ:F4@BZ5_:9(E@;>N5Z9'U(#>E"'T=G[&
M>#0">$S,7BM26>]O8<GX_N;W&:@YS8)/Q16?0M55W'I!(IB[,UJR^D3W=GB?
M0=XKX@B97!)$PUM,)"2G:FE0:::Y)$:Q4>:F*"1LX?'BS6W]3I-S;V6]=+=7
M]B5'#8='S:$Y5.J6");I1OZU>ML2YYS"DUBS2+-+4!N SDL5>1A[:2U"D"LX
MTU8OT'R!"'QPS9B2]ZI+?_NX6914O[WI910,8D70O/=A<H17DZNDTW=4A/4;
M)V$^(HI6KH<L,83%$<6,LJ)<T3L%*!:20-!O[K6M[V$U-,XO:_DK=<ON\LW2
M/+[VR)>=(Y8D"EWM*=#]F]90UTM*6P\Z"J8PL6U(AY_1R*'($LD2.$PM!DDC
M<<Y%G('%$W-(E1!>Q[\ Q9I9>O.<*@7!*R7VT^HGR+MBR"1IV_E1VB41N$()
M3('U#"TSFX.BQK:4+V\*1.SLJ8$!Q:0#FIW\>I 3HPT>QB%AJ3I__-V:1*56
M_8#2K-JU6EN_:**4[7[4G_&Z4[X]"9M7\9ZGQ/Q7J_=^IYO/YOE\?'Y<K'_^
MO_Y?FYU\5>Y3TMR5S_[4T?ZKHRL&?DGI3F]F@E76-!K(EDPOF,OU2<^_3IC?
M[;B[Q&6F)J$ELQJ)G*TB5I<%1S9\2 *I08: 8-FMM9;<?NE25P_[[<WZ<OSF
MF&3.LZ735MU^=*TL&9ZADMQ2JY>=5B"..4O@Q/2 I15\<K!R23EI:QI!JXVZ
M&DMCJ:62+UR][-PFWM^,OK'4?I[MI\Y?ZZXJIN90B/AH+KIULRM5%U*Y"L0.
M%=79%8H=-()%G5I,;A,IS#8C2WK2"%1BP@TE6E%KRB#AB:YELZQS\C7O!]"W
M/!>1&JA^;ZS,O;W"+=Z7*Y8;K,L63-%8L?*W/"U8(70=P.3+%U4J^=)BP(P+
MD+ SI3!'$K"A!4^77]X:\)+<WB*@=E>[;WTHY[GL2KN%U)073?,/>M%<H]5K
M&"P':41YVW:LGA+G4CI2:Q_JQS&HK>Z&5T5(Y">YA;Y#&$H?,D+6G&;T5&M=
M-<\\RSA8[K[WI;RYTNM[YN;H#RJS7%1O/M?V]T$FLFP[V5Q&;V1/6AR?T-#\
MT.L!IEV>7->)H:PC+D<J0,Z(1Z].2)'K>C1AJ:^W+,\XM?B>^Z]T=U<*RJWX
MSYI@KA$85[>,)ZNZ(,OJPI77=AM9/0M>OKS'J8JYO88@](M65'65&J./6O04
MS6>J3;(\R?6P'CF2:37]U[X6L]G)S #V0.0'9U"HDA)/)2E:N)<'!<2H>TQ"
M22FG)E3F T;BF$N(!LO9H![-*T+Q#OQUK*SOQ[EGW4-Y(]QNU6/G[VC.<N(N
M0:@CJWMCGWH:7P>*V9?MIN,"H4-+R'X\XQ]FKM&IG9$_C)J)>M4'Z%O3H8I&
M0F)V$L6S"S5TYMVO1U]]LGM"8=Q<ZO\ 8MEUXQ5A:]8WC<G.UK1>)/BV1PS4
M^I>6'1IY=H:[N:1$Z*(V\%[)/("J+T>4(0@"$/RZ&)&-]?&XG1SJ.]YVP63L
MNLJ?.)Y'MRC+7Z[3<E(UU 3.^Y=95>/4E>WV/PV3S*P'FH6GF]_<4[DV)RY!
M'6:0'.+4-2(!1JKT#1:-_'/'/.<)$J/W5+\M6'=4=L;ING(I[:O,#GTRP[?7
M*;35PZLM([F]KD"5?*XO#T$:U6C#'Y1-F/: A&X..EA) A&B&+RZT(ETDLUY
M\KC\&"6>Z!VQ4O%\4Z^Z$YIH ARZID7.L'X>H:K;7FSA+W&>=+N:P,'8NAIO
M)H>BB<<0-\8.1NBM:Q%+?DT>F]$!GD%H>&MV\9;QU8VR/=LZ@Y50]LU=UIS_
M $AKI+F#C@GMZN55(V1-G:CKBJ<4N)@+PTK%LRB35/H7*(E,#PI5(1I%92TH
M7K$>0(? 8FDN+.EN&0=/<Q[X7.G&-,1OE_G*/].]\N-FVK4,7F]O3M57-2<H
MUO7<0F^Y#=LBCL+$\K[C?#9"83MJ8$RAO0Z],.SCS-#UN'AKS<\123A[M"U>
M<^6^^+0?G#G*IKNG_O-](PA9#^DK-LMU@T?D:Z*PQRD\.K<NIH'+[+N%\:'A
M#HEK:F9G2#5(C1*S=I@EB!LUMKFR=O%8ED]\:[WCG:#S%AYKK>?7TZ>Y>S>V
M^]1-EGUAP.M9-(93"S9?$[.AKG8U:MEBQEF=2U[>!0VR!C(7H ?$;&$8@E@$
M3XYGKQC+/2#WI;YHVO.VHAT)SE6;UUSRUT7S9S9 (=2EAR0VF[EF?7S60YTN
MJU*IS'4,HB3:VIP*C'D:A&8/8$X0E +&9]Q2>W+BR_IL_P!&^=7^YSUGQ)%.
M;:OZ%B7&[!U7TO,[2&VR9MFE]KN7*OJ6K8S&GURDLR4(:W<[?D,S<':1%M*5
MK:V_X8T\6E U11(1:V372;9LSB+P^V_V^_=Y<UR2TET&98-8T$LRQ::D:%L6
M2E?64GE$&VB.:9[7;W)HU%Y<YU=.F9Y0."(U6VIUQ!9QA!@!&D[$(SMKXW'9
MRGF'\P%.(AS[SY8Y_+[,X6RLM#HV-]L56CGKGK7,5;\F6G%ZSNZPD"T<<VX2
M0+<.>L:Q 2K3H0*"U8]>?P+V+(W\7-F?P^^6<[6]P6)6VU6^VS'FN/6[SWSI
M[I_"W+58RTNWI]"SYG<CRYQ>06#81:J!?-WQ"&D9-*F\A"V[5JVU]-T<%;H)
M8= $)K9TO-EJ&+<Z<]PJQ+2]_.C;<^IX-!T)QV]EHV6+SR1#<ZH;)KS3;THK
M1ZK30*ICZ^;R&S_13K9?\]N*'4>/*"0V&+2BP[$6:ZR:V=;4Z^VKW3U/"5GM
M3<GW]1]5L-0=<<3$N7/L\A]ERF5VPVK.>Z4AD@6JKH:7>,-<:('8<3- XI2F
ME4KVWF*BR3U!Y@3=Z)MK/U;3M4U^[MTUWI0]\>W)"N3Q5,BAU\]/QRNGTB:2
M]W85]DS+;!,GM/5<V-259.#H93[DU-)2Q6_,QRE\VL)TFTAVG$(P9/;FMENW
M:.9:+L/L'C:__?LZ'J.GJ@M.OJ%OVD+1OQ/95KS9B6@9$=!PQ+(X'136SQ!R
M)6OJ9.)2Y?.+N8V(M)PD@TE.4'" 4:\=;-9;S5P>O/?8E%7W1)JMH>#T8$NK
M.>ZFON9@Z*E%N,DDM-SN2%#LB*4I2J"HJWGZ!OF08=\/L]WD)R=LTXN!"<)0
M@@-.#4U]O,S?5>;M/HE5;GLL=%=1UH;-*M<+"X,FUOQ/8UCI%I_7KC(*G4R-
M&D.7MPF]U9I-%EBGT3#DXBC"U!&Q%[U\F\,ZS'N27U<+O;.O.><Z]14?++4D
MW9U#T#9'MJ2BX)# NO+@E%^-O8=O5S#(]:$YM7F72F964R0!-$H$E6.YK<L=
MV=U4MJXHL+867ZNP3NZ;R6<8SGMV=(*C]W+JU6AXBZ)O_F.G()Q9[A]MQ*H*
M1<H+;$HD_0%3.ML%.RJD7VZX^ZP]I@CPU3]*T;VJ+85HC67U@[-];8=@%6;I
M.9+^J,=$O>@L(SLVFZ5>DW)5K4G>_2<BYJ89%S9,K[F4OKF1%DRPV(O,LL*5
MU'&^?9X)2=&@)7MLC;X>K:5*@7IB5ED&#V/C_3GG.&C-WO@],:Y0Z0[4D')M
M8-U,U/9,MY@J-D1VU(%<^NGJ(OHA!3<0UM.9$"&:&TTC9W()KNN4''.ACJ0<
M2E(^'"$X4R?'KGQSS^3.\FRWJQ_]^:;MO7<,K&!V:S>U"Q!V@HZ=RR9U-)6E
M?TRSNB21,Q<Q9(\^L[TVKEZQG7$*2#O$UOV<0H,3GEZ#3;Q^/]/3R_)<GH;N
MCJ=V[/E/"_"%,TE/[1I^AH_T'=LUZ-L&80:"MC5-GEQ9Z_K.&(X+&)$^.DUE
M>VDU0-P5;(:VXD0/4T8+S:T9FL\?+;IEQ#[YZSM3W1*I]GUWAU'50JI7HOKQ
M?";(Y\N&VYNV-4FZ3JA/;D6DU,6T;#:\=VYTHEK''#G%&_)/CURM5Z01M!8?
MN]1TUUFEV]9/\.K/OWO$OK;VP$:6!R:3U.[:O+D""'+ZHF<GAKHSL+W<D&B[
MZP,,JCRQDD)#6:TJ34NA:&4(TCP\X?EWK*S[6+O_ $J$)=%)S[9GN4<)4S3W
M1W0-N<T]V-_05?65S3T%<,KO(^ N]7UH;.&:V*TF<]7/5@15J,4;+2.A(EIR
M<0-#WK>]C!I.)C?6VR2Q%O+_ +DMG0+DKVG:;X<XNK-+(>YHOV$EK2LYQ?UE
M.$&IQ\I2?/3F-UDMC2=DE<^E$)5EJW-X==C\[D5H 4:$ M"+V7"Z3-NUZ,K;
MG\P'/*XN>Y65KK*C)#6W,]WM?/UFP N1W2?TS;4B87&-QZY;!H=E8ZP>:P30
MR"/[TKVV-\@=T[H]H6HXX6T8C"B]U9[>9WS5]*?[I[,ZXZ*Z78N4Z5YS*Y?Y
M6N*6<Z2:?7E95C,%EVI;\1B&G5\' V&$P:2LL8A;'*75M1*%#KLY6>C.,4$%
M",#\,$Q==9)Y6YKFYRK[M?;]:<7]#=!].PJN;WF3QWY*N/\ F:-QNP%; [/=
M^RBWU5=MM4/_ ):LC\9B5$UL2CT8W2()BY\=TI)PE2).>,(A&]M-;9-?3*U]
MB>[-U)RN3VA5/6_/]' Z/YLXL5=SUBLI"RIL[TA<%6H90"#/C Y+)G$6J>PN
M4Q.8&@3*/%(K)7$#V>3Y @\HXS-)<76\6X:!?'N^]HT56?*$VM"@>8.?6_L>
M12V31&V;FLBX'J@*$J!' X9)JU8.B9G7=<KU;%==IND@4@*+2@ P-:<H.C%)
MXRU.RJLTUMLEMPZOU!2EJ*NL9)V$^7<UR2L;:Y*H^N&FFH:^R5_K5BL".2&6
M363VG"7-6ZAC3LS3)NEJ9(D7$MB9<J1(RAFFB!L  &+9C'?*LML>X%T>W^XX
M^\*4O157/T7KRDJCZ9MN[;#L.1,:>&TR]S>1L%H%-\08HRZ+9)/ -K00",I"
ME!290K,.,6F$D$?WA9K/#RM4(YA_F!W^\;CH0R05Q3B:@.F+$DD&C,>@+_<<
MCZ4HEE)(DYT$LF^4+C6#=4"R+RW<;+ N(8'D\YC$YIO,8JV$W036WMXG'6+#
M4K[LG0LLX_N;W1[@HRGH#[?4=JZV+%IJ-QZ>S"1]735-!99N)PI1+&TV-):L
MCZ&QUR!6#112TQ2V#$1LS1Q8A#PETDV\)GR_P_V-^Z%V354XH..=G\UT/"V?
MLZC;GMCFAQI*VIC,%L4F50U&?=9U-7HFE4-8R]N[Q#- T![8=G-X5NA$^EL/
M]X$>$O[;>$!51[Q?N&6Z?P(>R<?\O-B#W-ZPL9XYO3.5]V,-;7LPJEB02652
MB\%2>L-D[KM='S3E[>WL)"MW&5LDHTX!XC %&K[>LSS>&YQ7WK>@IK0?$DCB
MW,E8NG0/47:5S\,RV&N5I2./UG$+)J0V<-9\X9)45$)"_KH,<OBQ2U02:B$N
M+0;.+)]8\)7G)\<S>>),H[+]ZSN2*1Z7S>S^4N<4T'YE[\C/ W53O#[@L!<[
MR>9S&>L$01S#GEA=(4F+*CT81RA H7:D:P*A8:IT6046$!IA8\->UN;,Q][A
M_F!)+ ;_ +L:8Q65.O\ 2'//3)W-4M@2F0W JZWLOZ-2MFA=F6U5K#'*R=J?
M31:&.[FH.3-+L]%.3J@:U!OJ)=C* *+/:S/O8W7HKWB^QZ\7^Y++*HY:H:0T
MK[8%IQUAM^13NWYLTSBTH4]QV*2%4AK*-,<$6M+5.&5O>SU:H]T7_-VD_P .
M62 \X9@05)IK<9O-.R_<7Z@O GW"Z+Y0H"LY)37,G$;5->BIO9=F2*&6<XF]
M+<_2&P69CI1IC\<>F#;_  6O5@G-2)X4$$+E24:0HX@8BC1#763%VO-J/JV]
MP2T^4?;M]KZ$U/*N2EDUE7!576"X17H"3="/]KRM&R0F.)$8X=6O/U769*@Q
MYR,*5%JI.\F)FU(K"$KRG[T=LJ%U\MK;GJ\SI[G7??1-]^S1+^:8?3T)IGMZ
MMK=G[C5$ZL9\2&S"5P*N3SK/C%DR1LJ&1ND>CE5J/5<8BI8S#A299LL+F0A+
M 'P+X:R;9ZQMU<>XLR\^UKT2W<W\LQTJ^;W]Z^^>+JJ@;Y<\[6PJR;P< L#E
M(KZLN62M+(7"NHP8RH1*U["PIS$B<1!9* L/K&& 93PS>;Q-<MWM7WENA.7Z
MU[_BW1_.]2*>L>$HESS:?S#4MD2Q=2-WU+T+8S! 6:119]E$3132(/T>7.2@
MA6WN*0[0E("A -V4,>P":2XQ>*VER]U?LRFY]UE5'0/'4 D-IU5P<+OJC8!S
M=8TQGCI+X?J8_05;4DX/?X0TK!3V-O2HLU<N9D!R,U*F4C3$&^!7F)X:W%EX
MSA=KVN^RY?W%S^NM^9S'EB4N?TC);=-W+TKL1_30CU8^T.:V$VLS6A'8U*HA
M9<?<UIY"E((C9!Q "SRM^4SRZK.^OC<<ND^&3 8'!;^9D_@S]5?ZA2OZ[Z^P
MZ>U_)':&G/R0U7^;>#_@PUX8O5)&$,!@,#A5_,I?P8>PO\&FOU]5CDKI[7[X
MZ]4#^0FE/S25Q^!S-E8O5+>$58Z.Y#K'J"6\R3.PW.9-[KRC?;%T56Y44=6Q
MM0N,YCS&^,"%#+B7!D=S72-#1/YPC$Z8Q&>(P(-Z.#K6];+-K,X[Q -7^VO$
M(;UTV]H65T'T-T9;$'BMB0.EDMPO%>?1RF(5:3WMYEC#&$T KN#NDAV8#042
M52_*W10F0!],(MB\#-%NW'C)B)RE?&U5S#KB,=GNCI-BK6BG.TUYE;6I$[M9
M4(,K^=RQ!,GAP6,YK$>ZFRDEU;BP)U(5X$X"-B"(@8MZ%HGE?'Q[95H@/M$\
MNU[!>%ZZ;7NW76,^WZXW,X4ZG?)5'U"B4!O5AET<G""SU"&(-VWY#\US58%'
MINTTFD"]/8AC\N_,:\]K;?5&-*^RA1U,OO+JXOHKK.=Q/B>PG&;<K5?,I[ A
MUY5+6Z,DA854*$TL58LKA,6@;?)#B]+W=6J>RB2RR2EI9&SRSA?<MSQ.>K4X
M][#7-L<=Z]0([_ZY^I6E.E6CJNA.;/K+B/U-4_:#?-#9TK*CZ ZNU$H=XNX/
M"D\HM$YNBO;>E5*-(S"#E!IXR_)?29QA81+[8$>B%VSNTZ3ZOZVY]@MN7,5?
M]O\ /%53>"I*AG=IJ')K=96^D;DM=22>P9'9"MH+^DB-@>FXAU",S6]%Z'\A
M//C%DM3CR1SM;=*2;JN<W/=;W;TBZ#Z0EUGPYI,>I4JAE.T^%"VL=95/#&"1
MN*U(Q;8FI":H=#4!25.O<%8S/3^Y"+9-K+B3M$.RWVO*FD]]=8W:AMV^(<V=
MN4\MJ;I"G8K(X<56$Y4F5@Y5"S6,4E>H,]29EG,7A;H8%"),X@;_ (SP./2G
M:\0"+-[))QPVMO\ ;8H1M<.$W)._6>(_V]JGGM.4B$V0L(BGN+6)3[92;XJL
M<(8J 3\]D1)I+.3'(MMA1:[8C!%#+WHK1/*\_=7>3>S-5[KR-5G"L5ZCZRKO
MEZ!U_+JLF=<QN25(KW=D&FDS439V06&]2"GW9>A=R5RP]*F<6#;,I*0G"+WL
M0M^?"^=\O+$RDSW-.29G<'M4]!\;<NP]"[RMUHJ-U33T(<I$W,J U'$U\42L
MC*JDDI7ID"8I(P,/DV>L4!\_I_="V(7RC7;&_E484I[.M5121MUG6[=?3%US
MALY;D/+E:,ULV)&)*T\W5O9$231ZQ6"JE+-#&E4Y.ZE/YT1#R_'OB_2$ "C#
MC]!T/8N]Z3&,I/EWM-<[R3ECE3F!HF5SP4[B(R)./+]^0^6LC??%8R.&LQT?
M0R B0F18^*/1KPS'C3.J)6S&-S@3OP&GUL(! 'G<V^K04_LO<ZN-2VY6%B6W
MTC:+ITM<5>7!UG:4LGT=)L7IS58;3_1.I[(6L<+:V1KI%(4E+)%'X\A9="3:
M$3Z^BS# B'R7.>..GV8>\^#89S?2W=XN7>>;0Z%:^[2S&FP>,HO8=1P&H6&3
M2Z&+(!);0KE/8":,MM>;<D8TZE_*3N:D*@P@H](B]4@ -%FUMF;C'=./M)<2
M.GM_\)4Y0$Q6HWBW-)'"?7G(D3@>[DOMO3<X#E*!EO"K6CW=-'TI:1E2J1:U
MZR-L)%K6M;UK1-]O+;,Z-GN_VU^<+_[*YW[FG09N5<O-B#3?$F]B?T#=!)8!
MO6OCK$U%B1\UD6+)$K@3Y(UJYF,+6)=I51VQ"]36M!T2;V:W6=*A:">S#Q_6
M\7[YB<54VJC;?<102MDMXTZ5L2A9 HQ,%D]='*)TJ,R)>A"XVG>;)=5I"946
MYA"J-",>Q^7PV7SVN/LW%R]J#FUT72UP42.W0GS/V[VWVSG4),HC@2RJ :M&
M:3/Z$(H</9-HB]3?G<1;&@W_ .B'6#SO^<K3%<MUV3R&7Q8!QEGU3E<ZAYC"
M[;<F[<Y^K\%;ZJ[3AMX^9_FG<J^CVO4^)^ ^'^+^[]#R?W>&<W/EWRY^TO[)
MG/%1SSGZ0/=T]-WE6_)\3D<8YMH*\)Y%9;4]4FS*)*(3*WU$B:X)'I#(G!QC
MZU02E*=%ZM(UEG[*1E$D%D%$L-WW+<],U,O*GMK-_(,GA*:M>NNNW7GZK"9(
MEJOE"83B"N]-0MMD3>YMR>/F.*>N4%IRN*P\IU&-A;7:1+$[8:40(.A[(!X$
MVW\NLF?5,G=W"]+>X=0BKGN\U<W9HSN6QB=,DJK1_21:?Q*5Q-2<8W/47?UK
M0^IFU6<A6JD1XA)3?.C6' UY1"T,)-=KK<Q%UX^V+0]N5SRU#8C)K/Y[F/$R
M1O0<MW-2#\RL5D58W)8<B@;DS%_2".R2(R>.RJ,MQ!#L@<VM2G6[*"+80B\=
M[$WLM^Z'EGLM\Q.G+EN<Y/<\O1_E5Y77&^EK,Z?>IFS+>AY%T%#7MF?HA99C
M_J+E0],;%U+"G3H6LIE TIT7G+"GT,8C=E^2^66TSGVM&Z0SV/W5 NR.O*3Z
M%,IR)T;<%YUK(:C*E?14.AAJY1'G6VX[):BD%>'SMF4.JK:%Z:&=J5HBU BB
M_ O0 A$WQ,62QAKJ]H"H[@LX%M(.BNLJHF,KY[C?+W0;Q6EFQ]"[=05'%4!S
M<V)[C>'^$R!P.F1R=2<!4_,XVIQ.+/,!H8-#W@F]DQB8RNESKRA6W,G*L X_
MKUPEJZKJXKA35[ XR=S;7"8FQU22X$#.<71O9FEK/= %N0_*86A*+UX!_N_D
MWXF;;;F]59:&]J/F_G=ZX>?8-([=7+. :ON6I:6!)91'7!.]1J\A%BEZFQ (
MH<V#?7A)LK7P!J(3:63\OJ%FX:N]N?NL;R;R%6'&T/LR$58Y3%U9[5OBV>AY
M(9-W5L>%J>;W(^@D$J0-)K8R,9*:-)EH-!1)S"SCRBOD&<;O[K#-VNW-4$@/
MLA4) %=/M:'H;K-QJ7G'I9JZEYUH9;8$'!5M2S]!,7B=JFY*D2UJ3))G'G%^
M?E>M!?W)R6H4IYA:-0G$<>8:;^2^DS9A)$(]I&G*XL"Y5,.N;H!LYIZ$>;>D
M]P\.G26(./,DLDUY1EZC5BN*9M6PDVQHPA>!/ACCI V2%(D*<RRC@ T$L!>B
M>=OIGU:*R>RU4.N>9+RE8W3?7-R4(2GKP%$1*P)_"A/G+#E5$@/D5=R>DIY'
M:[8I>GE434C*3)5;TJ=PA;DQ:39>R-C ,OR7.9)ED4_LQT7(8;U2V7E>?3'1
M-I=?TPAYXL[H&SYC"=6DQ4JU*]N+; :V3QBO6&OX<U =?*M4"TR*#ERX.CCQ
M&"^3">=XQB2)HZ1]M2L.@6_EEQ9;8NZA;<XU1GM-$7Q34@BS=9;''G:)-<(E
M<;?0RJ'RF'R=DE\?9TX5J=4UB+]8OSEZ $1A8Q-[,\2RJWM'L9\Z0N$1)DK"
M]NJ(#9=?=4V'V%!>@2YY");;L?MNW80S5]:/KJII6[[$)-'YK'F8.U1#LTKE
M&E9HS0'Z"+9>%^2]Y,8PD.(>S=S3$4;(0*Q^BY8O9^]8C[C9\AF]BL,DDD@Z
M(B473Q8.Y$\J826I<H6_$$?$KT6O34[4BWHA200$!(">=^W3#:+C]H_E2]5'
M:2R?J;05+NX9-0\YGR]LER%H<*VGO-K"%CJ>:TLXH(^2X1"0,@@!5&&*S7,!
MZC6P[!H@8R1";[3&.S"2+VK4,W@U4D3WL_L*6]"4+9,IL:CNOE<HJ]NO>MRY
MG$6>$R>OD@&BK$5;R:M9$Q,I?SBUO+"X;7J#!G&F[&+Y!-\7B3'HO=SY3SS1
MM<)8-(KKM_H)]T\O;\[6==[S'G>;NZU]7#6F(] B4:A\798^U:%HA WH&Y,F
M2)P:#K6]^80C-N;GHI,F]H/D%/>7:M]C13U9)>\*NF%2W)&ETC:U,%9(_8K<
MT(K$<ZX8AQWXB,R2=K&!$O<U1RE;HY>F ;H =:\N&O/;$GHPL9]F_E*)\?U/
MQ8UO]S#K6I>BHCU&BEJ^8L*ZT)E;$-L(=CM[C/9.=#]MSXA6NOI)%0"D"4XQ
MO3E% - (/J;'G<^7?#:K1]K6I+.O_I:]]6]?4&)[$H@ZA^DJJA$CAR:M[,:T
MU<2"K(M,E:1^@L@?V>9PJ*R0_P";S42\A()666:H3GZ]4LT3>R2<<5(L?]N^
MCHY,^"YT@?+),>/;LJJ74_1I*E_9#&]\B\TJ]@J1V5620",E'/[R5&8X080:
MA,;"@+!#&(L0-Z+"3RO/W9KMOAN!=O1FIV^26#:-/SJB+=8;OIRW:<=H^USR
M!3YA;79E"M0 EL;E\6<D2]G?%!)Q"UN4 WO8!:\-AWH0UVNO]8B1\]JGGJ20
M+OJ /<PN1>A]QX,?'T&\CD\6+?DJV/UXT5L!Q@!Y4) WQ]6Y-#,!2J^*3.!8
MEQA@P ++V$H)?.\?9@[ ]JN$.EAM-N45TQU%R79HZ6KWGZQ9;1,HKT)EPUQ5
M;:8T0(4^9+%K:>1O<WBS<H-)0O[:C;W!,4<(L(O)Y0AF";\8LEBY-O<V0V\.
M7ISR?8$CGKK!+&IUQI262TQ_3*;+=(\[Q?<4<W]5)W)J7I%4R<$8A*#EIR,T
M!JP8C!%;\=ARLRV7RG51FA/9KYJI:PH%94MM#I_IY[J.J9-2=--'3MO$V!"Z
M@K6914$$E,>@$*88M#(ZV ?(.';0>:>0I-V@%Z>MZ\ [T:N]LQQ&JU#[)?/%
M52ZDC'*ZNF[9HWEV6NDZY@Y7M2P(Z^T?24K<2'5,A<V=.VPMFG4L!#B7E0%@
M)?WIS*:0C_N]"W\N"^Y;Z9KRU3[(M$56X\ZIT_1'6DIKCD"[RKPY=IB13^"[
MK2I'32R0N"J, ;VNM&Y\FC$L4R=4'2A[7KG9*G%LE*L3@-4^N6^Y;GB9O5,1
M?M)\K[XEMO@IQ4V8]TU;]E6!;KL\N<I:P6+&;"GUEBMS4AALE:HXUI&=3$9P
M$I0T^=&?Z99(2E&U !&:&9\[Y>7=[N6/;%@?-'1+WUH\]"]-=&="RFD$W/\
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M'X',V5B]4MX0P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M&$,!@,#A5_,I?P8>PO\ !IK]?58Y*Z>U^^.O5 _D)I3\TE<?@<S96+U2WA#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8'!;^9D_@S]5?ZA2OZ[Z^PZ>U_)':&G/R0U7^;>#_ (,->&+U21A# 8#
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MU5_J%*_KOK[#I[7\D=H:<_)#5?YMX/\ @PUX8O5)&$,!@,#A5_,I?P8>PO\
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M'X',V5B]4MX0P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M&$,!@,#A5_,I?P8>PO\ !IK]?58Y*Z>U^^.O5 _D)I3\TE<?@<S96+U2WA#
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M=?0O $;N%!=B"024VV*5566)HE!M6C@+2,J 2I#62LE0I$\Z6(''8P:3'IP
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M@,!@,!@,!@,!@,!@,!@<%OYF3^#/U5_J%*_KOK[#I[7\D=H:<_)#5?YMX/\
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M([_O;;_F<!]+XG_RB._[VV_YG ?2^)_\HCO^]MO^9P'TOB?_ "B._P"]MO\
MF<!]+XG_ ,HCO^]MO^9P'TOB?_*([_O;;_F<!]+XG_RB._[VV_YG ?2^)_\
M*([_ +VV_P"9P'TOB?\ RB._[VV_YG ?2^)_\HCO^]MO^9P'TOB?_*([_O;;
M_F<#^=G^9<O2L73V]GKD>,RMFE_1O5MFTQ7U,5%%7)$^S>2N1%I19]4N>F!N
M.4."=B(+:?AOBA@"4-8I))"+8Q^&HZ^U/U>7:/Z&:]8UD9@,'C;CLK;A'HA&
MF-?L@?J$[6-+*B0*MDC^3SE>NG%Y=_\ KK*Y-OP& P&!^#2BSBS"3BP&DF@&
M4:4: )A9A9@=A&68 6MA& 8=[UO6];UO6\#AY;/\N9[25NSM^L-PYO7P9[DZ
MU0YOC?4UFV+6D46.:HX9ZE<GA\8D:.-M SC#-[V4A3)D^M[WO1>M[WO9TGN[
MSC*-OZ8+VB_LFMW]XNXOQIPOS;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_
MLFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'
MS;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^
MR:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?
M-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[
M)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP
M?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_L
MFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!
M\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_
MLFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'
MS;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^
MR:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?
M-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[
M)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP
M?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_L
MFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!
M\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_
MLFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'
MS;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^
MR:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?
M-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[
M)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP
M?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_L
MFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!
M\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_
MLFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'
MS;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^
MR:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?
M-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[
M)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP
M?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_L
MFMW]XNXOQIP?-O\ 4/Z8+VB_LFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!
M\V_U#^F"]HO[)K=_>+N+\:<'S;_4/Z8+VB_LFMW]XNXOQIP?-O\ 4/Z8+VB_
MLFMW]XNXOQIP?-O]0_I@O:+^R:W?WB[B_&G!\V_U#^F"]HO[)K=_>+N+\:<'
MS;_46UY"]D[VW.(+%*M^B^?DP;70EG$L=B6'+9?9\FBQ2@D:8_<3/FSR\(XT
MK.3FC+$K1D%+-E&#+]7TQB#LSM[F^TQ;PZM88,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
1@,!@,!@,!@,!@,!@,!@?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
